data_1rmk_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1rmk _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.761 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.8 p . . . . . 0 C--O 1.234 0.262 0 CA-C-O 121.042 0.448 . . . . 0.0 110.642 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.2 m -76.87 143.37 39.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.137 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.761 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.1 mttp -79.87 152.48 29.63 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 1.028 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.8 tttt -47.4 -72.58 0.05 Allowed 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 113.716 1.006 . . . . 0.0 113.716 -177.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.8 m95 -82.41 33.34 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.326 -0.859 . . . . 0.0 110.728 -178.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.761 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 27.0 tt0 . . . . . 0 C--N 1.33 -0.244 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.951 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.492 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 62.7 m . . . . . 0 CA--C 1.517 -0.306 0 CA-C-O 120.811 0.339 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.761 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 24.8 m -68.23 153.42 95.52 Favored Pre-proline 0 C--N 1.327 -0.39 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_exo -51.53 114.51 1.6 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.808 1.672 . . . . 0.0 112.033 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.13 -31.38 4.93 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.396 -1.275 . . . . 0.0 112.185 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.52 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.0 mt -105.3 149.33 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.673 0.237 . . . . 0.0 110.443 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.4 ' N ' HD12 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -130.43 135.12 61.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.984 0.421 . . . . 0.0 111.216 179.687 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.7 m -61.75 148.03 44.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.636 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.77 -126.3 1.8 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.633 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.21 68.02 1.39 Allowed 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 123.506 2.804 . . . . 0.0 113.722 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.457 ' O ' HG12 ' A' ' 29' ' ' VAL . 4.0 m-85 65.47 22.1 11.86 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 123.33 0.652 . . . . 0.0 110.858 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 28' ' ' PHE . 28.3 m -150.13 -160.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 1.028 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -133.87 156.72 47.57 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.519 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.6 m . . . . . 0 C--O 1.246 0.871 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.143 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.0 p . . . . . 0 N--CA 1.454 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 109.992 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' SER . . . . . 0.502 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 16.9 m -76.94 143.98 39.14 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.092 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.812 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.4 mttp -77.73 150.74 34.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.84 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.9 tttt -50.31 -66.9 0.31 Allowed 'General case' 0 C--O 1.218 -0.605 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -177.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -82.01 29.14 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.316 -0.865 . . . . 0.0 111.085 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.812 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 38.6 tt0 . . . . . 0 C--N 1.328 -0.363 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.528 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 65.8 m . . . . . 0 N--CA 1.452 -0.369 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.754 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 25.1 m -68.07 152.78 96.19 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.26 112.72 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 121.863 1.709 . . . . 0.0 112.303 -178.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.22 -29.46 5.51 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.299 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.528 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 33.4 mt -105.12 148.85 26.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.788 0.294 . . . . 0.0 110.642 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.6 pt -137.74 135.52 45.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.813 0.34 . . . . 0.0 111.616 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 m -62.09 145.82 52.17 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.39 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -149.48 -110.78 0.55 Allowed Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.594 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.99 63.67 3.3 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.419 2.746 . . . . 0.0 113.716 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.482 ' O ' HG11 ' A' ' 29' ' ' VAL . 9.6 m-85 64.26 20.65 12.26 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 123.408 0.683 . . . . 0.0 111.059 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.482 HG11 ' O ' ' A' ' 28' ' ' PHE . 17.3 m -151.12 -164.84 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.84 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 10.5 t -124.52 156.24 37.63 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.437 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.245 0.867 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.23 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.73 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 22.8 p . . . . . 0 N--CA 1.453 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.0 m -79.13 150.13 31.84 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.605 -178.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.684 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 6.6 ttpm? -65.81 145.48 55.91 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.326 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.958 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.1 tttt -50.6 -66.08 0.45 Allowed 'General case' 0 C--O 1.217 -0.636 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.9 m95 -80.8 32.47 0.31 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.328 -0.857 . . . . 0.0 110.728 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.684 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 31.7 tt0 . . . . . 0 C--N 1.324 -0.543 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.087 178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.449 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 95.0 m . . . . . 0 C--O 1.233 0.211 0 CA-C-O 121.04 0.448 . . . . 0.0 112.172 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.73 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 8.8 m -69.43 152.94 96.24 Favored Pre-proline 0 CA--C 1.517 -0.325 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.18 116.31 2.73 Favored 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 121.679 1.586 . . . . 0.0 111.723 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.91 -31.22 5.41 Favored Glycine 0 C--N 1.312 -0.788 0 CA-C-N 114.563 -1.199 . . . . 0.0 111.862 -178.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.782 HD11 ' HB2' ' A' ' 5' ' ' LYS . 59.1 mt -106.22 151.71 24.44 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.0 pt -142.76 135.22 25.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.892 0.377 . . . . 0.0 111.823 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 33.1 m -64.31 134.65 55.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.793 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.427 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -135.42 -100.99 0.64 Allowed Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.356 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.427 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 8.2 Cg_exo -72.13 58.52 2.88 Favored 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 123.611 2.874 . . . . 0.0 113.052 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 64.23 16.06 9.81 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.738 -179.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.8 m -150.11 163.02 3.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.958 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 9.1 t -88.56 151.92 22.19 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.96 0.409 . . . . 0.0 110.292 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.535 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.4 m . . . . . 0 C--O 1.246 0.919 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.847 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.706 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.2 p . . . . . 0 N--CA 1.455 -0.181 0 CA-C-O 121.012 0.434 . . . . 0.0 110.671 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -82.97 142.72 31.17 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.769 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.596 ' HZ3' ' CD ' ' A' ' 7' ' ' GLU . 36.1 mtmm -70.75 157.53 37.89 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.971 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.2 tttt -50.93 -66.33 0.4 Allowed 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -81.72 31.47 0.36 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.694 -0.629 . . . . 0.0 111.264 -178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.596 ' CD ' ' HZ3' ' A' ' 4' ' ' LYS . 7.0 tp10 . . . . . 0 CA--C 1.534 0.327 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.456 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 97.7 m . . . . . 0 CA--C 1.519 -0.246 0 CA-C-O 120.863 0.364 . . . . 0.0 111.46 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.706 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 33.2 m -70.02 153.23 95.54 Favored Pre-proline 0 C--N 1.326 -0.432 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.56 115.49 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 121.807 1.671 . . . . 0.0 111.932 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 -31.6 4.99 Favored Glycine 0 C--N 1.312 -0.801 0 CA-C-N 114.422 -1.263 . . . . 0.0 112.076 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.497 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 49.3 mt -105.4 150.09 25.55 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.466 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -134.88 131.7 53.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.058 0.456 . . . . 0.0 111.525 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.553 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 30.9 t -65.18 140.32 58.75 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.741 179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.76 -105.7 0.52 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.037 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.53 61.24 2.79 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.374 2.716 . . . . 0.0 113.735 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.75 11.64 8.35 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.691 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 m -150.43 162.41 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.971 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 6.3 t -89.59 155.13 19.46 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.469 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 22.8 m . . . . . 0 C--O 1.247 0.93 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.89 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.71 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.1 p . . . . . 0 N--CA 1.453 -0.286 0 CA-C-O 121.056 0.455 . . . . 0.0 110.625 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -75.51 143.71 42.38 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.359 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.475 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 7.3 ttpm? -64.08 146.47 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.493 178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.67 ' HB2' HD11 ' A' ' 23' ' ' LEU . 29.2 tttt -52.9 -57.52 9.99 Favored 'General case' 0 C--O 1.213 -0.836 0 CA-C-O 121.326 0.584 . . . . 0.0 112.282 -178.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -81.13 28.32 0.37 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 111.568 -178.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 3.8 tp10 . . . . . 0 C--N 1.33 -0.264 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 177.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.582 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 96.7 m . . . . . 0 C--O 1.233 0.235 0 CA-C-O 121.077 0.465 . . . . 0.0 112.078 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.71 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 16.6 m -68.46 154.03 94.9 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -51.49 115.6 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 121.813 1.676 . . . . 0.0 111.694 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.99 -31.36 5.71 Favored Glycine 0 C--N 1.311 -0.847 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.905 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.67 HD11 ' HB2' ' A' ' 5' ' ' LYS . 38.0 mt -101.04 148.62 24.83 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.5 pt -141.67 133.4 27.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.94 0.4 . . . . 0.0 111.486 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.532 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 72.2 m -60.26 137.95 58.03 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.55 179.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.6 -110.91 0.76 Allowed Glycine 0 CA--C 1.522 0.531 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.456 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.14 63.07 1.43 Allowed 'Trans proline' 0 N--CA 1.479 0.635 0 C-N-CA 123.609 2.872 . . . . 0.0 114.207 -178.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.443 ' O ' HG13 ' A' ' 29' ' ' VAL . 2.2 m-85 66.64 11.74 8.35 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.604 0.762 . . . . 0.0 110.787 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 7' ' ' GLU . 18.6 m -151.94 162.74 2.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.133 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.655 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 24.9 t -89.54 156.01 18.91 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.487 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.3 m . . . . . 0 C--N 1.317 -0.832 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.124 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.74 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p . . . . . 0 N--CA 1.453 -0.307 0 CA-C-O 120.984 0.421 . . . . 0.0 110.809 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 m -71.42 141.82 50.29 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.146 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.646 ' HB3' ' CB ' ' A' ' 7' ' ' GLU . 4.3 ttmp? -71.77 142.5 49.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.536 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.951 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 37.8 tttt -47.94 -68.61 0.17 Allowed 'General case' 0 C--O 1.218 -0.602 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -177.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -81.74 35.05 0.4 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.269 -0.894 . . . . 0.0 110.299 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.646 ' CB ' ' HB3' ' A' ' 4' ' ' LYS . 22.6 tt0 . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.429 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.573 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 67.4 m . . . . . 0 CA--C 1.52 -0.182 0 CA-C-O 121.075 0.464 . . . . 0.0 111.57 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.74 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 13.9 m -67.9 153.52 95.11 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_exo -51.65 115.57 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.841 1.694 . . . . 0.0 111.71 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.4 -30.43 6.0 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 114.376 -1.283 . . . . 0.0 111.922 -178.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.666 HD13 ' HB2' ' A' ' 5' ' ' LYS . 49.5 mt -101.18 147.18 26.56 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.8 pt -130.28 132.97 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 111.509 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 74.0 m -58.93 140.01 55.98 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.118 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.41 -130.22 2.7 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.934 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -66.69 70.5 0.48 Allowed 'Trans proline' 0 N--CA 1.479 0.627 0 C-N-CA 123.823 3.015 . . . . 0.0 113.845 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 64.47 21.4 12.45 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.333 0.653 . . . . 0.0 110.684 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -150.32 -155.88 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.951 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 11.6 t -140.3 155.64 46.75 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.514 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.3 m . . . . . 0 C--O 1.245 0.857 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.227 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.8 p . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.185 0.517 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.0 p -76.51 142.36 40.92 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.822 -178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.488 ' N ' ' HE3' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -75.02 157.01 35.6 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.297 178.895 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.957 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 31.2 tttt -49.35 -71.71 0.06 Allowed 'General case' 0 C--O 1.216 -0.663 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -80.6 31.39 0.29 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.254 -0.904 . . . . 0.0 110.542 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.5 ' H ' ' C ' ' A' ' 5' ' ' LYS . 27.8 tt0 . . . . . 0 C--N 1.324 -0.501 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.023 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.422 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 76.4 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.774 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 7.8 m -64.67 151.63 91.78 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -51.47 114.6 1.64 Allowed 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 121.748 1.632 . . . . 0.0 111.959 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.56 -35.6 2.75 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.165 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.55 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 69.5 mt -102.27 149.79 23.96 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.637 0.218 . . . . 0.0 110.526 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.6 pt -125.71 131.43 71.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.159 0.504 . . . . 0.0 111.543 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 45.9 t -69.67 141.65 53.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.632 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -138.57 -117.54 1.53 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.986 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.46 63.51 2.2 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.48 2.787 . . . . 0.0 113.698 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.437 ' O ' HG12 ' A' ' 29' ' ' VAL . 2.9 m-85 66.29 15.65 10.17 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.766 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 28' ' ' PHE . 18.7 m -151.02 155.18 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 177.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.957 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.02 159.51 17.56 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 120.897 0.379 . . . . 0.0 110.54 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.487 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 m . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.202 -0.904 . . . . 0.0 109.806 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.75 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.2 p . . . . . 0 N--CA 1.453 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.0 m -81.36 148.81 29.17 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.844 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.613 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 19.7 mtpt -65.46 151.05 47.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.703 179.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.922 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.5 tttt -52.24 -65.02 0.63 Allowed 'General case' 0 C--O 1.214 -0.804 0 N-CA-C 112.824 0.675 . . . . 0.0 112.824 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.7 m95 -80.77 27.73 0.36 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.368 -0.833 . . . . 0.0 111.123 -178.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.613 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 2.3 tp10 . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.3 m . . . . . 0 CA--C 1.521 -0.151 0 CA-C-O 120.665 0.269 . . . . 0.0 110.672 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.75 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.8 OUTLIER -69.78 156.32 91.94 Favored Pre-proline 0 C--N 1.326 -0.419 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.032 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.14 114.66 1.84 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.177 1.918 . . . . 0.0 111.584 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.18 -35.25 2.76 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 114.259 -1.337 . . . . 0.0 111.84 -178.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.541 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 2.5 mm? -112.59 150.02 31.95 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.1 pt -138.69 134.11 42.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.781 0.325 . . . . 0.0 111.169 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.615 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 37.1 t -65.8 139.59 58.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.787 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -142.93 -97.92 0.27 Allowed Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.7 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.38 58.76 3.77 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.151 2.567 . . . . 0.0 113.498 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 65.14 14.34 9.32 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.837 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.61 163.76 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.922 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.3 t -89.15 150.72 22.57 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.537 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 29.2 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.018 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.713 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 27.9 p . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.247 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -83.57 150.93 25.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.803 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 22.5 mtmt -65.51 157.37 29.8 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.845 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.5 tttt -49.8 -61.33 2.19 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 113.982 1.105 . . . . 0.0 113.982 -177.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -80.9 25.57 0.45 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 112.186 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.803 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 70.0 mm-40 . . . . . 0 C--N 1.329 -0.295 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 177.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.52 -0.177 0 CA-C-O 120.665 0.269 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.713 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.5 OUTLIER -72.19 157.03 90.03 Favored Pre-proline 0 CA--C 1.513 -0.45 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.558 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -53.0 114.19 1.61 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.211 1.94 . . . . 0.0 111.664 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.35 -36.06 2.46 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 114.192 -1.367 . . . . 0.0 111.662 -178.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' A' ' 5' ' ' LYS . 71.4 mt -108.25 148.26 30.23 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.9 pt -129.35 131.87 67.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.809 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.505 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.1 t -67.24 138.53 56.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.499 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.1 -116.9 1.57 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.946 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 63.74 1.94 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.549 2.833 . . . . 0.0 113.559 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 65.72 16.58 10.55 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.678 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 m -151.54 154.1 8.79 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.845 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.65 155.82 19.38 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.527 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.6 m . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.121 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.704 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.6 p . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.2 t -169.21 164.25 11.01 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.0 0.364 . . . . 0.0 110.446 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.563 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 30.1 mtmm -69.95 151.84 45.15 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.227 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.767 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.4 tttt -54.3 -60.79 2.86 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -80.85 26.07 0.43 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.47 -0.769 . . . . 0.0 111.206 -178.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.563 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.469 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.1 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.087 0.47 . . . . 0.0 111.454 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.704 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.1 m -70.5 151.05 95.63 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -49.69 113.35 0.94 Allowed 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.745 1.63 . . . . 0.0 112.139 -178.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.92 -33.47 3.53 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.513 HD12 ' HB2' ' A' ' 5' ' ' LYS . 57.4 mt -104.98 146.45 29.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.564 0.221 . . . . 0.0 110.628 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 24' ' ' ILE . 19.3 pt -133.27 133.61 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.972 0.415 . . . . 0.0 111.224 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.522 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 51.6 m -66.77 140.0 57.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.98 0.419 . . . . 0.0 111.515 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.35 -112.6 1.14 Allowed Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.198 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.62 62.8 2.27 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.367 2.711 . . . . 0.0 113.704 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 65.4 15.8 10.21 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 123.617 0.767 . . . . 0.0 110.976 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.18 160.33 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.767 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 3.4 t -89.33 156.14 18.91 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.926 0.393 . . . . 0.0 110.158 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.514 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.6 m . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.905 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.773 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.9 p . . . . . 0 N--CA 1.455 -0.176 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' SER . . . . . 0.447 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 31.0 m -84.97 153.81 22.55 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.151 -179.068 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -66.16 160.11 24.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.267 179.065 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.941 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.1 tttt -52.05 -63.69 1.06 Allowed 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 -178.442 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -82.02 31.63 0.38 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.781 -0.574 . . . . 0.0 111.153 -178.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.577 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.534 0.35 0 CA-C-O 121.232 0.539 . . . . 0.0 110.006 178.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 94.7 m . . . . . 0 C--O 1.233 0.233 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.773 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 4.5 m -62.64 152.41 81.46 Favored Pre-proline 0 N--CA 1.452 -0.338 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -50.85 115.18 1.84 Allowed 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 121.784 1.656 . . . . 0.0 111.847 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.14 -35.32 3.4 Favored Glycine 0 C--N 1.312 -0.774 0 CA-C-N 114.388 -1.278 . . . . 0.0 111.935 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.731 HD21 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -98.9 147.88 24.52 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 pt -132.74 132.33 59.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.105 0.479 . . . . 0.0 111.766 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.538 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.7 t -68.82 143.93 54.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.314 179.477 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -144.59 -109.43 0.65 Allowed Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.929 -179.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -70.52 61.87 2.17 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.724 2.949 . . . . 0.0 113.525 -178.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.459 ' O ' HG11 ' A' ' 29' ' ' VAL . 3.1 m-85 65.79 13.89 9.24 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.565 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 28' ' ' PHE . 19.6 m -150.35 161.04 4.2 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.941 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.3 155.85 19.11 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.51 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.877 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.814 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.8 p . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -76.22 146.89 38.74 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.321 -179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.827 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 28.5 mtpt -66.75 148.65 51.64 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.925 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.6 tttt -51.37 -66.06 0.45 Allowed 'General case' 0 C--O 1.218 -0.565 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 10.3 m95 -80.92 29.32 0.33 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.802 -0.561 . . . . 0.0 110.94 -179.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.827 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 13.8 tp10 . . . . . 0 C--N 1.326 -0.451 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.549 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 92.9 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.801 0.334 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.814 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -68.89 156.6 90.98 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -52.12 113.08 1.03 Allowed 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.095 1.863 . . . . 0.0 111.629 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.84 -34.93 2.87 Favored Glycine 0 C--N 1.311 -0.857 0 CA-C-N 114.114 -1.403 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.549 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 54.6 mt -103.95 139.95 38.39 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.703 0.252 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 21.1 pt -127.31 133.09 68.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.999 0.428 . . . . 0.0 111.573 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -63.4 139.43 58.77 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.7 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.425 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -140.97 -117.22 1.35 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.967 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.425 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.0 Cg_exo -70.96 62.68 2.46 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 123.727 2.951 . . . . 0.0 113.222 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.506 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.0 m-85 65.7 16.16 10.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.496 -179.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.506 HG11 ' O ' ' A' ' 28' ' ' PHE . 23.4 m -151.15 155.47 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.132 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.925 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 1.8 t -89.52 153.87 20.46 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.523 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.9 m . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.98 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.776 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.3 t -85.21 143.3 28.85 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.613 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.639 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 5.1 ttpm? -66.48 153.37 43.04 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 1.006 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 36.2 tttt -50.54 -68.59 0.16 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.447 0.536 . . . . 0.0 112.447 -178.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.9 m95 -82.1 32.04 0.38 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.75 -0.593 . . . . 0.0 110.657 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.639 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 2.6 tp10 . . . . . 0 C--N 1.33 -0.253 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.453 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.0 m . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.807 0.337 . . . . 0.0 111.303 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.776 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 12.3 m -66.33 151.88 95.22 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.47 116.25 2.73 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 121.806 1.671 . . . . 0.0 111.758 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.18 -29.66 5.89 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.958 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.494 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.9 mt -106.15 147.17 29.32 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.434 HG21 HD12 ' A' ' 24' ' ' ILE . 22.9 pt -130.09 132.47 65.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.063 0.459 . . . . 0.0 111.473 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.2 t -64.1 140.77 58.9 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -140.68 -117.96 1.44 Allowed Glycine 0 CA--C 1.522 0.513 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.954 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 64.74 2.33 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.494 2.796 . . . . 0.0 113.814 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 67.02 13.1 9.35 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.8 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 m -150.46 159.26 4.85 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 1.006 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.5 t -89.29 154.06 20.4 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.529 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.3 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.042 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.67 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.5 p . . . . . 0 N--CA 1.454 -0.27 0 CA-C-O 121.038 0.447 . . . . 0.0 110.544 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -80.18 143.12 34.09 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.051 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.809 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 12.7 mtmt -67.98 149.48 49.68 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.857 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.6 tttt -51.81 -57.12 10.23 Favored 'General case' 0 C--O 1.213 -0.828 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 20.4 m95 -81.23 23.02 0.62 Allowed 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 112.689 -177.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.809 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 6.0 mm-40 . . . . . 0 CA--C 1.518 -0.286 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 93.6 m . . . . . 0 CA--C 1.519 -0.226 0 CA-C-O 121.139 0.495 . . . . 0.0 111.824 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.67 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 21.2 m -72.64 154.23 91.44 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 177.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -51.62 115.16 1.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.801 1.667 . . . . 0.0 111.9 -179.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.25 -31.71 5.35 Favored Glycine 0 C--N 1.311 -0.81 0 CA-C-N 114.479 -1.237 . . . . 0.0 112.179 -178.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.532 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -103.45 150.48 23.83 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.7 132.74 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.856 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.648 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 99.0 m -68.24 134.41 50.35 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.377 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.16 -84.02 0.05 OUTLIER Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.72 -0.753 . . . . 0.0 113.131 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.13 55.5 4.03 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 123.284 2.656 . . . . 0.0 112.966 -179.188 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.454 ' O ' HG11 ' A' ' 29' ' ' VAL . 1.8 m-85 64.74 12.42 7.62 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.36 -179.281 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.454 HG11 ' O ' ' A' ' 28' ' ' PHE . 20.4 m -151.77 167.45 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.857 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 15.0 t -89.38 153.19 21.05 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.016 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.458 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 34.9 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.852 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.803 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 15.7 p . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -115.2 -162.86 0.84 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.222 0.534 . . . . 0.0 112.251 -177.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.444 ' HZ1' ' CD ' ' A' ' 7' ' ' GLU . 24.6 mttp -80.65 150.05 29.57 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.123 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.763 ' HB2' HD12 ' A' ' 23' ' ' LEU . 29.0 tttt -57.39 -55.54 33.48 Favored 'General case' 0 C--O 1.211 -0.969 0 CA-C-O 121.514 0.673 . . . . 0.0 112.063 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.7 m95 -81.04 24.01 0.53 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.936 -1.103 . . . . 0.0 111.596 -178.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.444 ' CD ' ' HZ1' ' A' ' 4' ' ' LYS . 13.9 tp10 . . . . . 0 C--O 1.235 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.445 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 66.0 m . . . . . 0 CA--C 1.515 -0.383 0 CA-C-O 121.185 0.517 . . . . 0.0 111.41 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.803 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -70.89 160.62 81.65 Favored Pre-proline 0 N--CA 1.445 -0.702 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.96 111.45 0.52 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.254 1.969 . . . . 0.0 112.056 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.31 -39.28 1.67 Allowed Glycine 0 C--N 1.309 -0.944 0 CA-C-N 113.847 -1.524 . . . . 0.0 111.659 -178.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.763 HD12 ' HB2' ' A' ' 5' ' ' LYS . 64.5 mt -111.17 145.46 38.61 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 120.535 0.207 . . . . 0.0 110.47 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.42 HD11 HG23 ' A' ' 24' ' ' ILE . 22.0 pt -138.91 140.4 38.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.957 0.408 . . . . 0.0 111.591 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.72 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 22.7 m -77.5 139.5 39.62 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.103 0.478 . . . . 0.0 111.445 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.91 -85.73 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.079 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -75.78 55.43 4.35 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.826 2.351 . . . . 0.0 112.793 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 63.95 15.2 9.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.889 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.4 m -147.25 164.33 7.02 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.72 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 6.7 t -90.51 150.92 21.58 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-O 120.931 0.396 . . . . 0.0 109.953 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.531 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 35.2 m . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.963 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.682 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.4 p . . . . . 0 N--CA 1.456 -0.168 0 N-CA-C 110.553 -0.166 . . . . 0.0 110.553 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.3 t -164.22 157.92 18.42 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.781 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 14.2 ttmt -64.35 146.75 53.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.599 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.864 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.1 tttt -52.13 -64.57 0.77 Allowed 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.671 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.0 m95 -80.5 27.35 0.35 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 111.151 -178.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.781 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.8 tp10 . . . . . 0 N--CA 1.451 -0.409 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.4 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.821 0.343 . . . . 0.0 110.506 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.682 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 6.4 m -66.45 151.82 95.56 Favored Pre-proline 0 C--N 1.327 -0.403 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.97 115.8 2.37 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 121.913 1.742 . . . . 0.0 112.219 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.73 -21.98 12.11 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.232 -178.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.662 HD13 ' HB2' ' A' ' 5' ' ' LYS . 45.2 mt -116.72 152.67 33.84 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.8 pt -142.15 135.59 28.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.69 0.281 . . . . 0.0 111.366 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.538 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 15.6 m -67.12 136.21 54.78 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.752 0.31 . . . . 0.0 110.964 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -135.71 -105.95 0.82 Allowed Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.204 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.13 60.24 3.11 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.249 2.632 . . . . 0.0 113.34 -179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.453 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.2 m-85 65.08 17.29 11.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.964 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 28' ' ' PHE . 17.2 m -150.52 160.52 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 178.041 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.864 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.53 151.18 22.68 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.547 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 23.3 m . . . . . 0 C--O 1.244 0.802 0 CA-C-O 118.064 -0.97 . . . . 0.0 110.013 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.708 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.9 p . . . . . 0 N--CA 1.455 -0.198 0 CA-C-O 120.807 0.337 . . . . 0.0 110.548 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m -87.69 148.46 24.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.067 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.513 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 2.7 tmmm? -68.95 145.79 53.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.251 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.962 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 38.0 tttt -49.23 -68.52 0.17 Allowed 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -81.22 32.72 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.461 -0.774 . . . . 0.0 111.048 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.513 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.4 tp10 . . . . . 0 C--N 1.33 -0.272 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.502 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 99.1 m . . . . . 0 CA--C 1.519 -0.218 0 CA-C-O 121.116 0.484 . . . . 0.0 111.955 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.708 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 23.2 m -71.18 154.04 94.08 Favored Pre-proline 0 CA--C 1.515 -0.375 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.086 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -51.82 115.52 2.18 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 121.85 1.7 . . . . 0.0 111.896 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.02 -31.6 5.07 Favored Glycine 0 C--N 1.312 -0.805 0 CA-C-N 114.491 -1.231 . . . . 0.0 111.963 -178.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.664 HD11 ' HB2' ' A' ' 5' ' ' LYS . 46.7 mt -103.87 149.99 24.57 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.8 pt -136.15 133.57 50.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.042 0.448 . . . . 0.0 111.849 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 20.8 m -63.26 139.31 58.76 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.503 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.33 -118.62 1.6 Allowed Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.622 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.39 65.37 1.12 Allowed 'Trans proline' 0 N--CA 1.479 0.651 0 C-N-CA 123.657 2.905 . . . . 0.0 113.97 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 66.49 12.57 8.79 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 123.601 0.76 . . . . 0.0 110.875 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 m -150.13 161.33 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.962 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.7 t -89.41 152.45 21.48 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.537 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.8 m . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.083 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.723 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 21.4 p . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 121.06 0.457 . . . . 0.0 110.987 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' SER . . . . . 0.408 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 34.1 t -75.62 140.84 42.84 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.8 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.842 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -68.68 150.82 47.49 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.823 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.6 tttt -54.22 -66.24 0.43 Allowed 'General case' 0 C--O 1.214 -0.798 0 CA-C-O 121.153 0.502 . . . . 0.0 112.211 -178.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m95 -80.59 26.89 0.38 Allowed 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.282 -0.886 . . . . 0.0 111.039 -178.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.842 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 12.4 tp10 . . . . . 0 C--O 1.235 0.308 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 177.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.453 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 35.1 m . . . . . 0 CA--C 1.52 -0.191 0 CA-C-O 120.792 0.329 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.723 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 22.5 m -68.03 153.25 95.62 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.27 115.55 2.26 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.863 1.709 . . . . 0.0 111.89 -179.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.9 -26.0 9.13 Favored Glycine 0 C--N 1.312 -0.768 0 CA-C-N 114.429 -1.259 . . . . 0.0 112.231 -178.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.66 HD13 ' HB2' ' A' ' 5' ' ' LYS . 41.6 mt -107.41 149.53 27.79 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.703 0.252 . . . . 0.0 110.453 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.2 pt -137.79 131.41 42.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.9 0.381 . . . . 0.0 111.301 179.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.597 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 42.9 t -67.47 135.5 53.17 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.158 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -136.96 -106.07 0.77 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.869 -0.682 . . . . 0.0 113.054 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.44 60.51 2.66 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 123.389 2.726 . . . . 0.0 113.539 -179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.475 ' O ' HG11 ' A' ' 29' ' ' VAL . 2.4 m-85 66.0 14.5 9.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.759 -179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.475 HG11 ' O ' ' A' ' 28' ' ' PHE . 19.3 m -151.15 155.77 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.823 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -88.86 154.68 20.06 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.454 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.2 m . . . . . 0 C--O 1.246 0.905 0 CA-C-O 117.915 -1.04 . . . . 0.0 109.972 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.712 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.3 p . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -169.44 152.88 4.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.838 0.29 . . . . 0.0 110.707 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.642 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 7.2 ttpt -64.29 146.22 54.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.678 179.101 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 1.01 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.9 tttt -51.4 -66.03 0.45 Allowed 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.211 0.529 . . . . 0.0 111.99 -179.032 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -82.04 33.61 0.39 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.882 -0.511 . . . . 0.0 110.839 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.642 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 7.2 tp10 . . . . . 0 CA--C 1.534 0.357 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.511 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 11.3 m . . . . . 0 CA--C 1.514 -0.436 0 CA-C-O 120.783 0.325 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.712 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.7 m -72.02 152.25 92.82 Favored Pre-proline 0 N--CA 1.448 -0.549 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -50.5 113.85 1.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.772 1.648 . . . . 0.0 112.275 -178.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.0 -28.5 5.85 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.606 -179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.518 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.8 mt -111.91 152.0 28.52 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.942 0.371 . . . . 0.0 111.053 -179.102 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.1 pt -130.85 133.2 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.002 0.43 . . . . 0.0 110.975 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 46.6 t -75.67 134.54 40.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.446 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.497 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -136.42 -108.29 0.9 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.841 -0.695 . . . . 0.0 113.407 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.497 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 16.4 Cg_exo -68.68 61.61 1.2 Allowed 'Trans proline' 0 N--CA 1.478 0.609 0 C-N-CA 123.99 3.127 . . . . 0.0 113.925 -178.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 65.73 13.04 8.73 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.734 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 m -149.98 160.75 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.332 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 1.01 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.7 t -89.73 153.17 20.91 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.538 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.0 m . . . . . 0 C--O 1.246 0.895 0 CA-C-O 118.105 -0.95 . . . . 0.0 109.927 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.691 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 17.6 p . . . . . 0 N--CA 1.454 -0.259 0 CA-C-O 120.843 0.354 . . . . 0.0 110.578 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.4 t -80.81 145.17 31.56 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.387 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.593 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -75.14 155.93 36.48 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.555 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.881 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.2 tttt -53.07 -66.66 0.35 Allowed 'General case' 0 C--O 1.217 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 112.217 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.0 m95 -81.31 27.29 0.42 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.574 -0.704 . . . . 0.0 110.914 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.593 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 37.4 tt0 . . . . . 0 C--N 1.329 -0.322 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' CYS . . . . . 0.427 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 64.0 m . . . . . 0 CA--C 1.519 -0.226 0 CA-C-O 120.821 0.344 . . . . 0.0 111.368 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.691 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 17.3 m -69.34 153.9 95.43 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.16 116.05 2.56 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 121.76 1.64 . . . . 0.0 111.742 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.19 -27.27 8.65 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.187 -178.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.829 HD21 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -102.83 150.32 23.61 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.5 pt -135.68 131.2 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.052 0.453 . . . . 0.0 111.617 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.6 t -68.78 137.58 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.041 179.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.26 -109.33 0.92 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.102 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.89 61.21 2.34 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 123.441 2.76 . . . . 0.0 113.543 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.41 ' O ' HG13 ' A' ' 29' ' ' VAL . 2.1 m-85 65.75 15.78 10.2 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 123.667 0.787 . . . . 0.0 110.658 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 28' ' ' PHE . 18.7 m -151.79 155.85 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 178.079 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' CYS . . . . . 0.881 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 7.0 t -88.33 158.27 18.48 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.406 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.6 m . . . . . 0 C--O 1.248 0.984 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.129 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.761 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.8 p -89.61 132.0 35.33 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.042 0.448 . . . . 0.0 110.642 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.2 m -76.87 143.37 39.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.137 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.761 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.1 mttp -79.87 152.48 29.63 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 1.028 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.8 tttt -47.4 -72.58 0.05 Allowed 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 113.716 1.006 . . . . 0.0 113.716 -177.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.8 m95 -82.41 33.34 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.326 -0.859 . . . . 0.0 110.728 -178.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.761 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 27.0 tt0 -96.17 -125.89 0.13 Allowed 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.951 179.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -142.17 131.65 23.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.88 0.372 . . . . 0.0 110.559 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.47 ' SG ' ' HB ' ' A' ' 17' ' ' VAL . 42.1 t -165.04 123.14 1.65 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.42 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.453 ' C ' ' HD3' ' A' ' 12' ' ' PRO . 14.7 tt -107.67 143.99 17.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.26 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.671 ' HA ' ' HB3' ' A' ' 16' ' ' PHE . 5.7 m -120.28 67.43 12.87 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -178.704 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.55 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 12.1 Cg_exo -69.18 137.65 37.67 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.486 2.124 . . . . 0.0 111.385 178.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 13.9 pt -69.52 67.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-O 121.614 0.721 . . . . 0.0 112.126 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.441 HD11 ' O ' ' A' ' 14' ' ' LEU . 1.7 tm? -173.4 -32.31 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.55 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . -179.72 135.47 2.51 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.405 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.671 ' HB3' ' HA ' ' A' ' 11' ' ' VAL . 1.8 p90 -146.64 166.22 27.2 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 117.203 0.501 . . . . 0.0 111.704 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.47 ' HB ' ' SG ' ' A' ' 9' ' ' CYS . 1.7 t -81.28 -169.43 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.761 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.567 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 53.0 p90 -149.02 135.81 19.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.107 0.479 . . . . 0.0 110.87 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.492 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 62.7 m -83.93 171.86 12.63 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.008 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.761 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 24.8 m -68.23 153.42 95.52 Favored Pre-proline 0 C--N 1.327 -0.39 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_exo -51.53 114.51 1.6 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.808 1.672 . . . . 0.0 112.033 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.13 -31.38 4.93 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.396 -1.275 . . . . 0.0 112.185 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.52 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.0 mt -105.3 149.33 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.673 0.237 . . . . 0.0 110.443 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.4 ' N ' HD12 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -130.43 135.12 61.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.984 0.421 . . . . 0.0 111.216 179.687 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.7 m -61.75 148.03 44.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.636 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.77 -126.3 1.8 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.633 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.21 68.02 1.39 Allowed 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 123.506 2.804 . . . . 0.0 113.722 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.457 ' O ' HG12 ' A' ' 29' ' ' VAL . 4.0 m-85 65.47 22.1 11.86 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 123.33 0.652 . . . . 0.0 110.858 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 28' ' ' PHE . 28.3 m -150.13 -160.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 1.028 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -133.87 156.72 47.57 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.519 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.6 m . . . . . 0 C--O 1.246 0.871 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.143 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.0 p -150.78 133.55 15.81 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 123.349 0.406 . . . . 0.0 109.992 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.502 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 16.9 m -76.94 143.98 39.14 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.092 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.812 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.4 mttp -77.73 150.74 34.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.84 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.9 tttt -50.31 -66.9 0.31 Allowed 'General case' 0 C--O 1.218 -0.605 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -177.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -82.01 29.14 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.316 -0.865 . . . . 0.0 111.085 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.812 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 38.6 tt0 -97.75 141.12 31.16 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 50.2 t80 -63.24 113.8 3.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.047 0.451 . . . . 0.0 111.283 -179.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 16.7 t -96.49 123.81 40.28 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.429 HD13 ' H ' ' A' ' 10' ' ' ILE . 3.9 mp -59.78 -44.95 95.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.395 -178.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.469 HG11 ' O ' ' A' ' 11' ' ' VAL . 11.5 p -88.72 128.32 52.92 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.181 0.515 . . . . 0.0 111.223 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -85.21 -148.27 0.03 OUTLIER 'Trans proline' 0 C--O 1.244 0.797 0 C-N-CA 122.694 2.263 . . . . 0.0 112.31 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.2 mt -63.79 81.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.289 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.5 ' HA ' HD22 ' A' ' 14' ' ' LEU . 2.2 tm? -171.38 -39.39 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -178.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.16 147.43 8.16 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.223 -0.899 . . . . 0.0 113.539 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -173.9 -51.09 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 1.9 t -91.42 -171.3 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.441 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 25.4 t80 -149.73 126.36 10.97 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.297 0.57 . . . . 0.0 111.324 179.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.528 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 65.8 m -76.96 178.5 6.88 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.139 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.754 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 25.1 m -68.07 152.78 96.19 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.26 112.72 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 121.863 1.709 . . . . 0.0 112.303 -178.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.22 -29.46 5.51 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.299 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.528 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 33.4 mt -105.12 148.85 26.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.788 0.294 . . . . 0.0 110.642 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.6 pt -137.74 135.52 45.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.813 0.34 . . . . 0.0 111.616 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 m -62.09 145.82 52.17 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.39 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -149.48 -110.78 0.55 Allowed Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.594 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.99 63.67 3.3 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.419 2.746 . . . . 0.0 113.716 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.482 ' O ' HG11 ' A' ' 29' ' ' VAL . 9.6 m-85 64.26 20.65 12.26 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 123.408 0.683 . . . . 0.0 111.059 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.482 HG11 ' O ' ' A' ' 28' ' ' PHE . 17.3 m -151.12 -164.84 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.84 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 10.5 t -124.52 156.24 37.63 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.437 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.245 0.867 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.23 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.232 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.798 ' HA ' ' O ' ' A' ' 18' ' ' TYR . 22.8 p -125.8 133.54 51.98 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.0 m -79.13 150.13 31.84 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.605 -178.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.684 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 6.6 ttpm? -65.81 145.48 55.91 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.326 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.958 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.1 tttt -50.6 -66.08 0.45 Allowed 'General case' 0 C--O 1.217 -0.636 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.9 m95 -80.8 32.47 0.31 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.328 -0.857 . . . . 0.0 110.728 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.684 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 31.7 tt0 -103.84 138.37 40.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.087 178.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.582 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 32.6 t80 -63.13 118.9 8.55 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -179.531 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 77.5 m -75.66 55.85 0.87 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.05 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.582 ' HB ' ' CD2' ' A' ' 8' ' ' TYR . 14.4 tt -80.53 61.82 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 122.305 1.05 . . . . 0.0 109.562 178.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.582 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 27.2 m -64.44 128.29 93.18 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.758 -178.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 22.9 Cg_exo -64.89 137.29 52.58 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.841 2.361 . . . . 0.0 111.759 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.2 pt -55.88 -35.67 41.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.745 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -101.45 29.1 5.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.753 0.311 . . . . 0.0 111.116 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.435 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . 175.04 57.27 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.18 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.582 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 8.1 p90 -60.5 134.83 57.46 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.247 0.546 . . . . 0.0 111.468 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.536 ' H ' HG12 ' A' ' 11' ' ' VAL . 1.6 t -95.16 -170.71 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.998 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.798 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.7 p90 -157.59 149.18 21.89 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.449 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 95.0 m -71.09 165.8 22.76 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.04 0.448 . . . . 0.0 112.172 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.73 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 8.8 m -69.43 152.94 96.24 Favored Pre-proline 0 CA--C 1.517 -0.325 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.18 116.31 2.73 Favored 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 121.679 1.586 . . . . 0.0 111.723 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.91 -31.22 5.41 Favored Glycine 0 C--N 1.312 -0.788 0 CA-C-N 114.563 -1.199 . . . . 0.0 111.862 -178.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.782 HD11 ' HB2' ' A' ' 5' ' ' LYS . 59.1 mt -106.22 151.71 24.44 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.0 pt -142.76 135.22 25.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.892 0.377 . . . . 0.0 111.823 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 33.1 m -64.31 134.65 55.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.793 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.427 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -135.42 -100.99 0.64 Allowed Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.356 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.427 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 8.2 Cg_exo -72.13 58.52 2.88 Favored 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 123.611 2.874 . . . . 0.0 113.052 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.417 ' HB3' ' CE1' ' A' ' 8' ' ' TYR . 7.6 m-85 64.23 16.06 9.81 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.738 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.8 m -150.11 163.02 3.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.958 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 9.1 t -88.56 151.92 22.19 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.96 0.409 . . . . 0.0 110.292 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.535 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.4 m . . . . . 0 C--O 1.246 0.919 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.847 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.141 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.707 ' HA ' ' O ' ' A' ' 18' ' ' TYR . 20.2 p -94.39 133.35 38.06 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.012 0.434 . . . . 0.0 110.671 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -82.97 142.72 31.17 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.769 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.596 ' HZ3' ' CD ' ' A' ' 7' ' ' GLU . 36.1 mtmm -70.75 157.53 37.89 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.971 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.2 tttt -50.93 -66.33 0.4 Allowed 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -81.72 31.47 0.36 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.694 -0.629 . . . . 0.0 111.264 -178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.596 ' CD ' ' HZ3' ' A' ' 4' ' ' LYS . 7.0 tp10 -77.92 -126.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 37.9 t80 -162.07 133.82 5.44 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 7.4 p -150.69 130.59 13.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.258 0.552 . . . . 0.0 111.301 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 pt -135.5 48.68 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.5 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.614 ' HB ' ' HA2' ' A' ' 15' ' ' GLY . 35.4 m -68.47 135.44 90.78 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.623 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.402 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 72.3 Cg_endo -75.86 -162.42 0.16 Allowed 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.629 2.219 . . . . 0.0 112.375 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.442 HG13 ' HG ' ' A' ' 14' ' ' LEU . 28.8 pt -58.72 -35.05 53.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.345 -179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.442 ' HG ' HG13 ' A' ' 13' ' ' ILE . 92.9 mt -96.21 15.93 19.61 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.604 0.24 . . . . 0.0 111.072 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.614 ' HA2' ' HB ' ' A' ' 11' ' ' VAL . . . 62.53 -157.78 36.98 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.523 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.504 ' HB3' HG11 ' A' ' 11' ' ' VAL . 15.1 t80 175.81 -50.82 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.336 0.588 . . . . 0.0 109.444 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 1.2 t -119.85 -174.24 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.081 179.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.707 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 38.4 p90 -162.68 146.15 11.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.456 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 97.7 m -77.63 167.95 20.76 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.863 0.364 . . . . 0.0 111.46 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.706 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 33.2 m -70.02 153.23 95.54 Favored Pre-proline 0 C--N 1.326 -0.432 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.56 115.49 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 121.807 1.671 . . . . 0.0 111.932 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 -31.6 4.99 Favored Glycine 0 C--N 1.312 -0.801 0 CA-C-N 114.422 -1.263 . . . . 0.0 112.076 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.497 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 49.3 mt -105.4 150.09 25.55 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.466 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -134.88 131.7 53.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.058 0.456 . . . . 0.0 111.525 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.553 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 30.9 t -65.18 140.32 58.75 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.741 179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.76 -105.7 0.52 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.037 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.53 61.24 2.79 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.374 2.716 . . . . 0.0 113.735 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.437 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 2.2 m-85 66.75 11.64 8.35 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.691 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 m -150.43 162.41 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.971 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 6.3 t -89.59 155.13 19.46 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.469 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 22.8 m . . . . . 0 C--O 1.247 0.93 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.89 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.216 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.71 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.1 p -115.16 132.48 56.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.056 0.455 . . . . 0.0 110.625 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -75.51 143.71 42.38 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.359 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.475 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 7.3 ttpm? -64.08 146.47 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.493 178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.67 ' HB2' HD11 ' A' ' 23' ' ' LEU . 29.2 tttt -52.9 -57.52 9.99 Favored 'General case' 0 C--O 1.213 -0.836 0 CA-C-O 121.326 0.584 . . . . 0.0 112.282 -178.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -81.13 28.32 0.37 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 111.568 -178.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 3.8 tp10 -82.99 145.43 29.34 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -74.96 58.97 0.88 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.502 0.668 . . . . 0.0 110.259 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.22 102.99 3.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.848 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.446 HD12 HG23 ' A' ' 10' ' ' ILE . 29.2 pt -113.04 28.63 2.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.4 m 35.15 59.32 2.52 Favored Pre-proline 0 N--CA 1.476 0.854 0 O-C-N 124.367 1.042 . . . . 0.0 113.604 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.538 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 56.1 Cg_endo -71.25 140.3 36.91 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.042 1.828 . . . . 0.0 111.869 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.4 HG22 HD13 ' A' ' 13' ' ' ILE . 31.9 pt -57.5 -29.83 34.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.6 tp -68.92 -24.1 64.25 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.238 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 176.49 80.71 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.088 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.538 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 4.0 p90 -69.88 -31.86 69.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -179.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.548 ' CG1' ' H ' ' A' ' 18' ' ' TYR . 2.0 t 58.35 -152.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.203 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.703 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 48.0 p90 -167.81 142.78 3.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.637 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.582 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 96.7 m -70.61 167.95 17.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.077 0.465 . . . . 0.0 112.078 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.71 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 16.6 m -68.46 154.03 94.9 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -51.49 115.6 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 121.813 1.676 . . . . 0.0 111.694 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.99 -31.36 5.71 Favored Glycine 0 C--N 1.311 -0.847 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.905 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.67 HD11 ' HB2' ' A' ' 5' ' ' LYS . 38.0 mt -101.04 148.62 24.83 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.5 pt -141.67 133.4 27.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.94 0.4 . . . . 0.0 111.486 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.532 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 72.2 m -60.26 137.95 58.03 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.55 179.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.6 -110.91 0.76 Allowed Glycine 0 CA--C 1.522 0.531 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.456 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.14 63.07 1.43 Allowed 'Trans proline' 0 N--CA 1.479 0.635 0 C-N-CA 123.609 2.872 . . . . 0.0 114.207 -178.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.443 ' O ' HG13 ' A' ' 29' ' ' VAL . 2.2 m-85 66.64 11.74 8.35 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.604 0.762 . . . . 0.0 110.787 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 7' ' ' GLU . 18.6 m -151.94 162.74 2.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.133 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.655 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 24.9 t -89.54 156.01 18.91 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.487 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.3 m . . . . . 0 C--N 1.317 -0.832 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.124 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.74 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p -111.23 131.62 54.98 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.984 0.421 . . . . 0.0 110.809 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 m -71.42 141.82 50.29 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.146 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.646 ' HB3' ' CB ' ' A' ' 7' ' ' GLU . 4.3 ttmp? -71.77 142.5 49.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.536 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.951 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 37.8 tttt -47.94 -68.61 0.17 Allowed 'General case' 0 C--O 1.218 -0.602 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -177.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -81.74 35.05 0.4 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.269 -0.894 . . . . 0.0 110.299 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.646 ' CB ' ' HB3' ' A' ' 4' ' ' LYS . 22.6 tt0 -127.1 151.64 48.37 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.429 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -61.31 126.36 27.09 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.73 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.5 t -59.69 -42.62 93.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.47 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.41 ' HA ' HD12 ' A' ' 10' ' ' ILE . 46.5 mm 70.93 133.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 123.83 0.706 . . . . 0.0 111.786 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.416 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 16.7 m -137.11 108.37 8.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-O 121.415 0.626 . . . . 0.0 110.141 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.45 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 8.2 Cg_exo -72.74 149.38 48.32 Favored 'Trans proline' 0 N--CA 1.463 -0.265 0 C-N-CA 123.03 2.487 . . . . 0.0 111.913 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.9 mt -71.54 64.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 121.44 0.638 . . . . 0.0 110.475 179.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.6 pp -176.84 -21.42 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.052 -0.977 . . . . 0.0 109.398 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -175.07 -134.93 1.98 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.222 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.45 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 14.2 p90 -167.55 154.45 8.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.77 0.285 . . . . 0.0 110.261 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.491 ' CG1' ' H ' ' A' ' 18' ' ' TYR . 2.2 t -86.01 -166.68 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.709 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 48.6 p90 -156.56 143.64 18.84 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.573 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 67.4 m -74.31 168.53 19.46 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.075 0.464 . . . . 0.0 111.57 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.74 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 13.9 m -67.9 153.52 95.11 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_exo -51.65 115.57 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.841 1.694 . . . . 0.0 111.71 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.4 -30.43 6.0 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 114.376 -1.283 . . . . 0.0 111.922 -178.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.666 HD13 ' HB2' ' A' ' 5' ' ' LYS . 49.5 mt -101.18 147.18 26.56 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.8 pt -130.28 132.97 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 111.509 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 74.0 m -58.93 140.01 55.98 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.118 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.41 -130.22 2.7 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.934 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -66.69 70.5 0.48 Allowed 'Trans proline' 0 N--CA 1.479 0.627 0 C-N-CA 123.823 3.015 . . . . 0.0 113.845 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 64.47 21.4 12.45 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.333 0.653 . . . . 0.0 110.684 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -150.32 -155.88 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.951 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 11.6 t -140.3 155.64 46.75 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.514 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.3 m . . . . . 0 C--O 1.245 0.857 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.227 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.225 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.774 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.8 p -87.97 126.57 35.14 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.185 0.517 . . . . 0.0 109.655 179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.0 p -76.51 142.36 40.92 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.822 -178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.488 ' N ' ' HE3' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -75.02 157.01 35.6 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.297 178.895 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.957 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 31.2 tttt -49.35 -71.71 0.06 Allowed 'General case' 0 C--O 1.216 -0.663 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -80.6 31.39 0.29 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.254 -0.904 . . . . 0.0 110.542 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.5 ' H ' ' C ' ' A' ' 5' ' ' LYS . 27.8 tt0 -108.99 143.07 38.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.023 178.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.433 ' HE1' ' HD2' ' A' ' 28' ' ' PHE . 40.3 t80 -59.32 134.42 56.99 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.965 0.412 . . . . 0.0 111.223 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 30.1 p -151.63 158.19 43.14 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.507 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.46 HD13 ' O ' ' A' ' 10' ' ' ILE . 1.6 pp -145.39 145.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.578 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 1.086 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 3.3 m -72.97 125.63 90.97 Favored Pre-proline 0 CA--C 1.538 0.486 0 CA-C-O 121.1 0.476 . . . . 0.0 110.19 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.86 54.97 1.27 Allowed 'Trans proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.362 2.708 . . . . 0.0 114.233 -178.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.412 ' HA ' HD13 ' A' ' 13' ' ' ILE . 39.1 mm 53.81 -86.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.814 0.845 . . . . 0.0 113.025 178.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.8 pp -67.4 -11.36 57.56 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.558 0.694 . . . . 0.0 109.97 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -127.54 158.04 21.1 Favored Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 178.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 1.086 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 8.5 m-85 -121.64 -32.44 3.8 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 117.303 0.551 . . . . 0.0 111.107 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -76.14 174.26 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.674 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 10.5 t80 179.09 -34.29 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.309 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.422 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 76.4 m -59.93 163.76 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.402 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.774 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 7.8 m -64.67 151.63 91.78 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -51.47 114.6 1.64 Allowed 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 121.748 1.632 . . . . 0.0 111.959 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.56 -35.6 2.75 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.165 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.55 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 69.5 mt -102.27 149.79 23.96 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.637 0.218 . . . . 0.0 110.526 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.6 pt -125.71 131.43 71.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.159 0.504 . . . . 0.0 111.543 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 45.9 t -69.67 141.65 53.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.632 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -138.57 -117.54 1.53 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.986 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.46 63.51 2.2 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.48 2.787 . . . . 0.0 113.698 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.437 ' O ' HG12 ' A' ' 29' ' ' VAL . 2.9 m-85 66.29 15.65 10.17 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.766 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 28' ' ' PHE . 18.7 m -151.02 155.18 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 177.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.957 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.02 159.51 17.56 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 120.897 0.379 . . . . 0.0 110.54 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.487 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 m . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.202 -0.904 . . . . 0.0 109.806 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.215 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.75 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.2 p -137.65 134.97 36.09 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.979 0.419 . . . . 0.0 110.927 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.0 m -81.36 148.81 29.17 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.844 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.613 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 19.7 mtpt -65.46 151.05 47.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.703 179.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.922 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.5 tttt -52.24 -65.02 0.63 Allowed 'General case' 0 C--O 1.214 -0.804 0 N-CA-C 112.824 0.675 . . . . 0.0 112.824 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.7 m95 -80.77 27.73 0.36 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.368 -0.833 . . . . 0.0 111.123 -178.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.613 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 2.3 tp10 -94.98 138.46 32.68 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.163 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.426 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 49.6 t80 -64.49 130.41 43.61 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 74.0 m -73.54 61.95 0.73 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.772 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.437 HD12 HG23 ' A' ' 10' ' ' ILE . 15.1 tt -79.01 52.7 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 122.484 1.135 . . . . 0.0 109.626 178.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.667 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 35.3 m -79.31 134.63 58.54 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.517 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 21.6 Cg_exo -65.23 136.01 45.71 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.612 2.208 . . . . 0.0 111.493 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 12.4 tt -55.07 -37.87 44.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.665 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.507 HD21 ' H ' ' A' ' 14' ' ' LEU . 2.5 pt? -99.8 29.78 3.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.687 0.28 . . . . 0.0 111.217 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.425 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . 174.89 55.77 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.203 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.667 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 23.6 p90 -62.54 138.2 58.43 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.181 0.515 . . . . 0.0 111.554 -179.269 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.503 ' H ' HG12 ' A' ' 11' ' ' VAL . 1.9 t -87.34 -169.19 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.697 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.721 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 51.8 p90 -150.61 147.54 27.54 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.3 m -75.73 162.4 28.24 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.665 0.269 . . . . 0.0 110.672 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.75 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.8 OUTLIER -69.78 156.32 91.94 Favored Pre-proline 0 C--N 1.326 -0.419 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.032 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.14 114.66 1.84 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.177 1.918 . . . . 0.0 111.584 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.18 -35.25 2.76 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 114.259 -1.337 . . . . 0.0 111.84 -178.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.541 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 2.5 mm? -112.59 150.02 31.95 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.1 pt -138.69 134.11 42.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.781 0.325 . . . . 0.0 111.169 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.615 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 37.1 t -65.8 139.59 58.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.787 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -142.93 -97.92 0.27 Allowed Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.7 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.38 58.76 3.77 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.151 2.567 . . . . 0.0 113.498 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 65.14 14.34 9.32 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.837 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.61 163.76 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.922 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.3 t -89.15 150.72 22.57 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.537 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 29.2 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.018 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.713 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 27.9 p -118.3 129.33 55.39 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.904 0.383 . . . . 0.0 110.247 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -83.57 150.93 25.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.803 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 22.5 mtmt -65.51 157.37 29.8 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.845 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.5 tttt -49.8 -61.33 2.19 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 113.982 1.105 . . . . 0.0 113.982 -177.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -80.9 25.57 0.45 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 112.186 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.803 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 70.0 mm-40 -97.53 145.37 26.3 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 177.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.555 ' HA ' ' O ' ' A' ' 28' ' ' PHE . 5.5 m-85 -72.78 94.38 1.78 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.8 p -75.79 49.2 0.51 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.081 -179.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.81 127.56 33.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.276 179.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 20.7 m -75.85 130.76 77.84 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 121.109 0.481 . . . . 0.0 111.409 -179.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' HD3' HG22 ' A' ' 17' ' ' VAL . 12.2 Cg_exo -70.07 144.0 51.03 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.846 2.364 . . . . 0.0 111.303 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.423 HG23 ' HG ' ' A' ' 14' ' ' LEU . 8.6 tp -53.87 -30.63 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.611 -179.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.423 ' HG ' HG23 ' A' ' 13' ' ' ILE . 95.1 mt -105.62 33.81 3.57 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.598 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.55 -144.74 8.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.944 -1.122 . . . . 0.0 113.101 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -171.15 151.59 3.23 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.436 HG22 ' HD3' ' A' ' 12' ' ' PRO . 1.0 OUTLIER -112.45 -177.02 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.613 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.676 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.2 p90 -170.46 151.57 3.73 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.5 m -84.06 162.3 20.39 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.713 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.5 OUTLIER -72.19 157.03 90.03 Favored Pre-proline 0 CA--C 1.513 -0.45 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.558 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -53.0 114.19 1.61 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.211 1.94 . . . . 0.0 111.664 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.35 -36.06 2.46 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 114.192 -1.367 . . . . 0.0 111.662 -178.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.666 HD12 ' HB2' ' A' ' 5' ' ' LYS . 71.4 mt -108.25 148.26 30.23 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.9 pt -129.35 131.87 67.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.809 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.505 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.1 t -67.24 138.53 56.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.499 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.1 -116.9 1.57 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.946 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 63.74 1.94 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.549 2.833 . . . . 0.0 113.559 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.555 ' O ' ' HA ' ' A' ' 8' ' ' TYR . 4.1 m-85 65.72 16.58 10.55 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.678 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 m -151.54 154.1 8.79 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.845 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.65 155.82 19.38 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.527 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.6 m . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.121 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.024 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.704 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.6 p -150.96 -148.64 0.27 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.2 t -169.21 164.25 11.01 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.0 0.364 . . . . 0.0 110.446 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.563 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 30.1 mtmm -69.95 151.84 45.15 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.227 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.767 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.4 tttt -54.3 -60.79 2.86 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -80.85 26.07 0.43 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.47 -0.769 . . . . 0.0 111.206 -178.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.563 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 0.6 OUTLIER -92.68 145.1 24.68 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.276 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.437 ' HE1' ' HD2' ' A' ' 28' ' ' PHE . 25.9 t80 -67.32 116.93 8.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.991 0.424 . . . . 0.0 110.233 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 72.1 m -76.45 78.12 3.17 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.103 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 tp -71.23 85.45 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.825 0.822 . . . . 0.0 110.328 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.513 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 29.7 m -74.64 136.95 74.03 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.374 -179.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -68.17 150.66 77.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.639 2.226 . . . . 0.0 111.793 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.576 ' H ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -55.67 128.37 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.662 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.4 mt 64.36 28.09 13.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.394 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.83 -158.94 9.33 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.936 179.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.513 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 12.4 p90 -168.07 153.13 6.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.636 0.255 . . . . 0.0 110.448 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 1.4 t -94.31 -172.77 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.486 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 25.0 t80 -146.05 132.29 19.48 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.917 0.389 . . . . 0.0 110.133 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.469 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.1 m -75.36 177.76 6.36 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.454 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.704 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.1 m -70.5 151.05 95.63 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -49.69 113.35 0.94 Allowed 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.745 1.63 . . . . 0.0 112.139 -178.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.92 -33.47 3.53 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.513 HD12 ' HB2' ' A' ' 5' ' ' LYS . 57.4 mt -104.98 146.45 29.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.564 0.221 . . . . 0.0 110.628 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 24' ' ' ILE . 19.3 pt -133.27 133.61 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.972 0.415 . . . . 0.0 111.224 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.522 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 51.6 m -66.77 140.0 57.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.98 0.419 . . . . 0.0 111.515 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.35 -112.6 1.14 Allowed Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.198 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.62 62.8 2.27 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.367 2.711 . . . . 0.0 113.704 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.437 ' HD2' ' HE1' ' A' ' 8' ' ' TYR . 4.4 m-85 65.4 15.8 10.21 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 123.617 0.767 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.18 160.33 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.767 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 3.4 t -89.33 156.14 18.91 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.926 0.393 . . . . 0.0 110.158 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.514 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.6 m . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.905 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.773 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.9 p -150.27 130.56 13.7 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.447 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 31.0 m -84.97 153.81 22.55 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.151 -179.068 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.577 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -66.16 160.11 24.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.267 179.065 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.941 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.1 tttt -52.05 -63.69 1.06 Allowed 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 -178.442 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -82.02 31.63 0.38 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.781 -0.574 . . . . 0.0 111.153 -178.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.577 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 0.5 OUTLIER -79.34 -125.55 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.232 0.539 . . . . 0.0 110.006 178.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.427 ' H ' ' HB3' ' A' ' 7' ' ' GLU . 46.9 t80 -160.53 134.37 7.03 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 7.5 p -160.15 139.64 11.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.943 0.402 . . . . 0.0 111.007 -179.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 tp -122.11 74.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 122.101 0.953 . . . . 0.0 109.996 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.418 ' HB ' ' HB3' ' A' ' 16' ' ' PHE . 27.8 m -80.25 141.82 54.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.862 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.1 140.4 89.32 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.679 2.253 . . . . 0.0 112.04 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 52.5 mt -54.62 -28.89 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.815 -179.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -59.23 -29.5 67.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.146 179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 127.53 3.03 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.152 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.418 ' HB3' ' HB ' ' A' ' 11' ' ' VAL . 21.9 t80 -173.11 136.97 0.67 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.54 -176.91 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 15.7 t80 179.69 -37.43 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.961 0.41 . . . . 0.0 110.009 179.215 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.476 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 94.7 m -59.27 160.64 6.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.006 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.773 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 4.5 m -62.64 152.41 81.46 Favored Pre-proline 0 N--CA 1.452 -0.338 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -50.85 115.18 1.84 Allowed 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 121.784 1.656 . . . . 0.0 111.847 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.14 -35.32 3.4 Favored Glycine 0 C--N 1.312 -0.774 0 CA-C-N 114.388 -1.278 . . . . 0.0 111.935 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.731 HD21 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -98.9 147.88 24.52 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 pt -132.74 132.33 59.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.105 0.479 . . . . 0.0 111.766 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.538 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.7 t -68.82 143.93 54.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.314 179.477 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -144.59 -109.43 0.65 Allowed Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.929 -179.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -70.52 61.87 2.17 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.724 2.949 . . . . 0.0 113.525 -178.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 3.1 m-85 65.79 13.89 9.24 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.565 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 28' ' ' PHE . 19.6 m -150.35 161.04 4.2 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.718 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.941 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.3 155.85 19.11 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.51 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.877 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.814 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.8 p -150.85 135.13 16.94 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -76.22 146.89 38.74 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.321 -179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.827 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 28.5 mtpt -66.75 148.65 51.64 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.925 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.6 tttt -51.37 -66.06 0.45 Allowed 'General case' 0 C--O 1.218 -0.565 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 10.3 m95 -80.92 29.32 0.33 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.802 -0.561 . . . . 0.0 110.94 -179.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.827 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 13.8 tp10 -110.71 147.58 34.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 21.5 t80 -65.2 113.43 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.983 0.42 . . . . 0.0 110.345 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.7 p -82.44 116.28 21.83 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 178.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.569 HG22 ' HD3' ' A' ' 12' ' ' PRO . 22.5 mt -68.79 130.85 34.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.491 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.1 m -126.56 67.69 66.8 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.96 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.873 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 25.4 Cg_exo -62.78 147.79 94.24 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.549 2.166 . . . . 0.0 112.018 179.496 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.705 HG23 HD13 ' A' ' 14' ' ' LEU . 48.4 mm -56.59 117.24 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.677 -179.691 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.705 HD13 HG23 ' A' ' 13' ' ' ILE . 11.1 mp 60.18 32.01 20.73 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.601 -179.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 41.79 0.22 Allowed Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.028 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.873 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 11.1 p90 -70.96 146.42 49.48 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.767 0.318 . . . . 0.0 111.209 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.42 ' CG1' ' H ' ' A' ' 18' ' ' TYR . 1.7 t -83.87 -172.26 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.42 ' H ' ' CG1' ' A' ' 17' ' ' VAL . 23.6 t80 -152.19 141.39 21.38 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.839 0.352 . . . . 0.0 110.259 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.549 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 92.9 m -74.0 173.52 9.89 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.904 179.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.814 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -68.89 156.6 90.98 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -52.12 113.08 1.03 Allowed 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.095 1.863 . . . . 0.0 111.629 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.84 -34.93 2.87 Favored Glycine 0 C--N 1.311 -0.857 0 CA-C-N 114.114 -1.403 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.549 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 54.6 mt -103.95 139.95 38.39 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.703 0.252 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 21.1 pt -127.31 133.09 68.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.999 0.428 . . . . 0.0 111.573 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -63.4 139.43 58.77 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.7 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.425 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -140.97 -117.22 1.35 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.967 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.425 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.0 Cg_exo -70.96 62.68 2.46 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 123.727 2.951 . . . . 0.0 113.222 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.506 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.0 m-85 65.7 16.16 10.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.496 -179.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.506 HG11 ' O ' ' A' ' 28' ' ' PHE . 23.4 m -151.15 155.47 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.132 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.925 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 1.8 t -89.52 153.87 20.46 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.523 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.9 m . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.98 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.776 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p -149.98 136.87 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.3 t -85.21 143.3 28.85 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.613 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.639 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 5.1 ttpm? -66.48 153.37 43.04 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 1.006 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 36.2 tttt -50.54 -68.59 0.16 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.447 0.536 . . . . 0.0 112.447 -178.516 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.9 m95 -82.1 32.04 0.38 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.75 -0.593 . . . . 0.0 110.657 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.639 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 2.6 tp10 -85.98 -116.76 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -160.31 140.29 11.35 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.454 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 28.8 p -157.32 151.25 24.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.233 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.7 tp -167.83 -32.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.831 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.414 HG22 HG23 ' A' ' 17' ' ' VAL . 20.0 m -59.92 144.27 86.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.747 179.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.04 103.11 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.861 2.374 . . . . 0.0 112.939 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.529 ' HA ' ' O ' ' A' ' 17' ' ' VAL . 33.6 pt -62.32 -17.2 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.118 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.2 tp -65.82 -23.24 66.64 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.272 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.0 57.91 0.24 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 119.48 -1.343 . . . . 0.0 113.971 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.447 ' C ' HG21 ' A' ' 17' ' ' VAL . 3.6 t80 -165.41 -65.46 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.917 0.358 . . . . 0.0 110.275 178.48 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 13' ' ' ILE . 1.2 t -144.3 -178.23 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.707 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 16.4 t80 -172.6 154.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.453 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.0 m -68.0 166.3 16.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.807 0.337 . . . . 0.0 111.303 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.776 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 12.3 m -66.33 151.88 95.22 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.47 116.25 2.73 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 121.806 1.671 . . . . 0.0 111.758 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.18 -29.66 5.89 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.958 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.494 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.9 mt -106.15 147.17 29.32 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.434 HG21 HD12 ' A' ' 24' ' ' ILE . 22.9 pt -130.09 132.47 65.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.063 0.459 . . . . 0.0 111.473 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.2 t -64.1 140.77 58.9 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -140.68 -117.96 1.44 Allowed Glycine 0 CA--C 1.522 0.513 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.954 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 64.74 2.33 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.494 2.796 . . . . 0.0 113.814 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 3.8 m-85 67.02 13.1 9.35 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.8 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 m -150.46 159.26 4.85 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 1.006 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.5 t -89.29 154.06 20.4 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.529 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.3 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.042 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.068 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.67 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.5 p -91.98 134.17 35.04 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.038 0.447 . . . . 0.0 110.544 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -80.18 143.12 34.09 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.051 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.809 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 12.7 mtmt -67.98 149.48 49.68 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.857 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.6 tttt -51.81 -57.12 10.23 Favored 'General case' 0 C--O 1.213 -0.828 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.691 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 20.4 m95 -81.23 23.02 0.62 Allowed 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 112.689 -177.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.809 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 6.0 mm-40 -81.24 142.04 33.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 176.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -76.35 58.47 1.3 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.231 0.539 . . . . 0.0 110.462 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.19 75.57 5.73 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.452 0.644 . . . . 0.0 110.948 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.8 tt -61.81 -30.23 48.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.469 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 16' ' ' PHE . 15.5 m -68.5 134.11 90.85 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.017 179.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.714 ' HB2' HD23 ' A' ' 14' ' ' LEU . 45.6 Cg_endo -69.13 140.94 46.37 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 122.67 2.246 . . . . 0.0 112.566 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 65.3 mt -51.96 -42.76 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.882 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.764 HD11 ' H ' ' A' ' 14' ' ' LEU . 0.0 OUTLIER -83.83 33.24 0.48 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.064 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.17 -42.75 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 121.171 -0.538 . . . . 0.0 111.902 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.498 ' HB3' ' HB ' ' A' ' 11' ' ' VAL . 7.1 t80 -162.71 133.14 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.671 0.272 . . . . 0.0 110.416 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.499 ' CG1' ' H ' ' A' ' 18' ' ' TYR . 1.8 t 62.12 -173.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 123.59 0.756 . . . . 0.0 110.838 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.565 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 45.0 p90 -176.37 144.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.465 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 93.6 m -76.33 172.8 12.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.139 0.495 . . . . 0.0 111.824 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.67 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 21.2 m -72.64 154.23 91.44 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 177.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -51.62 115.16 1.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.801 1.667 . . . . 0.0 111.9 -179.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.25 -31.71 5.35 Favored Glycine 0 C--N 1.311 -0.81 0 CA-C-N 114.479 -1.237 . . . . 0.0 112.179 -178.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.532 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 44.4 mt -103.45 150.48 23.83 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.7 132.74 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.856 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.648 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 99.0 m -68.24 134.41 50.35 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.377 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.16 -84.02 0.05 OUTLIER Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.72 -0.753 . . . . 0.0 113.131 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.13 55.5 4.03 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 123.284 2.656 . . . . 0.0 112.966 -179.188 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.454 ' O ' HG11 ' A' ' 29' ' ' VAL . 1.8 m-85 64.74 12.42 7.62 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.36 -179.281 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.454 HG11 ' O ' ' A' ' 28' ' ' PHE . 20.4 m -151.77 167.45 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.857 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 15.0 t -89.38 153.19 21.05 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.016 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.458 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 34.9 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.852 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.005 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.803 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 15.7 p -88.74 143.09 27.15 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -115.2 -162.86 0.84 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.222 0.534 . . . . 0.0 112.251 -177.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.444 ' HZ1' ' CD ' ' A' ' 7' ' ' GLU . 24.6 mttp -80.65 150.05 29.57 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.123 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.763 ' HB2' HD12 ' A' ' 23' ' ' LEU . 29.0 tttt -57.39 -55.54 33.48 Favored 'General case' 0 C--O 1.211 -0.969 0 CA-C-O 121.514 0.673 . . . . 0.0 112.063 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.7 m95 -81.04 24.01 0.53 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.936 -1.103 . . . . 0.0 111.596 -178.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.444 ' CD ' ' HZ1' ' A' ' 4' ' ' LYS . 13.9 tp10 -77.47 134.44 38.36 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -77.71 67.04 3.53 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.7 p -60.41 -26.39 66.65 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.299 0.852 . . . . 0.0 113.299 -178.093 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.551 HD11 ' HD2' ' A' ' 28' ' ' PHE . 45.5 mm 65.27 84.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.654 0.74 . . . . 0.0 110.313 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.598 HG21 ' HB3' ' A' ' 25' ' ' CYS . 35.5 m -137.35 159.31 69.98 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.086 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -59.66 140.06 91.81 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.51 2.14 . . . . 0.0 111.495 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.1 tp -55.36 -22.6 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.97 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.618 ' H ' HD23 ' A' ' 14' ' ' LEU . 3.1 mm? -61.43 -30.42 70.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.077 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 118.96 139.09 5.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.404 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 21.6 t80 -162.99 133.65 4.66 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.469 ' H ' HG22 ' A' ' 17' ' ' VAL . 0.7 OUTLIER -73.41 169.71 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 121.038 0.447 . . . . 0.0 110.195 -179.477 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 24.4 t80 178.18 -44.6 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.861 179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.445 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 66.0 m -70.54 174.45 5.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.872 -1.058 . . . . 0.0 111.41 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.803 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -70.89 160.62 81.65 Favored Pre-proline 0 N--CA 1.445 -0.702 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.96 111.45 0.52 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.254 1.969 . . . . 0.0 112.056 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.31 -39.28 1.67 Allowed Glycine 0 C--N 1.309 -0.944 0 CA-C-N 113.847 -1.524 . . . . 0.0 111.659 -178.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.763 HD12 ' HB2' ' A' ' 5' ' ' LYS . 64.5 mt -111.17 145.46 38.61 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 120.535 0.207 . . . . 0.0 110.47 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.42 HD11 HG23 ' A' ' 24' ' ' ILE . 22.0 pt -138.91 140.4 38.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.957 0.408 . . . . 0.0 111.591 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.72 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 22.7 m -77.5 139.5 39.62 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.103 0.478 . . . . 0.0 111.445 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.91 -85.73 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.079 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -75.78 55.43 4.35 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.826 2.351 . . . . 0.0 112.793 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.551 ' HD2' HD11 ' A' ' 10' ' ' ILE . 12.4 m-85 63.95 15.2 9.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.889 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.4 m -147.25 164.33 7.02 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.72 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 6.7 t -90.51 150.92 21.58 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-O 120.931 0.396 . . . . 0.0 109.953 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.531 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 35.2 m . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.963 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.682 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.4 p -150.43 -149.45 0.3 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 123.05 0.219 . . . . 0.0 110.553 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.3 t -164.22 157.92 18.42 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.781 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 14.2 ttmt -64.35 146.75 53.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.599 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.864 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.1 tttt -52.13 -64.57 0.77 Allowed 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.671 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.0 m95 -80.5 27.35 0.35 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 111.151 -178.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.781 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.8 tp10 -95.93 138.49 33.49 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 41.9 t80 -62.41 119.18 8.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.209 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 71.4 m -73.79 87.64 1.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.422 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.748 HD11 ' H ' ' A' ' 10' ' ' ILE . 0.2 OUTLIER -65.92 -23.75 32.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.533 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.821 HG11 HG21 ' A' ' 17' ' ' VAL . 35.5 m -66.95 137.58 94.76 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.828 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.455 ' HD2' ' HB2' ' A' ' 16' ' ' PHE . 55.8 Cg_exo -53.24 121.66 9.82 Favored 'Trans proline' 0 C--O 1.24 0.601 0 C-N-CA 122.777 2.318 . . . . 0.0 112.723 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 16.5 tt -55.54 -17.07 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.774 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.7 tp -55.43 -35.56 65.55 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.789 179.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.38 47.97 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.773 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.455 ' HB2' ' HD2' ' A' ' 12' ' ' PRO . 5.0 m-85 -108.74 131.91 54.47 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 122.696 -0.296 . . . . 0.0 110.539 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.821 HG21 HG11 ' A' ' 11' ' ' VAL . 2.5 t 61.47 -161.13 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.977 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.593 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 51.6 p90 -166.96 151.11 6.95 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.485 0.183 . . . . 0.0 110.545 -178.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.4 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -74.08 170.86 14.62 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.821 0.343 . . . . 0.0 110.506 178.425 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.682 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 6.4 m -66.45 151.82 95.56 Favored Pre-proline 0 C--N 1.327 -0.403 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.97 115.8 2.37 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 121.913 1.742 . . . . 0.0 112.219 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.73 -21.98 12.11 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.232 -178.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.662 HD13 ' HB2' ' A' ' 5' ' ' LYS . 45.2 mt -116.72 152.67 33.84 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.8 pt -142.15 135.59 28.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.69 0.281 . . . . 0.0 111.366 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.538 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 15.6 m -67.12 136.21 54.78 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.752 0.31 . . . . 0.0 110.964 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -135.71 -105.95 0.82 Allowed Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.204 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.13 60.24 3.11 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.249 2.632 . . . . 0.0 113.34 -179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.453 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.2 m-85 65.08 17.29 11.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.964 -179.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 28' ' ' PHE . 17.2 m -150.52 160.52 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 178.041 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.864 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.53 151.18 22.68 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.547 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 23.3 m . . . . . 0 C--O 1.244 0.802 0 CA-C-O 118.064 -0.97 . . . . 0.0 110.013 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.708 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.9 p -92.22 137.5 32.32 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 123.311 0.382 . . . . 0.0 110.548 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m -87.69 148.46 24.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.067 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.513 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 2.7 tmmm? -68.95 145.79 53.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.251 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.962 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 38.0 tttt -49.23 -68.52 0.17 Allowed 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -81.22 32.72 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.461 -0.774 . . . . 0.0 111.048 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.513 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.4 tp10 -86.91 -119.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.158 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.467 ' H ' ' HB3' ' A' ' 7' ' ' GLU . 31.9 t80 -151.27 136.76 17.78 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 93.1 m -119.69 -178.77 3.7 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.375 -179.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.4 mt 68.06 50.54 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 CA-C-O 122.175 0.988 . . . . 0.0 109.734 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' CG1' ' HD2' ' A' ' 12' ' ' PRO . 17.4 t -132.06 142.26 44.46 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.482 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.459 ' HD2' ' CG1' ' A' ' 11' ' ' VAL . 4.3 Cg_endo -47.6 154.74 1.66 Allowed 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 123.448 2.765 . . . . 0.0 113.496 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.476 ' HA ' HG21 ' A' ' 17' ' ' VAL . 27.3 mm -46.83 -23.34 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.862 0.865 . . . . 0.0 113.091 -179.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 85.8 mt -57.27 -31.0 65.14 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 111.796 0.295 . . . . 0.0 111.796 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.76 151.67 13.73 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.336 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 63.29 48.55 3.58 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.663 0.744 . . . . 0.0 110.613 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.476 HG21 ' HA ' ' A' ' 13' ' ' ILE . 1.0 OUTLIER -90.66 -142.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.756 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.703 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 48.2 p90 -53.01 143.38 17.44 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.652 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.502 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 99.1 m -75.16 169.67 17.57 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.955 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.708 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 23.2 m -71.18 154.04 94.08 Favored Pre-proline 0 CA--C 1.515 -0.375 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.086 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -51.82 115.52 2.18 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 121.85 1.7 . . . . 0.0 111.896 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.02 -31.6 5.07 Favored Glycine 0 C--N 1.312 -0.805 0 CA-C-N 114.491 -1.231 . . . . 0.0 111.963 -178.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.664 HD11 ' HB2' ' A' ' 5' ' ' LYS . 46.7 mt -103.87 149.99 24.57 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.8 pt -136.15 133.57 50.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.042 0.448 . . . . 0.0 111.849 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 20.8 m -63.26 139.31 58.76 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.503 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.33 -118.62 1.6 Allowed Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.622 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.39 65.37 1.12 Allowed 'Trans proline' 0 N--CA 1.479 0.651 0 C-N-CA 123.657 2.905 . . . . 0.0 113.97 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 66.49 12.57 8.79 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 123.601 0.76 . . . . 0.0 110.875 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 m -150.13 161.33 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.962 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.7 t -89.41 152.45 21.48 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.537 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.8 m . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.083 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.23 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.723 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 21.4 p -121.08 137.1 54.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.06 0.457 . . . . 0.0 110.987 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.408 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 34.1 t -75.62 140.84 42.84 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.8 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.842 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -68.68 150.82 47.49 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.823 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.6 tttt -54.22 -66.24 0.43 Allowed 'General case' 0 C--O 1.214 -0.798 0 CA-C-O 121.153 0.502 . . . . 0.0 112.211 -178.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m95 -80.59 26.89 0.38 Allowed 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.282 -0.886 . . . . 0.0 111.039 -178.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.842 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 12.4 tp10 -84.67 136.23 33.83 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 177.634 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -74.88 77.55 2.13 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.4 ' C ' ' H ' ' A' ' 11' ' ' VAL . 7.3 p -72.41 59.96 0.44 Allowed 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.669 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.42 ' O ' HG12 ' A' ' 10' ' ' ILE . 15.0 tt -83.71 41.63 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-O 122.695 1.236 . . . . 0.0 109.17 178.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.718 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 0.2 OUTLIER -81.68 136.8 47.96 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.963 -179.255 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.81 150.93 83.24 Favored 'Trans proline' 0 N--CA 1.463 -0.278 0 C-N-CA 122.905 2.403 . . . . 0.0 111.941 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.567 ' HA ' ' HD2' ' A' ' 16' ' ' PHE . 0.2 OUTLIER -54.13 -23.5 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.467 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.496 HD23 ' H ' ' A' ' 14' ' ' LEU . 3.0 mm? -61.63 -29.13 69.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.77 0.319 . . . . 0.0 111.181 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.23 61.01 0.24 Allowed Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.718 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 0.3 OUTLIER -74.94 3.18 8.71 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.491 ' CG1' ' H ' ' A' ' 18' ' ' TYR . 2.1 t 55.11 -142.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.916 0.388 . . . . 0.0 110.459 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.636 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 51.5 p90 -163.66 145.95 9.6 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.307 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.453 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 35.1 m -75.58 171.24 14.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.792 0.329 . . . . 0.0 110.927 179.233 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.723 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 22.5 m -68.03 153.25 95.62 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.27 115.55 2.26 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.863 1.709 . . . . 0.0 111.89 -179.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.9 -26.0 9.13 Favored Glycine 0 C--N 1.312 -0.768 0 CA-C-N 114.429 -1.259 . . . . 0.0 112.231 -178.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.66 HD13 ' HB2' ' A' ' 5' ' ' LYS . 41.6 mt -107.41 149.53 27.79 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.703 0.252 . . . . 0.0 110.453 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.2 pt -137.79 131.41 42.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.9 0.381 . . . . 0.0 111.301 179.339 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.597 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 42.9 t -67.47 135.5 53.17 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.158 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -136.96 -106.07 0.77 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.869 -0.682 . . . . 0.0 113.054 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.44 60.51 2.66 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 123.389 2.726 . . . . 0.0 113.539 -179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.475 ' O ' HG11 ' A' ' 29' ' ' VAL . 2.4 m-85 66.0 14.5 9.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.759 -179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.475 HG11 ' O ' ' A' ' 28' ' ' PHE . 19.3 m -151.15 155.77 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.823 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -88.86 154.68 20.06 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.454 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.2 m . . . . . 0 C--O 1.246 0.905 0 CA-C-O 117.915 -1.04 . . . . 0.0 109.972 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.712 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.3 p -88.99 -148.25 0.17 Allowed 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -169.44 152.88 4.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.838 0.29 . . . . 0.0 110.707 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.642 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 7.2 ttpt -64.29 146.22 54.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.678 179.101 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 1.01 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.9 tttt -51.4 -66.03 0.45 Allowed 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.211 0.529 . . . . 0.0 111.99 -179.032 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -82.04 33.61 0.39 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.882 -0.511 . . . . 0.0 110.839 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.642 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 7.2 tp10 -81.74 -123.93 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 1.9 t80 -166.5 56.4 0.09 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.9 p -60.35 -52.4 65.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.26 -178.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.66 ' HA ' ' HA ' ' A' ' 28' ' ' PHE . 67.7 mt 66.75 115.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 O-C-N 123.592 0.558 . . . . 0.0 111.516 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.5 m -85.51 125.37 69.66 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-O 120.875 0.369 . . . . 0.0 110.605 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.604 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 37.9 Cg_endo -68.7 138.48 41.49 Favored 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.466 2.111 . . . . 0.0 111.733 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.1 mm -52.26 -37.98 24.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.628 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.511 ' HA ' HD11 ' A' ' 14' ' ' LEU . 3.3 mm? -95.65 32.98 1.71 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.891 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 169.11 -142.5 7.4 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . 0.604 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 22.6 p90 -175.14 147.43 0.92 Allowed 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.403 ' CG1' ' H ' ' A' ' 18' ' ' TYR . 1.7 t -93.44 -171.77 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 179.483 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.403 ' H ' ' CG1' ' A' ' 17' ' ' VAL . 52.2 p90 -141.19 137.54 32.72 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.262 0.553 . . . . 0.0 110.49 179.291 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.511 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 11.3 m -95.65 -177.62 4.12 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.649 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.712 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.7 m -72.02 152.25 92.82 Favored Pre-proline 0 N--CA 1.448 -0.549 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -50.5 113.85 1.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.772 1.648 . . . . 0.0 112.275 -178.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.0 -28.5 5.85 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.606 -179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.518 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.8 mt -111.91 152.0 28.52 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.942 0.371 . . . . 0.0 111.053 -179.102 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.1 pt -130.85 133.2 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.002 0.43 . . . . 0.0 110.975 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 46.6 t -75.67 134.54 40.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.446 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.497 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -136.42 -108.29 0.9 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.841 -0.695 . . . . 0.0 113.407 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.497 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 16.4 Cg_exo -68.68 61.61 1.2 Allowed 'Trans proline' 0 N--CA 1.478 0.609 0 C-N-CA 123.99 3.127 . . . . 0.0 113.925 -178.666 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.66 ' HA ' ' HA ' ' A' ' 10' ' ' ILE . 2.2 m-85 65.73 13.04 8.73 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.734 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 m -149.98 160.75 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.332 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 1.01 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.7 t -89.73 153.17 20.91 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.538 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.0 m . . . . . 0 C--O 1.246 0.895 0 CA-C-O 118.105 -0.95 . . . . 0.0 109.927 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.112 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.691 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 17.6 p -95.44 139.22 32.03 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.578 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.4 t -80.81 145.17 31.56 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.387 -179.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.593 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -75.14 155.93 36.48 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.555 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.881 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.2 tttt -53.07 -66.66 0.35 Allowed 'General case' 0 C--O 1.217 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 112.217 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.0 m95 -81.31 27.29 0.42 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.574 -0.704 . . . . 0.0 110.914 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.593 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 37.4 tt0 -93.32 133.44 36.55 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -71.0 86.4 0.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.995 0.426 . . . . 0.0 112.124 -178.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.6 p -78.61 64.0 3.54 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.279 178.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.42 ' H ' HG13 ' A' ' 10' ' ' ILE . 1.6 pp -70.34 52.93 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.633 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.682 ' HB ' ' HA2' ' A' ' 15' ' ' GLY . 16.2 m -75.0 130.99 79.67 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 121.168 0.508 . . . . 0.0 111.401 179.715 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -81.72 156.32 18.38 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.888 2.392 . . . . 0.0 112.605 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.484 ' C ' ' H ' ' A' ' 15' ' ' GLY . 0.1 OUTLIER 41.06 -122.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.823 0.849 . . . . 0.0 113.18 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.8 mt -75.61 28.78 0.1 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.902 0.382 . . . . 0.0 111.631 -179.361 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.682 ' HA2' ' HB ' ' A' ' 11' ' ' VAL . . . 75.95 -149.76 38.32 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 121.175 -0.536 . . . . 0.0 113.117 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 24.6 t80 179.39 -51.52 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.562 ' H ' HG12 ' A' ' 11' ' ' VAL . 1.9 t -93.82 -170.91 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.25 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.668 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.7 p90 -157.34 146.29 19.83 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . 0.427 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 64.0 m -76.76 169.28 18.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.821 0.344 . . . . 0.0 111.368 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.691 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 17.3 m -69.34 153.9 95.43 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.756 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.16 116.05 2.56 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 121.76 1.64 . . . . 0.0 111.742 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.19 -27.27 8.65 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.187 -178.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.829 HD21 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -102.83 150.32 23.61 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.5 pt -135.68 131.2 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.052 0.453 . . . . 0.0 111.617 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . 0.563 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.6 t -68.78 137.58 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.041 179.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.26 -109.33 0.92 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.102 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.89 61.21 2.34 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 123.441 2.76 . . . . 0.0 113.543 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.41 ' O ' HG13 ' A' ' 29' ' ' VAL . 2.1 m-85 65.75 15.78 10.2 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 123.667 0.787 . . . . 0.0 110.658 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 28' ' ' PHE . 18.7 m -151.79 155.85 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 178.079 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' CYS . . . . . 0.881 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 7.0 t -88.33 158.27 18.48 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.406 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.6 m . . . . . 0 C--O 1.248 0.984 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.129 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.8 p . . . . . 0 C--O 1.234 0.262 0 CA-C-O 121.042 0.448 . . . . 0.0 110.642 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.2 m -76.87 143.37 39.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.137 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.776 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.1 mttp -79.87 152.48 29.63 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 1.036 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.8 tttt -47.4 -72.58 0.05 Allowed 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 113.716 1.006 . . . . 0.0 113.716 -177.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.411 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.8 m95 -82.41 33.34 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.326 -0.859 . . . . 0.0 110.728 -178.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.776 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 27.0 tt0 . . . . . 0 C--N 1.33 -0.244 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.951 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.515 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 62.7 m . . . . . 0 CA--C 1.517 -0.306 0 CA-C-O 120.811 0.339 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 24.8 m -68.23 153.42 95.52 Favored Pre-proline 0 C--N 1.327 -0.39 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_exo -51.53 114.51 1.6 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.808 1.672 . . . . 0.0 112.033 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.13 -31.38 4.93 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.396 -1.275 . . . . 0.0 112.185 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.538 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.0 mt -105.3 149.33 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.673 0.237 . . . . 0.0 110.443 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.412 HD13 ' N ' ' A' ' 24' ' ' ILE . 0.2 OUTLIER -130.43 135.12 61.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.984 0.421 . . . . 0.0 111.216 179.687 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.7 m -61.75 148.03 44.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.636 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.77 -126.3 1.8 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.633 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.21 68.02 1.39 Allowed 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 123.506 2.804 . . . . 0.0 113.722 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.47 22.1 11.86 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 123.33 0.652 . . . . 0.0 110.858 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.3 m -150.13 -160.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -133.87 156.72 47.57 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.6 m . . . . . 0 C--O 1.246 0.871 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.143 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.0 p . . . . . 0 N--CA 1.454 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 109.992 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.56 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 16.9 m -76.94 143.98 39.14 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.092 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.83 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.4 mttp -77.73 150.74 34.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.852 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.9 tttt -50.31 -66.9 0.31 Allowed 'General case' 0 C--O 1.218 -0.605 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -177.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -82.01 29.14 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.316 -0.865 . . . . 0.0 111.085 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.83 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 38.6 tt0 . . . . . 0 C--N 1.328 -0.363 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.56 ' HA ' ' H ' ' A' ' 3' ' ' SER . 65.8 m . . . . . 0 N--CA 1.452 -0.369 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.754 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 25.1 m -68.07 152.78 96.19 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.26 112.72 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 121.863 1.709 . . . . 0.0 112.303 -178.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.22 -29.46 5.51 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.299 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.53 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 33.4 mt -105.12 148.85 26.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.788 0.294 . . . . 0.0 110.642 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.6 pt -137.74 135.52 45.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.813 0.34 . . . . 0.0 111.616 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 m -62.09 145.82 52.17 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.39 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -149.48 -110.78 0.55 Allowed Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.594 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.99 63.67 3.3 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.419 2.746 . . . . 0.0 113.716 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 64.26 20.65 12.26 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 123.408 0.683 . . . . 0.0 111.059 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 m -151.12 -164.84 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.852 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 10.5 t -124.52 156.24 37.63 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.425 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.245 0.867 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.23 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.741 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 22.8 p . . . . . 0 N--CA 1.453 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.0 m -79.13 150.13 31.84 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.605 -178.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.693 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 6.6 ttpm? -65.81 145.48 55.91 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.326 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.964 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.1 tttt -50.6 -66.08 0.45 Allowed 'General case' 0 C--O 1.217 -0.636 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.9 m95 -80.8 32.47 0.31 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.328 -0.857 . . . . 0.0 110.728 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.693 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 31.7 tt0 . . . . . 0 C--N 1.324 -0.543 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.087 178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.47 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 95.0 m . . . . . 0 C--O 1.233 0.211 0 CA-C-O 121.04 0.448 . . . . 0.0 112.172 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.741 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 8.8 m -69.43 152.94 96.24 Favored Pre-proline 0 CA--C 1.517 -0.325 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.18 116.31 2.73 Favored 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 121.679 1.586 . . . . 0.0 111.723 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.91 -31.22 5.41 Favored Glycine 0 C--N 1.312 -0.788 0 CA-C-N 114.563 -1.199 . . . . 0.0 111.862 -178.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.676 HD13 ' HB2' ' A' ' 5' ' ' LYS . 59.1 mt -106.22 151.71 24.44 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.0 pt -142.76 135.22 25.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.892 0.377 . . . . 0.0 111.823 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 33.1 m -64.31 134.65 55.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.793 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.418 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -135.42 -100.99 0.64 Allowed Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.356 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.418 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 8.2 Cg_exo -72.13 58.52 2.88 Favored 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 123.611 2.874 . . . . 0.0 113.052 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 64.23 16.06 9.81 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.738 -179.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.8 m -150.11 163.02 3.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.964 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 9.1 t -88.56 151.92 22.19 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.96 0.409 . . . . 0.0 110.292 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.4 m . . . . . 0 C--O 1.246 0.919 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.847 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.714 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.2 p . . . . . 0 N--CA 1.455 -0.181 0 CA-C-O 121.012 0.434 . . . . 0.0 110.671 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -82.97 142.72 31.17 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.769 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.526 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 36.1 mtmm -70.75 157.53 37.89 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.984 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.2 tttt -50.93 -66.33 0.4 Allowed 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -81.72 31.47 0.36 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.694 -0.629 . . . . 0.0 111.264 -178.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 7.0 tp10 . . . . . 0 CA--C 1.534 0.327 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.478 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 97.7 m . . . . . 0 CA--C 1.519 -0.246 0 CA-C-O 120.863 0.364 . . . . 0.0 111.46 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.714 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 33.2 m -70.02 153.23 95.54 Favored Pre-proline 0 C--N 1.326 -0.432 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.56 115.49 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 121.807 1.671 . . . . 0.0 111.932 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 -31.6 4.99 Favored Glycine 0 C--N 1.312 -0.801 0 CA-C-N 114.422 -1.263 . . . . 0.0 112.076 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.514 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 49.3 mt -105.4 150.09 25.55 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.434 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -134.88 131.7 53.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.058 0.456 . . . . 0.0 111.525 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 30.9 t -65.18 140.32 58.75 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.741 179.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.76 -105.7 0.52 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.037 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.53 61.24 2.79 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.374 2.716 . . . . 0.0 113.735 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.75 11.64 8.35 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.691 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 m -150.43 162.41 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.984 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 6.3 t -89.59 155.13 19.46 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.453 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 22.8 m . . . . . 0 C--O 1.247 0.93 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.89 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.713 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.1 p . . . . . 0 N--CA 1.453 -0.286 0 CA-C-O 121.056 0.455 . . . . 0.0 110.625 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -75.51 143.71 42.38 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.359 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.495 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 7.3 ttpm? -64.08 146.47 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.493 178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.659 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.2 tttt -52.9 -57.52 9.99 Favored 'General case' 0 C--O 1.213 -0.836 0 CA-C-O 121.326 0.584 . . . . 0.0 112.282 -178.75 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -81.13 28.32 0.37 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 111.568 -178.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 3.8 tp10 . . . . . 0 C--N 1.33 -0.264 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 177.386 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 96.7 m . . . . . 0 C--O 1.233 0.235 0 CA-C-O 121.077 0.465 . . . . 0.0 112.078 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.713 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 16.6 m -68.46 154.03 94.9 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -51.49 115.6 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 121.813 1.676 . . . . 0.0 111.694 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.99 -31.36 5.71 Favored Glycine 0 C--N 1.311 -0.847 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.905 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.588 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 38.0 mt -101.04 148.62 24.83 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.5 pt -141.67 133.4 27.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.94 0.4 . . . . 0.0 111.486 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 72.2 m -60.26 137.95 58.03 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.55 179.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.6 -110.91 0.76 Allowed Glycine 0 CA--C 1.522 0.531 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.456 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.14 63.07 1.43 Allowed 'Trans proline' 0 N--CA 1.479 0.635 0 C-N-CA 123.609 2.872 . . . . 0.0 114.207 -178.65 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.64 11.74 8.35 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.604 0.762 . . . . 0.0 110.787 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 7' ' ' GLU . 18.6 m -151.94 162.74 2.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.133 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.659 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 24.9 t -89.54 156.01 18.91 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.3 m . . . . . 0 C--N 1.317 -0.832 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.124 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.745 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p . . . . . 0 N--CA 1.453 -0.307 0 CA-C-O 120.984 0.421 . . . . 0.0 110.809 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 m -71.42 141.82 50.29 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.146 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.659 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 4.3 ttmp? -71.77 142.5 49.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.536 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.955 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 37.8 tttt -47.94 -68.61 0.17 Allowed 'General case' 0 C--O 1.218 -0.602 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -177.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -81.74 35.05 0.4 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.269 -0.894 . . . . 0.0 110.299 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 22.6 tt0 . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.429 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.587 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 67.4 m . . . . . 0 CA--C 1.52 -0.182 0 CA-C-O 121.075 0.464 . . . . 0.0 111.57 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.745 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 13.9 m -67.9 153.52 95.11 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_exo -51.65 115.57 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.841 1.694 . . . . 0.0 111.71 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.4 -30.43 6.0 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 114.376 -1.283 . . . . 0.0 111.922 -178.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.587 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 49.5 mt -101.18 147.18 26.56 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.8 pt -130.28 132.97 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 111.509 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 74.0 m -58.93 140.01 55.98 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.118 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.41 -130.22 2.7 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.934 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -66.69 70.5 0.48 Allowed 'Trans proline' 0 N--CA 1.479 0.627 0 C-N-CA 123.823 3.015 . . . . 0.0 113.845 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 64.47 21.4 12.45 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.333 0.653 . . . . 0.0 110.684 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -150.32 -155.88 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.955 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 11.6 t -140.3 155.64 46.75 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.3 m . . . . . 0 C--O 1.245 0.857 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.227 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.775 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.8 p . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.185 0.517 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.0 p -76.51 142.36 40.92 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.822 -178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.489 ' HE3' ' N ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -75.02 157.01 35.6 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.297 178.895 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.981 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 31.2 tttt -49.35 -71.71 0.06 Allowed 'General case' 0 C--O 1.216 -0.663 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -80.6 31.39 0.29 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.254 -0.904 . . . . 0.0 110.542 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.488 ' OE1' ' HE3' ' A' ' 4' ' ' LYS . 27.8 tt0 . . . . . 0 C--N 1.324 -0.501 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.023 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 76.4 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.775 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 7.8 m -64.67 151.63 91.78 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -51.47 114.6 1.64 Allowed 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 121.748 1.632 . . . . 0.0 111.959 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.56 -35.6 2.75 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.165 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.567 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 69.5 mt -102.27 149.79 23.96 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.637 0.218 . . . . 0.0 110.526 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.6 pt -125.71 131.43 71.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.159 0.504 . . . . 0.0 111.543 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 45.9 t -69.67 141.65 53.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.632 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -138.57 -117.54 1.53 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.986 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.46 63.51 2.2 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.48 2.787 . . . . 0.0 113.698 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 66.29 15.65 10.17 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.766 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.02 155.18 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 177.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.981 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.02 159.51 17.56 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 120.897 0.379 . . . . 0.0 110.54 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 m . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.202 -0.904 . . . . 0.0 109.806 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.2 p . . . . . 0 N--CA 1.453 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.0 m -81.36 148.81 29.17 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.844 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.629 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 19.7 mtpt -65.46 151.05 47.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.703 179.109 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.936 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.5 tttt -52.24 -65.02 0.63 Allowed 'General case' 0 C--O 1.214 -0.804 0 N-CA-C 112.824 0.675 . . . . 0.0 112.824 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.7 m95 -80.77 27.73 0.36 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.368 -0.833 . . . . 0.0 111.123 -178.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.629 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 2.3 tp10 . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.3 m . . . . . 0 CA--C 1.521 -0.151 0 CA-C-O 120.665 0.269 . . . . 0.0 110.672 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.8 OUTLIER -69.78 156.32 91.94 Favored Pre-proline 0 C--N 1.326 -0.419 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.032 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.14 114.66 1.84 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.177 1.918 . . . . 0.0 111.584 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.18 -35.25 2.76 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 114.259 -1.337 . . . . 0.0 111.84 -178.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.555 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 2.5 mm? -112.59 150.02 31.95 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.1 pt -138.69 134.11 42.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.781 0.325 . . . . 0.0 111.169 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.632 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 37.1 t -65.8 139.59 58.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.787 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -142.93 -97.92 0.27 Allowed Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.7 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.38 58.76 3.77 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.151 2.567 . . . . 0.0 113.498 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 65.14 14.34 9.32 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.837 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.61 163.76 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.936 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.3 t -89.15 150.72 22.57 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 29.2 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.018 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.728 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 27.9 p . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.247 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -83.57 150.93 25.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.393 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.844 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 22.5 mtmt -65.51 157.37 29.8 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.869 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.5 tttt -49.8 -61.33 2.19 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 113.982 1.105 . . . . 0.0 113.982 -177.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -80.9 25.57 0.45 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 112.186 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.844 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 70.0 mm-40 . . . . . 0 C--N 1.329 -0.295 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 177.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.52 -0.177 0 CA-C-O 120.665 0.269 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.728 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.5 OUTLIER -72.19 157.03 90.03 Favored Pre-proline 0 CA--C 1.513 -0.45 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.558 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -53.0 114.19 1.61 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.211 1.94 . . . . 0.0 111.664 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.35 -36.06 2.46 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 114.192 -1.367 . . . . 0.0 111.662 -178.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.504 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 71.4 mt -108.25 148.26 30.23 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.9 pt -129.35 131.87 67.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.809 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.514 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.1 t -67.24 138.53 56.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.499 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.1 -116.9 1.57 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.946 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 63.74 1.94 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.549 2.833 . . . . 0.0 113.559 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 65.72 16.58 10.55 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.678 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 m -151.54 154.1 8.79 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.869 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.65 155.82 19.38 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.512 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.6 m . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.121 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.712 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.6 p . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.2 t -169.21 164.25 11.01 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.0 0.364 . . . . 0.0 110.446 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.573 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 30.1 mtmm -69.95 151.84 45.15 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.227 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.792 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.4 tttt -54.3 -60.79 2.86 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -80.85 26.07 0.43 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.47 -0.769 . . . . 0.0 111.206 -178.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.573 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.493 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.1 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.087 0.47 . . . . 0.0 111.454 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.712 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.1 m -70.5 151.05 95.63 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -49.69 113.35 0.94 Allowed 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.745 1.63 . . . . 0.0 112.139 -178.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.92 -33.47 3.53 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.497 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.4 mt -104.98 146.45 29.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.564 0.221 . . . . 0.0 110.628 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.3 pt -133.27 133.61 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.972 0.415 . . . . 0.0 111.224 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 51.6 m -66.77 140.0 57.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.98 0.419 . . . . 0.0 111.515 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.35 -112.6 1.14 Allowed Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.198 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.62 62.8 2.27 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.367 2.711 . . . . 0.0 113.704 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 65.4 15.8 10.21 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 123.617 0.767 . . . . 0.0 110.976 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.18 160.33 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.792 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 3.4 t -89.33 156.14 18.91 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.926 0.393 . . . . 0.0 110.158 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.6 m . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.905 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.785 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.9 p . . . . . 0 N--CA 1.455 -0.176 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.427 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 31.0 m -84.97 153.81 22.55 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.151 -179.068 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.596 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -66.16 160.11 24.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.267 179.065 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.943 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.1 tttt -52.05 -63.69 1.06 Allowed 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 -178.442 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -82.02 31.63 0.38 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.781 -0.574 . . . . 0.0 111.153 -178.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.596 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.534 0.35 0 CA-C-O 121.232 0.539 . . . . 0.0 110.006 178.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 94.7 m . . . . . 0 C--O 1.233 0.233 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.785 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 4.5 m -62.64 152.41 81.46 Favored Pre-proline 0 N--CA 1.452 -0.338 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -50.85 115.18 1.84 Allowed 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 121.784 1.656 . . . . 0.0 111.847 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.14 -35.32 3.4 Favored Glycine 0 C--N 1.312 -0.774 0 CA-C-N 114.388 -1.278 . . . . 0.0 111.935 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.612 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 5.2 mp -98.9 147.88 24.52 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 pt -132.74 132.33 59.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.105 0.479 . . . . 0.0 111.766 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.7 t -68.82 143.93 54.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.314 179.477 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.434 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -144.59 -109.43 0.65 Allowed Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.929 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.434 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.5 Cg_exo -70.52 61.87 2.17 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.724 2.949 . . . . 0.0 113.525 -178.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 65.79 13.89 9.24 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.565 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 m -150.35 161.04 4.2 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.943 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.3 155.85 19.11 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.877 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.828 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.8 p . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -76.22 146.89 38.74 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.321 -179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.856 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 28.5 mtpt -66.75 148.65 51.64 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.945 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.6 tttt -51.37 -66.06 0.45 Allowed 'General case' 0 C--O 1.218 -0.565 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.613 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 10.3 m95 -80.92 29.32 0.33 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.802 -0.561 . . . . 0.0 110.94 -179.267 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.856 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 13.8 tp10 . . . . . 0 C--N 1.326 -0.451 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.403 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.554 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 92.9 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.801 0.334 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.828 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -68.89 156.6 90.98 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -52.12 113.08 1.03 Allowed 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.095 1.863 . . . . 0.0 111.629 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.84 -34.93 2.87 Favored Glycine 0 C--N 1.311 -0.857 0 CA-C-N 114.114 -1.403 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.554 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 54.6 mt -103.95 139.95 38.39 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.703 0.252 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 21.1 pt -127.31 133.09 68.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.999 0.428 . . . . 0.0 111.573 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -63.4 139.43 58.77 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.7 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.423 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -140.97 -117.22 1.35 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.967 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.0 Cg_exo -70.96 62.68 2.46 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 123.727 2.951 . . . . 0.0 113.222 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.7 16.16 10.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.496 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.4 m -151.15 155.47 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.132 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.945 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 1.8 t -89.52 153.87 20.46 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.515 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.9 m . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.98 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.784 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.3 t -85.21 143.3 28.85 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.613 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.644 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 5.1 ttpm? -66.48 153.37 43.04 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.022 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 1.047 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 36.2 tttt -50.54 -68.59 0.16 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.447 0.536 . . . . 0.0 112.447 -178.516 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.41 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.9 m95 -82.1 32.04 0.38 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.75 -0.593 . . . . 0.0 110.657 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.644 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 2.6 tp10 . . . . . 0 C--N 1.33 -0.253 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.305 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.477 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.0 m . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.807 0.337 . . . . 0.0 111.303 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.784 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 12.3 m -66.33 151.88 95.22 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.47 116.25 2.73 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 121.806 1.671 . . . . 0.0 111.758 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.18 -29.66 5.89 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.958 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.511 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.9 mt -106.15 147.17 29.32 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.9 pt -130.09 132.47 65.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.063 0.459 . . . . 0.0 111.473 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.2 t -64.1 140.77 58.9 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -140.68 -117.96 1.44 Allowed Glycine 0 CA--C 1.522 0.513 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.954 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 64.74 2.33 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.494 2.796 . . . . 0.0 113.814 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 67.02 13.1 9.35 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.8 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 m -150.46 159.26 4.85 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.358 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 1.047 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.5 t -89.29 154.06 20.4 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.52 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.3 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.042 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.672 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.5 p . . . . . 0 N--CA 1.454 -0.27 0 CA-C-O 121.038 0.447 . . . . 0.0 110.544 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -80.18 143.12 34.09 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.051 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.814 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 12.7 mtmt -67.98 149.48 49.68 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.419 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.879 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.6 tttt -51.81 -57.12 10.23 Favored 'General case' 0 C--O 1.213 -0.828 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.691 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 20.4 m95 -81.23 23.02 0.62 Allowed 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 112.689 -177.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.814 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 6.0 mm-40 . . . . . 0 CA--C 1.518 -0.286 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.471 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 93.6 m . . . . . 0 CA--C 1.519 -0.226 0 CA-C-O 121.139 0.495 . . . . 0.0 111.824 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.672 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 21.2 m -72.64 154.23 91.44 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 177.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -51.62 115.16 1.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.801 1.667 . . . . 0.0 111.9 -179.509 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.25 -31.71 5.35 Favored Glycine 0 C--N 1.311 -0.81 0 CA-C-N 114.479 -1.237 . . . . 0.0 112.179 -178.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.618 HD13 ' HB2' ' A' ' 5' ' ' LYS . 44.4 mt -103.45 150.48 23.83 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -143.7 132.74 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.856 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.662 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 99.0 m -68.24 134.41 50.35 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.377 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.16 -84.02 0.05 OUTLIER Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.72 -0.753 . . . . 0.0 113.131 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.13 55.5 4.03 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 123.284 2.656 . . . . 0.0 112.966 -179.188 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 64.74 12.42 7.62 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.36 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.4 m -151.77 167.45 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.879 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 15.0 t -89.38 153.19 21.05 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.016 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.446 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 34.9 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.852 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.813 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 15.7 p . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -115.2 -162.86 0.84 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.222 0.534 . . . . 0.0 112.251 -177.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -80.65 150.05 29.57 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.123 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.691 ' HB2' HD13 ' A' ' 23' ' ' LEU . 29.0 tttt -57.39 -55.54 33.48 Favored 'General case' 0 C--O 1.211 -0.969 0 CA-C-O 121.514 0.673 . . . . 0.0 112.063 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.7 m95 -81.04 24.01 0.53 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.936 -1.103 . . . . 0.0 111.596 -178.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 . . . . . 0 C--O 1.235 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.857 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 66.0 m . . . . . 0 CA--C 1.515 -0.383 0 CA-C-O 121.185 0.517 . . . . 0.0 111.41 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.813 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -70.89 160.62 81.65 Favored Pre-proline 0 N--CA 1.445 -0.702 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.96 111.45 0.52 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.254 1.969 . . . . 0.0 112.056 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.31 -39.28 1.67 Allowed Glycine 0 C--N 1.309 -0.944 0 CA-C-N 113.847 -1.524 . . . . 0.0 111.659 -178.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 5' ' ' LYS . 64.5 mt -111.17 145.46 38.61 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 120.535 0.207 . . . . 0.0 110.47 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.0 pt -138.91 140.4 38.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.957 0.408 . . . . 0.0 111.591 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.733 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 22.7 m -77.5 139.5 39.62 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.103 0.478 . . . . 0.0 111.445 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.91 -85.73 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.079 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -75.78 55.43 4.35 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.826 2.351 . . . . 0.0 112.793 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 63.95 15.2 9.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.889 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.4 m -147.25 164.33 7.02 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.733 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 6.7 t -90.51 150.92 21.58 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-O 120.931 0.396 . . . . 0.0 109.953 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.519 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 35.2 m . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.963 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.694 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.4 p . . . . . 0 N--CA 1.456 -0.168 0 N-CA-C 110.553 -0.166 . . . . 0.0 110.553 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.3 t -164.22 157.92 18.42 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.794 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 14.2 ttmt -64.35 146.75 53.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.599 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.878 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.1 tttt -52.13 -64.57 0.77 Allowed 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.671 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.0 m95 -80.5 27.35 0.35 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 111.151 -178.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.8 tp10 . . . . . 0 N--CA 1.451 -0.409 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.423 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.821 0.343 . . . . 0.0 110.506 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.694 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 6.4 m -66.45 151.82 95.56 Favored Pre-proline 0 C--N 1.327 -0.403 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.97 115.8 2.37 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 121.913 1.742 . . . . 0.0 112.219 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.73 -21.98 12.11 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.232 -178.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.52 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 45.2 mt -116.72 152.67 33.84 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.8 pt -142.15 135.59 28.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.69 0.281 . . . . 0.0 111.366 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 15.6 m -67.12 136.21 54.78 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.752 0.31 . . . . 0.0 110.964 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -135.71 -105.95 0.82 Allowed Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.204 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.13 60.24 3.11 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.249 2.632 . . . . 0.0 113.34 -179.652 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 65.08 17.29 11.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.964 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.52 160.52 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 178.041 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.878 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.53 151.18 22.68 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.54 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 23.3 m . . . . . 0 C--O 1.244 0.802 0 CA-C-O 118.064 -0.97 . . . . 0.0 110.013 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.717 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.9 p . . . . . 0 N--CA 1.455 -0.198 0 CA-C-O 120.807 0.337 . . . . 0.0 110.548 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m -87.69 148.46 24.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.067 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.514 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 2.7 tmmm? -68.95 145.79 53.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.251 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.966 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 38.0 tttt -49.23 -68.52 0.17 Allowed 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' TRP . . . . . 0.409 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 8.5 m95 -81.22 32.72 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.461 -0.774 . . . . 0.0 111.048 -178.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.4 tp10 . . . . . 0 C--N 1.33 -0.272 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 99.1 m . . . . . 0 CA--C 1.519 -0.218 0 CA-C-O 121.116 0.484 . . . . 0.0 111.955 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.717 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 23.2 m -71.18 154.04 94.08 Favored Pre-proline 0 CA--C 1.515 -0.375 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.086 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -51.82 115.52 2.18 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 121.85 1.7 . . . . 0.0 111.896 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.02 -31.6 5.07 Favored Glycine 0 C--N 1.312 -0.805 0 CA-C-N 114.491 -1.231 . . . . 0.0 111.963 -178.67 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 46.7 mt -103.87 149.99 24.57 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.8 pt -136.15 133.57 50.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.042 0.448 . . . . 0.0 111.849 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 20.8 m -63.26 139.31 58.76 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.503 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.33 -118.62 1.6 Allowed Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.622 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.39 65.37 1.12 Allowed 'Trans proline' 0 N--CA 1.479 0.651 0 C-N-CA 123.657 2.905 . . . . 0.0 113.97 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 66.49 12.57 8.79 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 123.601 0.76 . . . . 0.0 110.875 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 m -150.13 161.33 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.966 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.7 t -89.41 152.45 21.48 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.531 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.8 m . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.083 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.733 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 21.4 p . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 121.06 0.457 . . . . 0.0 110.987 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.484 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 34.1 t -75.62 140.84 42.84 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.8 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.852 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -68.68 150.82 47.49 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.6 tttt -54.22 -66.24 0.43 Allowed 'General case' 0 C--O 1.214 -0.798 0 CA-C-O 121.153 0.502 . . . . 0.0 112.211 -178.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m95 -80.59 26.89 0.38 Allowed 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.282 -0.886 . . . . 0.0 111.039 -178.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.852 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 12.4 tp10 . . . . . 0 C--O 1.235 0.308 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 177.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.484 ' HA ' ' H ' ' A' ' 3' ' ' SER . 35.1 m . . . . . 0 CA--C 1.52 -0.191 0 CA-C-O 120.792 0.329 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.733 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 22.5 m -68.03 153.25 95.62 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.27 115.55 2.26 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.863 1.709 . . . . 0.0 111.89 -179.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.9 -26.0 9.13 Favored Glycine 0 C--N 1.312 -0.768 0 CA-C-N 114.429 -1.259 . . . . 0.0 112.231 -178.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.55 HD13 ' HB2' ' A' ' 5' ' ' LYS . 41.6 mt -107.41 149.53 27.79 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.703 0.252 . . . . 0.0 110.453 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.2 pt -137.79 131.41 42.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.9 0.381 . . . . 0.0 111.301 179.339 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.596 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 42.9 t -67.47 135.5 53.17 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.158 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -136.96 -106.07 0.77 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.869 -0.682 . . . . 0.0 113.054 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.44 60.51 2.66 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 123.389 2.726 . . . . 0.0 113.539 -179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 66.0 14.5 9.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.759 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.3 m -151.15 155.77 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.808 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -88.86 154.68 20.06 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.443 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.2 m . . . . . 0 C--O 1.246 0.905 0 CA-C-O 117.915 -1.04 . . . . 0.0 109.972 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.725 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.3 p . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -169.44 152.88 4.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.838 0.29 . . . . 0.0 110.707 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.638 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 7.2 ttpt -64.29 146.22 54.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.678 179.101 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 1.05 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.9 tttt -51.4 -66.03 0.45 Allowed 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.211 0.529 . . . . 0.0 111.99 -179.032 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -82.04 33.61 0.39 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.882 -0.511 . . . . 0.0 110.839 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.638 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 7.2 tp10 . . . . . 0 CA--C 1.534 0.357 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.538 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 11.3 m . . . . . 0 CA--C 1.514 -0.436 0 CA-C-O 120.783 0.325 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.725 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.7 m -72.02 152.25 92.82 Favored Pre-proline 0 N--CA 1.448 -0.549 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -50.5 113.85 1.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.772 1.648 . . . . 0.0 112.275 -178.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.0 -28.5 5.85 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.606 -179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.534 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.8 mt -111.91 152.0 28.52 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.942 0.371 . . . . 0.0 111.053 -179.102 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.1 pt -130.85 133.2 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.002 0.43 . . . . 0.0 110.975 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.576 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 46.6 t -75.67 134.54 40.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.446 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.508 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -136.42 -108.29 0.9 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.841 -0.695 . . . . 0.0 113.407 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.508 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 16.4 Cg_exo -68.68 61.61 1.2 Allowed 'Trans proline' 0 N--CA 1.478 0.609 0 C-N-CA 123.99 3.127 . . . . 0.0 113.925 -178.666 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 65.73 13.04 8.73 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.734 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 m -149.98 160.75 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.332 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 1.05 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.7 t -89.73 153.17 20.91 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.53 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.0 m . . . . . 0 C--O 1.246 0.895 0 CA-C-O 118.105 -0.95 . . . . 0.0 109.927 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.702 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 17.6 p . . . . . 0 N--CA 1.454 -0.259 0 CA-C-O 120.843 0.354 . . . . 0.0 110.578 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.435 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 9.4 t -80.81 145.17 31.56 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.387 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.604 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -75.14 155.93 36.48 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.555 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.891 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.2 tttt -53.07 -66.66 0.35 Allowed 'General case' 0 C--O 1.217 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 112.217 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.0 m95 -81.31 27.29 0.42 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.574 -0.704 . . . . 0.0 110.914 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.604 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 37.4 tt0 . . . . . 0 C--N 1.329 -0.322 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' CYS . . . . . 0.447 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 64.0 m . . . . . 0 CA--C 1.519 -0.226 0 CA-C-O 120.821 0.344 . . . . 0.0 111.368 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.702 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 17.3 m -69.34 153.9 95.43 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.16 116.05 2.56 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 121.76 1.64 . . . . 0.0 111.742 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.19 -27.27 8.65 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.187 -178.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.613 HD23 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -102.83 150.32 23.61 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.5 pt -135.68 131.2 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.052 0.453 . . . . 0.0 111.617 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' CYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.6 t -68.78 137.58 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.041 179.628 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.26 -109.33 0.92 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.102 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.89 61.21 2.34 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 123.441 2.76 . . . . 0.0 113.543 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 65.75 15.78 10.2 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 123.667 0.787 . . . . 0.0 110.658 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.79 155.85 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' CYS . . . . . 0.891 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 7.0 t -88.33 158.27 18.48 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.6 m . . . . . 0 C--O 1.248 0.984 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.129 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.8 p -89.61 132.0 35.33 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.042 0.448 . . . . 0.0 110.642 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.2 m -76.87 143.37 39.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.137 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.776 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.1 mttp -79.87 152.48 29.63 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 1.036 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.8 tttt -47.4 -72.58 0.05 Allowed 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 113.716 1.006 . . . . 0.0 113.716 -177.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.411 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.8 m95 -82.41 33.34 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.326 -0.859 . . . . 0.0 110.728 -178.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.776 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 27.0 tt0 -96.17 -125.89 0.13 Allowed 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.951 179.113 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -142.17 131.65 23.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.88 0.372 . . . . 0.0 110.559 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.478 ' SG ' ' HB ' ' A' ' 17' ' ' VAL . 42.1 t -165.04 123.14 1.65 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.42 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.467 ' C ' ' HD3' ' A' ' 12' ' ' PRO . 14.7 tt -107.67 143.99 17.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.26 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.693 ' HA ' ' HB3' ' A' ' 16' ' ' PHE . 5.7 m -120.28 67.43 12.87 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -178.704 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.543 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 12.1 Cg_exo -69.18 137.65 37.67 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.486 2.124 . . . . 0.0 111.385 178.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 13.9 pt -69.52 67.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-O 121.614 0.721 . . . . 0.0 112.126 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.439 HD13 ' O ' ' A' ' 14' ' ' LEU . 1.7 tm? -173.4 -32.31 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.543 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . -179.72 135.47 2.51 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.405 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.693 ' HB3' ' HA ' ' A' ' 11' ' ' VAL . 1.8 p90 -146.64 166.22 27.2 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 117.203 0.501 . . . . 0.0 111.704 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.759 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.7 t -81.28 -169.43 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.761 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.759 ' H ' HG12 ' A' ' 17' ' ' VAL . 53.0 p90 -149.02 135.81 19.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.107 0.479 . . . . 0.0 110.87 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.515 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 62.7 m -83.93 171.86 12.63 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.008 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 24.8 m -68.23 153.42 95.52 Favored Pre-proline 0 C--N 1.327 -0.39 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_exo -51.53 114.51 1.6 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.808 1.672 . . . . 0.0 112.033 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.13 -31.38 4.93 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.396 -1.275 . . . . 0.0 112.185 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.538 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.0 mt -105.3 149.33 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.673 0.237 . . . . 0.0 110.443 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.412 HD13 ' N ' ' A' ' 24' ' ' ILE . 0.2 OUTLIER -130.43 135.12 61.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.984 0.421 . . . . 0.0 111.216 179.687 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.7 m -61.75 148.03 44.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.636 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.77 -126.3 1.8 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.633 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.21 68.02 1.39 Allowed 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 123.506 2.804 . . . . 0.0 113.722 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.47 22.1 11.86 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 123.33 0.652 . . . . 0.0 110.858 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.3 m -150.13 -160.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -133.87 156.72 47.57 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.6 m . . . . . 0 C--O 1.246 0.871 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.143 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.0 p -150.78 133.55 15.81 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 123.349 0.406 . . . . 0.0 109.992 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.56 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 16.9 m -76.94 143.98 39.14 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.092 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.83 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.4 mttp -77.73 150.74 34.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.852 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.9 tttt -50.31 -66.9 0.31 Allowed 'General case' 0 C--O 1.218 -0.605 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -177.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -82.01 29.14 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.316 -0.865 . . . . 0.0 111.085 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.83 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 38.6 tt0 -97.75 141.12 31.16 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 50.2 t80 -63.24 113.8 3.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.047 0.451 . . . . 0.0 111.283 -179.018 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 16.7 t -96.49 123.81 40.28 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.557 HD12 ' H ' ' A' ' 10' ' ' ILE . 3.9 mp -59.78 -44.95 95.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.395 -178.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.482 HG11 ' HB3' ' A' ' 16' ' ' PHE . 11.5 p -88.72 128.32 52.92 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.181 0.515 . . . . 0.0 111.223 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.472 ' HB2' ' H ' ' A' ' 13' ' ' ILE . 88.3 Cg_endo -85.21 -148.27 0.03 OUTLIER 'Trans proline' 0 C--O 1.244 0.797 0 C-N-CA 122.694 2.263 . . . . 0.0 112.31 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.472 ' H ' ' HB2' ' A' ' 12' ' ' PRO . 43.2 mt -63.79 81.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.289 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -171.38 -39.39 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -178.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.16 147.43 8.16 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.223 -0.899 . . . . 0.0 113.539 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.482 ' HB3' HG11 ' A' ' 11' ' ' VAL . 28.3 t80 -173.9 -51.09 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.702 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.9 t -91.42 -171.3 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.702 ' H ' HG12 ' A' ' 17' ' ' VAL . 25.4 t80 -149.73 126.36 10.97 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.297 0.57 . . . . 0.0 111.324 179.609 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.56 ' HA ' ' H ' ' A' ' 3' ' ' SER . 65.8 m -76.96 178.5 6.88 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.139 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.754 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 25.1 m -68.07 152.78 96.19 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.26 112.72 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 121.863 1.709 . . . . 0.0 112.303 -178.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.22 -29.46 5.51 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.299 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.53 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 33.4 mt -105.12 148.85 26.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.788 0.294 . . . . 0.0 110.642 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.6 pt -137.74 135.52 45.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.813 0.34 . . . . 0.0 111.616 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 m -62.09 145.82 52.17 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.39 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -149.48 -110.78 0.55 Allowed Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.594 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.99 63.67 3.3 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.419 2.746 . . . . 0.0 113.716 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 64.26 20.65 12.26 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 123.408 0.683 . . . . 0.0 111.059 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 m -151.12 -164.84 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.852 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 10.5 t -124.52 156.24 37.63 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.425 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.245 0.867 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.23 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.232 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.806 ' HA ' ' O ' ' A' ' 18' ' ' TYR . 22.8 p -125.8 133.54 51.98 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.0 m -79.13 150.13 31.84 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.605 -178.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.693 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 6.6 ttpm? -65.81 145.48 55.91 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.326 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.964 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.1 tttt -50.6 -66.08 0.45 Allowed 'General case' 0 C--O 1.217 -0.636 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.9 m95 -80.8 32.47 0.31 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.328 -0.857 . . . . 0.0 110.728 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.693 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 31.7 tt0 -103.84 138.37 40.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.087 178.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.59 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 32.6 t80 -63.13 118.9 8.55 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -179.531 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 77.5 m -75.66 55.85 0.87 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.05 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.59 ' HB ' ' CD2' ' A' ' 8' ' ' TYR . 14.4 tt -80.53 61.82 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 122.305 1.05 . . . . 0.0 109.562 178.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.612 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 27.2 m -64.44 128.29 93.18 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.758 -178.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.459 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 22.9 Cg_exo -64.89 137.29 52.58 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.841 2.361 . . . . 0.0 111.759 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.2 pt -55.88 -35.67 41.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.745 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.758 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.5 pt? -101.45 29.1 5.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.753 0.311 . . . . 0.0 111.116 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.428 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . 175.04 57.27 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.18 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.612 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 8.1 p90 -60.5 134.83 57.46 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.247 0.546 . . . . 0.0 111.468 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.759 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.6 t -95.16 -170.71 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.998 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.806 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.7 p90 -157.59 149.18 21.89 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.47 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 95.0 m -71.09 165.8 22.76 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.04 0.448 . . . . 0.0 112.172 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.741 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 8.8 m -69.43 152.94 96.24 Favored Pre-proline 0 CA--C 1.517 -0.325 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.18 116.31 2.73 Favored 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 121.679 1.586 . . . . 0.0 111.723 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.91 -31.22 5.41 Favored Glycine 0 C--N 1.312 -0.788 0 CA-C-N 114.563 -1.199 . . . . 0.0 111.862 -178.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.676 HD13 ' HB2' ' A' ' 5' ' ' LYS . 59.1 mt -106.22 151.71 24.44 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.0 pt -142.76 135.22 25.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.892 0.377 . . . . 0.0 111.823 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 33.1 m -64.31 134.65 55.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.793 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.418 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -135.42 -100.99 0.64 Allowed Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.356 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.418 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 8.2 Cg_exo -72.13 58.52 2.88 Favored 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 123.611 2.874 . . . . 0.0 113.052 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.43 ' HB3' ' CE1' ' A' ' 8' ' ' TYR . 7.6 m-85 64.23 16.06 9.81 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.738 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.8 m -150.11 163.02 3.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.964 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 9.1 t -88.56 151.92 22.19 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.96 0.409 . . . . 0.0 110.292 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.4 m . . . . . 0 C--O 1.246 0.919 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.847 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.141 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.714 ' HA ' ' O ' ' A' ' 18' ' ' TYR . 20.2 p -94.39 133.35 38.06 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.012 0.434 . . . . 0.0 110.671 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -82.97 142.72 31.17 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.769 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.526 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 36.1 mtmm -70.75 157.53 37.89 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.984 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.2 tttt -50.93 -66.33 0.4 Allowed 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -81.72 31.47 0.36 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.694 -0.629 . . . . 0.0 111.264 -178.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 7.0 tp10 -77.92 -126.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 37.9 t80 -162.07 133.82 5.44 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 7.4 p -150.69 130.59 13.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.258 0.552 . . . . 0.0 111.301 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 pt -135.5 48.68 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.5 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.623 ' HB ' ' HA2' ' A' ' 15' ' ' GLY . 35.4 m -68.47 135.44 90.78 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.623 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.86 -162.42 0.16 Allowed 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.629 2.219 . . . . 0.0 112.375 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.46 HG13 ' HG ' ' A' ' 14' ' ' LEU . 28.8 pt -58.72 -35.05 53.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.345 -179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.46 ' HG ' HG13 ' A' ' 13' ' ' ILE . 92.9 mt -96.21 15.93 19.61 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.604 0.24 . . . . 0.0 111.072 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.623 ' HA2' ' HB ' ' A' ' 11' ' ' VAL . . . 62.53 -157.78 36.98 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.523 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.483 ' HB3' HG12 ' A' ' 11' ' ' VAL . 15.1 t80 175.81 -50.82 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.336 0.588 . . . . 0.0 109.444 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.667 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.2 t -119.85 -174.24 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.081 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.714 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 38.4 p90 -162.68 146.15 11.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.478 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 97.7 m -77.63 167.95 20.76 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.863 0.364 . . . . 0.0 111.46 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.714 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 33.2 m -70.02 153.23 95.54 Favored Pre-proline 0 C--N 1.326 -0.432 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.56 115.49 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 121.807 1.671 . . . . 0.0 111.932 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 -31.6 4.99 Favored Glycine 0 C--N 1.312 -0.801 0 CA-C-N 114.422 -1.263 . . . . 0.0 112.076 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.514 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 49.3 mt -105.4 150.09 25.55 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.434 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -134.88 131.7 53.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.058 0.456 . . . . 0.0 111.525 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 30.9 t -65.18 140.32 58.75 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.741 179.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.76 -105.7 0.52 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.037 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.53 61.24 2.79 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.374 2.716 . . . . 0.0 113.735 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.439 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 2.2 m-85 66.75 11.64 8.35 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.691 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 m -150.43 162.41 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.984 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 6.3 t -89.59 155.13 19.46 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.453 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 22.8 m . . . . . 0 C--O 1.247 0.93 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.89 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.216 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.713 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.1 p -115.16 132.48 56.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.056 0.455 . . . . 0.0 110.625 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -75.51 143.71 42.38 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.359 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.495 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 7.3 ttpm? -64.08 146.47 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.493 178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.659 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.2 tttt -52.9 -57.52 9.99 Favored 'General case' 0 C--O 1.213 -0.836 0 CA-C-O 121.326 0.584 . . . . 0.0 112.282 -178.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -81.13 28.32 0.37 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 111.568 -178.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 3.8 tp10 -82.99 145.43 29.34 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -74.96 58.97 0.88 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.502 0.668 . . . . 0.0 110.259 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.22 102.99 3.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.848 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 29.2 pt -113.04 28.63 2.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.4 m 35.15 59.32 2.52 Favored Pre-proline 0 N--CA 1.476 0.854 0 O-C-N 124.367 1.042 . . . . 0.0 113.604 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.535 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 56.1 Cg_endo -71.25 140.3 36.91 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.042 1.828 . . . . 0.0 111.869 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.9 pt -57.5 -29.83 34.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.6 tp -68.92 -24.1 64.25 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.238 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 176.49 80.71 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.088 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.535 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 4.0 p90 -69.88 -31.86 69.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -179.141 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.76 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.0 t 58.35 -152.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.203 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.76 ' H ' HG12 ' A' ' 17' ' ' VAL . 48.0 p90 -167.81 142.78 3.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.637 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 96.7 m -70.61 167.95 17.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.077 0.465 . . . . 0.0 112.078 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.713 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 16.6 m -68.46 154.03 94.9 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -51.49 115.6 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 121.813 1.676 . . . . 0.0 111.694 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.99 -31.36 5.71 Favored Glycine 0 C--N 1.311 -0.847 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.905 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.588 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 38.0 mt -101.04 148.62 24.83 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.5 pt -141.67 133.4 27.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.94 0.4 . . . . 0.0 111.486 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 72.2 m -60.26 137.95 58.03 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.55 179.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.6 -110.91 0.76 Allowed Glycine 0 CA--C 1.522 0.531 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.456 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.14 63.07 1.43 Allowed 'Trans proline' 0 N--CA 1.479 0.635 0 C-N-CA 123.609 2.872 . . . . 0.0 114.207 -178.65 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.64 11.74 8.35 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.604 0.762 . . . . 0.0 110.787 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 7' ' ' GLU . 18.6 m -151.94 162.74 2.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.133 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.659 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 24.9 t -89.54 156.01 18.91 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.3 m . . . . . 0 C--N 1.317 -0.832 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.124 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.745 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p -111.23 131.62 54.98 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.984 0.421 . . . . 0.0 110.809 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 m -71.42 141.82 50.29 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.146 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.659 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 4.3 ttmp? -71.77 142.5 49.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.536 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.955 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 37.8 tttt -47.94 -68.61 0.17 Allowed 'General case' 0 C--O 1.218 -0.602 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -177.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -81.74 35.05 0.4 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.269 -0.894 . . . . 0.0 110.299 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 22.6 tt0 -127.1 151.64 48.37 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.429 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -61.31 126.36 27.09 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.73 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.5 t -59.69 -42.62 93.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.47 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.437 ' O ' HG23 ' A' ' 17' ' ' VAL . 46.5 mm 70.93 133.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 123.83 0.706 . . . . 0.0 111.786 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.418 ' HA ' ' HD3' ' A' ' 12' ' ' PRO . 16.7 m -137.11 108.37 8.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-O 121.415 0.626 . . . . 0.0 110.141 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.471 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 8.2 Cg_exo -72.74 149.38 48.32 Favored 'Trans proline' 0 N--CA 1.463 -0.265 0 C-N-CA 123.03 2.487 . . . . 0.0 111.913 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.9 mt -71.54 64.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 121.44 0.638 . . . . 0.0 110.475 179.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.6 pp -176.84 -21.42 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.052 -0.977 . . . . 0.0 109.398 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -175.07 -134.93 1.98 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.222 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.471 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 14.2 p90 -167.55 154.45 8.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.77 0.285 . . . . 0.0 110.261 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.852 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.2 t -86.01 -166.68 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.852 ' H ' HG12 ' A' ' 17' ' ' VAL . 48.6 p90 -156.56 143.64 18.84 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.587 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 67.4 m -74.31 168.53 19.46 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.075 0.464 . . . . 0.0 111.57 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.745 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 13.9 m -67.9 153.52 95.11 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_exo -51.65 115.57 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.841 1.694 . . . . 0.0 111.71 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.4 -30.43 6.0 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 114.376 -1.283 . . . . 0.0 111.922 -178.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.587 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 49.5 mt -101.18 147.18 26.56 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.8 pt -130.28 132.97 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 111.509 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 74.0 m -58.93 140.01 55.98 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.118 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.41 -130.22 2.7 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.934 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -66.69 70.5 0.48 Allowed 'Trans proline' 0 N--CA 1.479 0.627 0 C-N-CA 123.823 3.015 . . . . 0.0 113.845 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 64.47 21.4 12.45 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.333 0.653 . . . . 0.0 110.684 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -150.32 -155.88 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.955 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 11.6 t -140.3 155.64 46.75 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.3 m . . . . . 0 C--O 1.245 0.857 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.227 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.225 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.775 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.8 p -87.97 126.57 35.14 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.185 0.517 . . . . 0.0 109.655 179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.0 p -76.51 142.36 40.92 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.822 -178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.489 ' HE3' ' N ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -75.02 157.01 35.6 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.297 178.895 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.981 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 31.2 tttt -49.35 -71.71 0.06 Allowed 'General case' 0 C--O 1.216 -0.663 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -80.6 31.39 0.29 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.254 -0.904 . . . . 0.0 110.542 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.488 ' OE1' ' HE3' ' A' ' 4' ' ' LYS . 27.8 tt0 -108.99 143.07 38.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.023 178.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.43 ' HE1' ' HD2' ' A' ' 28' ' ' PHE . 40.3 t80 -59.32 134.42 56.99 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.965 0.412 . . . . 0.0 111.223 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 30.1 p -151.63 158.19 43.14 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.507 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.419 ' O ' HD12 ' A' ' 10' ' ' ILE . 1.6 pp -145.39 145.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.578 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 1.052 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 3.3 m -72.97 125.63 90.97 Favored Pre-proline 0 CA--C 1.538 0.486 0 CA-C-O 121.1 0.476 . . . . 0.0 110.19 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.86 54.97 1.27 Allowed 'Trans proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.362 2.708 . . . . 0.0 114.233 -178.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.1 mm 53.81 -86.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.814 0.845 . . . . 0.0 113.025 178.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.414 ' H ' ' HG ' ' A' ' 14' ' ' LEU . 2.8 pp -67.4 -11.36 57.56 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.558 0.694 . . . . 0.0 109.97 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -127.54 158.04 21.1 Favored Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 178.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 1.052 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 8.5 m-85 -121.64 -32.44 3.8 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 117.303 0.551 . . . . 0.0 111.107 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.56 HG12 ' H ' ' A' ' 18' ' ' TYR . 0.8 OUTLIER -76.14 174.26 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.579 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.684 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 10.5 t80 179.09 -34.29 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.309 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 76.4 m -59.93 163.76 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.402 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.775 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 7.8 m -64.67 151.63 91.78 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -51.47 114.6 1.64 Allowed 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 121.748 1.632 . . . . 0.0 111.959 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.56 -35.6 2.75 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.165 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.567 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 69.5 mt -102.27 149.79 23.96 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.637 0.218 . . . . 0.0 110.526 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.6 pt -125.71 131.43 71.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.159 0.504 . . . . 0.0 111.543 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 45.9 t -69.67 141.65 53.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.632 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -138.57 -117.54 1.53 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.986 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.46 63.51 2.2 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.48 2.787 . . . . 0.0 113.698 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.43 ' HD2' ' HE1' ' A' ' 8' ' ' TYR . 2.9 m-85 66.29 15.65 10.17 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.766 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.02 155.18 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 177.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.981 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.02 159.51 17.56 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 120.897 0.379 . . . . 0.0 110.54 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 m . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.202 -0.904 . . . . 0.0 109.806 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.215 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.2 p -137.65 134.97 36.09 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.979 0.419 . . . . 0.0 110.927 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.0 m -81.36 148.81 29.17 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.844 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.629 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 19.7 mtpt -65.46 151.05 47.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.703 179.109 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.936 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.5 tttt -52.24 -65.02 0.63 Allowed 'General case' 0 C--O 1.214 -0.804 0 N-CA-C 112.824 0.675 . . . . 0.0 112.824 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.7 m95 -80.77 27.73 0.36 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.368 -0.833 . . . . 0.0 111.123 -178.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.629 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 2.3 tp10 -94.98 138.46 32.68 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.163 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.433 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 49.6 t80 -64.49 130.41 43.61 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 74.0 m -73.54 61.95 0.73 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.772 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.433 ' HB ' ' CD2' ' A' ' 8' ' ' TYR . 15.1 tt -79.01 52.7 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 122.484 1.135 . . . . 0.0 109.626 178.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.692 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 35.3 m -79.31 134.63 58.54 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.517 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.415 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 21.6 Cg_exo -65.23 136.01 45.71 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.612 2.208 . . . . 0.0 111.493 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 12.4 tt -55.07 -37.87 44.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.665 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.773 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.5 pt? -99.8 29.78 3.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.687 0.28 . . . . 0.0 111.217 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.415 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . 174.89 55.77 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.203 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.692 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 23.6 p90 -62.54 138.2 58.43 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.181 0.515 . . . . 0.0 111.554 -179.269 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.9 t -87.34 -169.19 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.697 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.784 ' H ' HG12 ' A' ' 17' ' ' VAL . 51.8 p90 -150.61 147.54 27.54 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.3 m -75.73 162.4 28.24 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.665 0.269 . . . . 0.0 110.672 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.8 OUTLIER -69.78 156.32 91.94 Favored Pre-proline 0 C--N 1.326 -0.419 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.032 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.14 114.66 1.84 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.177 1.918 . . . . 0.0 111.584 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.18 -35.25 2.76 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 114.259 -1.337 . . . . 0.0 111.84 -178.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.555 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 2.5 mm? -112.59 150.02 31.95 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.1 pt -138.69 134.11 42.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.781 0.325 . . . . 0.0 111.169 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.632 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 37.1 t -65.8 139.59 58.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.787 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -142.93 -97.92 0.27 Allowed Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.7 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.38 58.76 3.77 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.151 2.567 . . . . 0.0 113.498 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 65.14 14.34 9.32 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.837 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.61 163.76 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.936 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.3 t -89.15 150.72 22.57 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 29.2 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.018 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.728 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 27.9 p -118.3 129.33 55.39 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.904 0.383 . . . . 0.0 110.247 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -83.57 150.93 25.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.844 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 22.5 mtmt -65.51 157.37 29.8 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.869 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.5 tttt -49.8 -61.33 2.19 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 113.982 1.105 . . . . 0.0 113.982 -177.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -80.9 25.57 0.45 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 112.186 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.844 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 70.0 mm-40 -97.53 145.37 26.3 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 177.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.572 ' HA ' ' O ' ' A' ' 28' ' ' PHE . 5.5 m-85 -72.78 94.38 1.78 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.8 p -75.79 49.2 0.51 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.081 -179.062 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.81 127.56 33.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.276 179.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.478 HG12 ' H ' ' A' ' 17' ' ' VAL . 20.7 m -75.85 130.76 77.84 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 121.109 0.481 . . . . 0.0 111.409 -179.268 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 12.2 Cg_exo -70.07 144.0 51.03 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.846 2.364 . . . . 0.0 111.303 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.577 HG23 ' HG ' ' A' ' 14' ' ' LEU . 8.6 tp -53.87 -30.63 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.611 -179.679 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.577 ' HG ' HG23 ' A' ' 13' ' ' ILE . 95.1 mt -105.62 33.81 3.57 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.598 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.55 -144.74 8.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.944 -1.122 . . . . 0.0 113.101 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -171.15 151.59 3.23 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.67 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.0 OUTLIER -112.45 -177.02 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.613 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.681 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.2 p90 -170.46 151.57 3.73 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.5 m -84.06 162.3 20.39 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.728 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.5 OUTLIER -72.19 157.03 90.03 Favored Pre-proline 0 CA--C 1.513 -0.45 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.558 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -53.0 114.19 1.61 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.211 1.94 . . . . 0.0 111.664 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.35 -36.06 2.46 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 114.192 -1.367 . . . . 0.0 111.662 -178.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.504 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 71.4 mt -108.25 148.26 30.23 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.9 pt -129.35 131.87 67.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.809 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.514 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.1 t -67.24 138.53 56.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.499 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.1 -116.9 1.57 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.946 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 63.74 1.94 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.549 2.833 . . . . 0.0 113.559 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.572 ' O ' ' HA ' ' A' ' 8' ' ' TYR . 4.1 m-85 65.72 16.58 10.55 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.678 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 m -151.54 154.1 8.79 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.869 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.65 155.82 19.38 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.512 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.6 m . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.121 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.024 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.712 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.6 p -150.96 -148.64 0.27 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.2 t -169.21 164.25 11.01 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.0 0.364 . . . . 0.0 110.446 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.573 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 30.1 mtmm -69.95 151.84 45.15 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.227 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.792 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.4 tttt -54.3 -60.79 2.86 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -80.85 26.07 0.43 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.47 -0.769 . . . . 0.0 111.206 -178.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.573 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 0.6 OUTLIER -92.68 145.1 24.68 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.276 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.435 ' HE1' ' HD2' ' A' ' 28' ' ' PHE . 25.9 t80 -67.32 116.93 8.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.991 0.424 . . . . 0.0 110.233 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 72.1 m -76.45 78.12 3.17 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.103 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 tp -71.23 85.45 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.825 0.822 . . . . 0.0 110.328 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.516 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 29.7 m -74.64 136.95 74.03 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.374 -179.132 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -68.17 150.66 77.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.639 2.226 . . . . 0.0 111.793 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.608 ' H ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -55.67 128.37 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.662 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.4 mt 64.36 28.09 13.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.394 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.83 -158.94 9.33 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.936 179.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.516 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 12.4 p90 -168.07 153.13 6.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.636 0.255 . . . . 0.0 110.448 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.701 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.4 t -94.31 -172.77 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.701 ' H ' HG12 ' A' ' 17' ' ' VAL . 25.0 t80 -146.05 132.29 19.48 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.917 0.389 . . . . 0.0 110.133 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.493 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.1 m -75.36 177.76 6.36 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.454 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.712 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.1 m -70.5 151.05 95.63 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -49.69 113.35 0.94 Allowed 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.745 1.63 . . . . 0.0 112.139 -178.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.92 -33.47 3.53 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.497 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.4 mt -104.98 146.45 29.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.564 0.221 . . . . 0.0 110.628 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.3 pt -133.27 133.61 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.972 0.415 . . . . 0.0 111.224 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 51.6 m -66.77 140.0 57.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.98 0.419 . . . . 0.0 111.515 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.35 -112.6 1.14 Allowed Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.198 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.62 62.8 2.27 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.367 2.711 . . . . 0.0 113.704 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.435 ' HD2' ' HE1' ' A' ' 8' ' ' TYR . 4.4 m-85 65.4 15.8 10.21 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 123.617 0.767 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.18 160.33 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.792 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 3.4 t -89.33 156.14 18.91 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.926 0.393 . . . . 0.0 110.158 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.6 m . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.905 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.785 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.9 p -150.27 130.56 13.7 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.427 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 31.0 m -84.97 153.81 22.55 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.151 -179.068 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.596 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -66.16 160.11 24.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.267 179.065 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.943 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.1 tttt -52.05 -63.69 1.06 Allowed 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 -178.442 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -82.02 31.63 0.38 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.781 -0.574 . . . . 0.0 111.153 -178.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.596 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 0.5 OUTLIER -79.34 -125.55 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.232 0.539 . . . . 0.0 110.006 178.996 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.41 ' H ' ' HB3' ' A' ' 7' ' ' GLU . 46.9 t80 -160.53 134.37 7.03 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 7.5 p -160.15 139.64 11.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.943 0.402 . . . . 0.0 111.007 -179.238 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 tp -122.11 74.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 122.101 0.953 . . . . 0.0 109.996 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.43 ' HB ' ' HB3' ' A' ' 16' ' ' PHE . 27.8 m -80.25 141.82 54.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.862 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.1 140.4 89.32 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.679 2.253 . . . . 0.0 112.04 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 52.5 mt -54.62 -28.89 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.815 -179.428 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.441 ' H ' HD22 ' A' ' 14' ' ' LEU . 3.1 mm? -59.23 -29.5 67.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.146 179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 127.53 3.03 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.152 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.43 ' HB3' ' HB ' ' A' ' 11' ' ' VAL . 21.9 t80 -173.11 136.97 0.67 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.635 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.1 t -106.54 -176.91 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.635 ' H ' HG12 ' A' ' 17' ' ' VAL . 15.7 t80 179.69 -37.43 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.961 0.41 . . . . 0.0 110.009 179.215 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 94.7 m -59.27 160.64 6.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.006 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.785 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 4.5 m -62.64 152.41 81.46 Favored Pre-proline 0 N--CA 1.452 -0.338 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -50.85 115.18 1.84 Allowed 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 121.784 1.656 . . . . 0.0 111.847 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.14 -35.32 3.4 Favored Glycine 0 C--N 1.312 -0.774 0 CA-C-N 114.388 -1.278 . . . . 0.0 111.935 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.612 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 5.2 mp -98.9 147.88 24.52 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 pt -132.74 132.33 59.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.105 0.479 . . . . 0.0 111.766 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.7 t -68.82 143.93 54.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.314 179.477 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.434 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -144.59 -109.43 0.65 Allowed Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.929 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.434 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.5 Cg_exo -70.52 61.87 2.17 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.724 2.949 . . . . 0.0 113.525 -178.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 3.1 m-85 65.79 13.89 9.24 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.565 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 m -150.35 161.04 4.2 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.943 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.3 155.85 19.11 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.877 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.828 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.8 p -150.85 135.13 16.94 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -76.22 146.89 38.74 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.321 -179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.856 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 28.5 mtpt -66.75 148.65 51.64 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.945 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.6 tttt -51.37 -66.06 0.45 Allowed 'General case' 0 C--O 1.218 -0.565 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 10.3 m95 -80.92 29.32 0.33 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.802 -0.561 . . . . 0.0 110.94 -179.267 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.856 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 13.8 tp10 -110.71 147.58 34.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.403 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 21.5 t80 -65.2 113.43 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.983 0.42 . . . . 0.0 110.345 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.7 p -82.44 116.28 21.83 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 178.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.565 HG22 ' HD3' ' A' ' 12' ' ' PRO . 22.5 mt -68.79 130.85 34.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.491 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.1 m -126.56 67.69 66.8 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.96 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.896 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 25.4 Cg_exo -62.78 147.79 94.24 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.549 2.166 . . . . 0.0 112.018 179.496 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.59 117.24 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.677 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 11.1 mp 60.18 32.01 20.73 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.601 -179.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 41.79 0.22 Allowed Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.028 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.896 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 11.1 p90 -70.96 146.42 49.48 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.767 0.318 . . . . 0.0 111.209 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.751 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.7 t -83.87 -172.26 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.751 ' H ' HG12 ' A' ' 17' ' ' VAL . 23.6 t80 -152.19 141.39 21.38 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.839 0.352 . . . . 0.0 110.259 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.554 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 92.9 m -74.0 173.52 9.89 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.904 179.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.828 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -68.89 156.6 90.98 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -52.12 113.08 1.03 Allowed 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.095 1.863 . . . . 0.0 111.629 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.84 -34.93 2.87 Favored Glycine 0 C--N 1.311 -0.857 0 CA-C-N 114.114 -1.403 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.554 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 54.6 mt -103.95 139.95 38.39 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.703 0.252 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 21.1 pt -127.31 133.09 68.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.999 0.428 . . . . 0.0 111.573 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -63.4 139.43 58.77 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.7 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.423 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -140.97 -117.22 1.35 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.967 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.0 Cg_exo -70.96 62.68 2.46 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 123.727 2.951 . . . . 0.0 113.222 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.7 16.16 10.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.496 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.4 m -151.15 155.47 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.132 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.945 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 1.8 t -89.52 153.87 20.46 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.515 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.9 m . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.98 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.784 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p -149.98 136.87 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.3 t -85.21 143.3 28.85 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.613 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.644 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 5.1 ttpm? -66.48 153.37 43.04 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.022 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 1.047 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 36.2 tttt -50.54 -68.59 0.16 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.447 0.536 . . . . 0.0 112.447 -178.516 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.41 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.9 m95 -82.1 32.04 0.38 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.75 -0.593 . . . . 0.0 110.657 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.644 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 2.6 tp10 -85.98 -116.76 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -160.31 140.29 11.35 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 28.8 p -157.32 151.25 24.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.233 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.7 tp -167.83 -32.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.831 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 20.0 m -59.92 144.27 86.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.747 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.04 103.11 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.861 2.374 . . . . 0.0 112.939 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.526 ' HA ' ' O ' ' A' ' 17' ' ' VAL . 33.6 pt -62.32 -17.2 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.118 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.2 tp -65.82 -23.24 66.64 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.272 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.0 57.91 0.24 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 119.48 -1.343 . . . . 0.0 113.971 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -165.41 -65.46 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.917 0.358 . . . . 0.0 110.275 178.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.67 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.2 t -144.3 -178.23 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.714 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 16.4 t80 -172.6 154.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.477 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.0 m -68.0 166.3 16.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.807 0.337 . . . . 0.0 111.303 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.784 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 12.3 m -66.33 151.88 95.22 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.47 116.25 2.73 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 121.806 1.671 . . . . 0.0 111.758 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.18 -29.66 5.89 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.958 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.511 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.9 mt -106.15 147.17 29.32 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.9 pt -130.09 132.47 65.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.063 0.459 . . . . 0.0 111.473 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.2 t -64.1 140.77 58.9 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -140.68 -117.96 1.44 Allowed Glycine 0 CA--C 1.522 0.513 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.954 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 64.74 2.33 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.494 2.796 . . . . 0.0 113.814 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 3.8 m-85 67.02 13.1 9.35 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.8 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 m -150.46 159.26 4.85 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.358 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 1.047 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.5 t -89.29 154.06 20.4 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.52 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.3 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.042 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.068 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.672 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.5 p -91.98 134.17 35.04 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.038 0.447 . . . . 0.0 110.544 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -80.18 143.12 34.09 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.051 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.814 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 12.7 mtmt -67.98 149.48 49.68 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.879 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.6 tttt -51.81 -57.12 10.23 Favored 'General case' 0 C--O 1.213 -0.828 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.691 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 20.4 m95 -81.23 23.02 0.62 Allowed 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 112.689 -177.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.814 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 6.0 mm-40 -81.24 142.04 33.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 176.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -76.35 58.47 1.3 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.231 0.539 . . . . 0.0 110.462 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.19 75.57 5.73 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.452 0.644 . . . . 0.0 110.948 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.8 tt -61.81 -30.23 48.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.469 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.518 ' HB ' ' HB3' ' A' ' 16' ' ' PHE . 15.5 m -68.5 134.11 90.85 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.017 179.293 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.578 ' HB2' HD22 ' A' ' 14' ' ' LEU . 45.6 Cg_endo -69.13 140.94 46.37 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 122.67 2.246 . . . . 0.0 112.566 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.528 HD11 ' H ' ' A' ' 25' ' ' CYS . 65.3 mt -51.96 -42.76 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.823 HD13 ' H ' ' A' ' 14' ' ' LEU . 0.0 OUTLIER -83.83 33.24 0.48 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.064 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.17 -42.75 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 121.171 -0.538 . . . . 0.0 111.902 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.518 ' HB3' ' HB ' ' A' ' 11' ' ' VAL . 7.1 t80 -162.71 133.14 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.671 0.272 . . . . 0.0 110.416 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.844 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.8 t 62.12 -173.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 123.59 0.756 . . . . 0.0 110.838 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.844 ' H ' HG12 ' A' ' 17' ' ' VAL . 45.0 p90 -176.37 144.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.471 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 93.6 m -76.33 172.8 12.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.139 0.495 . . . . 0.0 111.824 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.672 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 21.2 m -72.64 154.23 91.44 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 177.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -51.62 115.16 1.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.801 1.667 . . . . 0.0 111.9 -179.509 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.25 -31.71 5.35 Favored Glycine 0 C--N 1.311 -0.81 0 CA-C-N 114.479 -1.237 . . . . 0.0 112.179 -178.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.618 HD13 ' HB2' ' A' ' 5' ' ' LYS . 44.4 mt -103.45 150.48 23.83 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -143.7 132.74 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.856 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.662 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 99.0 m -68.24 134.41 50.35 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.377 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.16 -84.02 0.05 OUTLIER Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.72 -0.753 . . . . 0.0 113.131 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.13 55.5 4.03 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 123.284 2.656 . . . . 0.0 112.966 -179.188 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 64.74 12.42 7.62 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.36 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.4 m -151.77 167.45 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.879 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 15.0 t -89.38 153.19 21.05 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.016 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.446 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 34.9 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.852 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.005 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.813 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 15.7 p -88.74 143.09 27.15 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -115.2 -162.86 0.84 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.222 0.534 . . . . 0.0 112.251 -177.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -80.65 150.05 29.57 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.123 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.691 ' HB2' HD13 ' A' ' 23' ' ' LEU . 29.0 tttt -57.39 -55.54 33.48 Favored 'General case' 0 C--O 1.211 -0.969 0 CA-C-O 121.514 0.673 . . . . 0.0 112.063 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.7 m95 -81.04 24.01 0.53 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.936 -1.103 . . . . 0.0 111.596 -178.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -77.47 134.44 38.36 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.416 ' CE2' HD11 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -77.71 67.04 3.53 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.7 p -60.41 -26.39 66.65 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.299 0.852 . . . . 0.0 113.299 -178.093 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.416 HD11 ' CE2' ' A' ' 8' ' ' TYR . 45.5 mm 65.27 84.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.654 0.74 . . . . 0.0 110.313 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.765 HG21 ' HB3' ' A' ' 25' ' ' CYS . 35.5 m -137.35 159.31 69.98 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.086 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -59.66 140.06 91.81 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.51 2.14 . . . . 0.0 111.495 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.1 tp -55.36 -22.6 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.97 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.431 ' H ' HD22 ' A' ' 14' ' ' LEU . 3.1 mm? -61.43 -30.42 70.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.077 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 118.96 139.09 5.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.419 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 21.6 t80 -162.99 133.65 4.66 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.626 HG13 HG22 ' A' ' 24' ' ' ILE . 0.7 OUTLIER -73.41 169.71 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 121.038 0.447 . . . . 0.0 110.195 -179.477 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.501 ' H ' HG12 ' A' ' 17' ' ' VAL . 24.4 t80 178.18 -44.6 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.861 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 66.0 m -70.54 174.45 5.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.872 -1.058 . . . . 0.0 111.41 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.813 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -70.89 160.62 81.65 Favored Pre-proline 0 N--CA 1.445 -0.702 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.96 111.45 0.52 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.254 1.969 . . . . 0.0 112.056 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.31 -39.28 1.67 Allowed Glycine 0 C--N 1.309 -0.944 0 CA-C-N 113.847 -1.524 . . . . 0.0 111.659 -178.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 5' ' ' LYS . 64.5 mt -111.17 145.46 38.61 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 120.535 0.207 . . . . 0.0 110.47 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.626 HG22 HG13 ' A' ' 17' ' ' VAL . 22.0 pt -138.91 140.4 38.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.957 0.408 . . . . 0.0 111.591 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.765 ' HB3' HG21 ' A' ' 11' ' ' VAL . 22.7 m -77.5 139.5 39.62 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.103 0.478 . . . . 0.0 111.445 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.91 -85.73 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.079 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -75.78 55.43 4.35 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.826 2.351 . . . . 0.0 112.793 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.555 ' HA ' ' H ' ' A' ' 11' ' ' VAL . 12.4 m-85 63.95 15.2 9.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.889 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.4 m -147.25 164.33 7.02 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.733 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 6.7 t -90.51 150.92 21.58 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-O 120.931 0.396 . . . . 0.0 109.953 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.519 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 35.2 m . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.963 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.694 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.4 p -150.43 -149.45 0.3 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 123.05 0.219 . . . . 0.0 110.553 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.3 t -164.22 157.92 18.42 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.794 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 14.2 ttmt -64.35 146.75 53.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.599 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.878 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.1 tttt -52.13 -64.57 0.77 Allowed 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.671 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.0 m95 -80.5 27.35 0.35 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 111.151 -178.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.8 tp10 -95.93 138.49 33.49 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 41.9 t80 -62.41 119.18 8.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.209 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 71.4 m -73.79 87.64 1.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.422 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.623 HD13 ' H ' ' A' ' 10' ' ' ILE . 0.2 OUTLIER -65.92 -23.75 32.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.533 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 35.5 m -66.95 137.58 94.76 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.828 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 16' ' ' PHE . 55.8 Cg_exo -53.24 121.66 9.82 Favored 'Trans proline' 0 C--O 1.24 0.601 0 C-N-CA 122.777 2.318 . . . . 0.0 112.723 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 16.5 tt -55.54 -17.07 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.774 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.7 tp -55.43 -35.56 65.55 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.789 179.177 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.38 47.97 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.773 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.444 ' HB2' ' HD2' ' A' ' 12' ' ' PRO . 5.0 m-85 -108.74 131.91 54.47 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 122.696 -0.296 . . . . 0.0 110.539 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.88 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.5 t 61.47 -161.13 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.977 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.88 ' H ' HG12 ' A' ' 17' ' ' VAL . 51.6 p90 -166.96 151.11 6.95 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.485 0.183 . . . . 0.0 110.545 -178.262 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.423 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -74.08 170.86 14.62 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.821 0.343 . . . . 0.0 110.506 178.425 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.694 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 6.4 m -66.45 151.82 95.56 Favored Pre-proline 0 C--N 1.327 -0.403 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.97 115.8 2.37 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 121.913 1.742 . . . . 0.0 112.219 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.73 -21.98 12.11 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.232 -178.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.52 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 45.2 mt -116.72 152.67 33.84 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.8 pt -142.15 135.59 28.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.69 0.281 . . . . 0.0 111.366 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 15.6 m -67.12 136.21 54.78 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.752 0.31 . . . . 0.0 110.964 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -135.71 -105.95 0.82 Allowed Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.204 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.13 60.24 3.11 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.249 2.632 . . . . 0.0 113.34 -179.652 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 65.08 17.29 11.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.964 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.52 160.52 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 178.041 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.878 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.53 151.18 22.68 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.54 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 23.3 m . . . . . 0 C--O 1.244 0.802 0 CA-C-O 118.064 -0.97 . . . . 0.0 110.013 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.717 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.9 p -92.22 137.5 32.32 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 123.311 0.382 . . . . 0.0 110.548 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m -87.69 148.46 24.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.067 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.514 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 2.7 tmmm? -68.95 145.79 53.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.251 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.966 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 38.0 tttt -49.23 -68.52 0.17 Allowed 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' TRP . . . . . 0.409 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 8.5 m95 -81.22 32.72 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.461 -0.774 . . . . 0.0 111.048 -178.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.4 tp10 -86.91 -119.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.158 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.454 ' H ' ' HB3' ' A' ' 7' ' ' GLU . 31.9 t80 -151.27 136.76 17.78 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 93.1 m -119.69 -178.77 3.7 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.375 -179.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.4 mt 68.06 50.54 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 CA-C-O 122.175 0.988 . . . . 0.0 109.734 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.444 ' CG1' ' HD2' ' A' ' 12' ' ' PRO . 17.4 t -132.06 142.26 44.46 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.482 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.444 ' HD2' ' CG1' ' A' ' 11' ' ' VAL . 4.3 Cg_endo -47.6 154.74 1.66 Allowed 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 123.448 2.765 . . . . 0.0 113.496 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.3 mm -46.83 -23.34 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.862 0.865 . . . . 0.0 113.091 -179.24 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 85.8 mt -57.27 -31.0 65.14 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 111.796 0.295 . . . . 0.0 111.796 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.76 151.67 13.73 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.336 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 63.29 48.55 3.58 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.663 0.744 . . . . 0.0 110.613 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.44 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.0 OUTLIER -90.66 -142.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.756 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.713 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 48.2 p90 -53.01 143.38 17.44 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.652 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 99.1 m -75.16 169.67 17.57 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.955 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.717 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 23.2 m -71.18 154.04 94.08 Favored Pre-proline 0 CA--C 1.515 -0.375 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.086 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -51.82 115.52 2.18 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 121.85 1.7 . . . . 0.0 111.896 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.02 -31.6 5.07 Favored Glycine 0 C--N 1.312 -0.805 0 CA-C-N 114.491 -1.231 . . . . 0.0 111.963 -178.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 46.7 mt -103.87 149.99 24.57 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.8 pt -136.15 133.57 50.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.042 0.448 . . . . 0.0 111.849 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 20.8 m -63.26 139.31 58.76 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.503 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.33 -118.62 1.6 Allowed Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.622 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.39 65.37 1.12 Allowed 'Trans proline' 0 N--CA 1.479 0.651 0 C-N-CA 123.657 2.905 . . . . 0.0 113.97 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 66.49 12.57 8.79 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 123.601 0.76 . . . . 0.0 110.875 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 m -150.13 161.33 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.966 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.7 t -89.41 152.45 21.48 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.531 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.8 m . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.083 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.23 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.733 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 21.4 p -121.08 137.1 54.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.06 0.457 . . . . 0.0 110.987 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.484 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 34.1 t -75.62 140.84 42.84 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.8 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.852 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -68.68 150.82 47.49 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.6 tttt -54.22 -66.24 0.43 Allowed 'General case' 0 C--O 1.214 -0.798 0 CA-C-O 121.153 0.502 . . . . 0.0 112.211 -178.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m95 -80.59 26.89 0.38 Allowed 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.282 -0.886 . . . . 0.0 111.039 -178.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.852 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 12.4 tp10 -84.67 136.23 33.83 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 177.634 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -74.88 77.55 2.13 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 7.3 p -72.41 59.96 0.44 Allowed 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.435 HG12 ' O ' ' A' ' 10' ' ' ILE . 15.0 tt -83.71 41.63 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-O 122.695 1.236 . . . . 0.0 109.17 178.252 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.725 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 0.2 OUTLIER -81.68 136.8 47.96 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.963 -179.255 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.81 150.93 83.24 Favored 'Trans proline' 0 N--CA 1.463 -0.278 0 C-N-CA 122.905 2.403 . . . . 0.0 111.941 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.601 HD13 ' H ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -54.13 -23.5 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.467 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.422 HD22 ' H ' ' A' ' 14' ' ' LEU . 3.0 mm? -61.63 -29.13 69.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.77 0.319 . . . . 0.0 111.181 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.23 61.01 0.24 Allowed Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.725 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 0.3 OUTLIER -74.94 3.18 8.71 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.61 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.1 t 55.11 -142.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.916 0.388 . . . . 0.0 110.459 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.643 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 51.5 p90 -163.66 145.95 9.6 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.307 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.484 ' HA ' ' H ' ' A' ' 3' ' ' SER . 35.1 m -75.58 171.24 14.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.792 0.329 . . . . 0.0 110.927 179.233 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.733 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 22.5 m -68.03 153.25 95.62 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.27 115.55 2.26 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.863 1.709 . . . . 0.0 111.89 -179.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.9 -26.0 9.13 Favored Glycine 0 C--N 1.312 -0.768 0 CA-C-N 114.429 -1.259 . . . . 0.0 112.231 -178.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.55 HD13 ' HB2' ' A' ' 5' ' ' LYS . 41.6 mt -107.41 149.53 27.79 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.703 0.252 . . . . 0.0 110.453 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.2 pt -137.79 131.41 42.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.9 0.381 . . . . 0.0 111.301 179.339 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.596 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 42.9 t -67.47 135.5 53.17 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.158 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -136.96 -106.07 0.77 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.869 -0.682 . . . . 0.0 113.054 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.44 60.51 2.66 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 123.389 2.726 . . . . 0.0 113.539 -179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 66.0 14.5 9.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.759 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.3 m -151.15 155.77 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.808 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -88.86 154.68 20.06 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.443 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.2 m . . . . . 0 C--O 1.246 0.905 0 CA-C-O 117.915 -1.04 . . . . 0.0 109.972 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.725 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.3 p -88.99 -148.25 0.17 Allowed 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -169.44 152.88 4.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.838 0.29 . . . . 0.0 110.707 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.638 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 7.2 ttpt -64.29 146.22 54.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.678 179.101 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 1.05 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.9 tttt -51.4 -66.03 0.45 Allowed 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.211 0.529 . . . . 0.0 111.99 -179.032 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -82.04 33.61 0.39 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.882 -0.511 . . . . 0.0 110.839 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.638 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 7.2 tp10 -81.74 -123.93 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.51 ' CE2' HD11 ' A' ' 10' ' ' ILE . 1.9 t80 -166.5 56.4 0.09 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.9 p -60.35 -52.4 65.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.26 -178.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.693 ' HA ' ' HA ' ' A' ' 28' ' ' PHE . 67.7 mt 66.75 115.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 O-C-N 123.592 0.558 . . . . 0.0 111.516 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.5 m -85.51 125.37 69.66 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-O 120.875 0.369 . . . . 0.0 110.605 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.593 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 37.9 Cg_endo -68.7 138.48 41.49 Favored 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.466 2.111 . . . . 0.0 111.733 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.1 mm -52.26 -37.98 24.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.628 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.65 32.98 1.71 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.891 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 169.11 -142.5 7.4 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 179.402 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PHE . . . . . 0.593 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 22.6 p90 -175.14 147.43 0.92 Allowed 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.745 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.7 t -93.44 -171.77 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 179.483 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.745 ' H ' HG12 ' A' ' 17' ' ' VAL . 52.2 p90 -141.19 137.54 32.72 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.262 0.553 . . . . 0.0 110.49 179.291 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.538 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 11.3 m -95.65 -177.62 4.12 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.649 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.725 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.7 m -72.02 152.25 92.82 Favored Pre-proline 0 N--CA 1.448 -0.549 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -50.5 113.85 1.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.772 1.648 . . . . 0.0 112.275 -178.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.0 -28.5 5.85 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.606 -179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.534 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.8 mt -111.91 152.0 28.52 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.942 0.371 . . . . 0.0 111.053 -179.102 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.1 pt -130.85 133.2 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.002 0.43 . . . . 0.0 110.975 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.576 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 46.6 t -75.67 134.54 40.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.446 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.508 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -136.42 -108.29 0.9 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.841 -0.695 . . . . 0.0 113.407 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.508 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 16.4 Cg_exo -68.68 61.61 1.2 Allowed 'Trans proline' 0 N--CA 1.478 0.609 0 C-N-CA 123.99 3.127 . . . . 0.0 113.925 -178.666 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.693 ' HA ' ' HA ' ' A' ' 10' ' ' ILE . 2.2 m-85 65.73 13.04 8.73 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.734 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 m -149.98 160.75 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.332 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 1.05 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.7 t -89.73 153.17 20.91 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.53 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.0 m . . . . . 0 C--O 1.246 0.895 0 CA-C-O 118.105 -0.95 . . . . 0.0 109.927 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.112 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.702 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 17.6 p -95.44 139.22 32.03 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.578 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.435 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 9.4 t -80.81 145.17 31.56 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.387 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.604 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -75.14 155.93 36.48 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.555 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.891 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.2 tttt -53.07 -66.66 0.35 Allowed 'General case' 0 C--O 1.217 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 112.217 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.0 m95 -81.31 27.29 0.42 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.574 -0.704 . . . . 0.0 110.914 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.604 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 37.4 tt0 -93.32 133.44 36.55 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -71.0 86.4 0.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.995 0.426 . . . . 0.0 112.124 -178.029 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.6 p -78.61 64.0 3.54 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.279 178.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.427 HG22 ' CD2' ' A' ' 28' ' ' PHE . 1.6 pp -70.34 52.93 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.633 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.705 ' HB ' ' HA2' ' A' ' 15' ' ' GLY . 16.2 m -75.0 130.99 79.67 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 121.168 0.508 . . . . 0.0 111.401 179.715 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.685 ' HB2' HD13 ' A' ' 13' ' ' ILE . 97.4 Cg_endo -81.72 156.32 18.38 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.888 2.392 . . . . 0.0 112.605 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.685 HD13 ' HB2' ' A' ' 12' ' ' PRO . 0.1 OUTLIER 41.06 -122.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.823 0.849 . . . . 0.0 113.18 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.8 mt -75.61 28.78 0.1 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.902 0.382 . . . . 0.0 111.631 -179.361 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.705 ' HA2' ' HB ' ' A' ' 11' ' ' VAL . . . 75.95 -149.76 38.32 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 121.175 -0.536 . . . . 0.0 113.117 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 24.6 t80 179.39 -51.52 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.772 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.9 t -93.82 -170.91 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.25 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.772 ' H ' HG12 ' A' ' 17' ' ' VAL . 41.7 p90 -157.34 146.29 19.83 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . 0.447 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 64.0 m -76.76 169.28 18.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.821 0.344 . . . . 0.0 111.368 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.702 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 17.3 m -69.34 153.9 95.43 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.16 116.05 2.56 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 121.76 1.64 . . . . 0.0 111.742 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.19 -27.27 8.65 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.187 -178.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.613 HD23 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -102.83 150.32 23.61 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.5 pt -135.68 131.2 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.052 0.453 . . . . 0.0 111.617 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' CYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.6 t -68.78 137.58 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.041 179.628 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.26 -109.33 0.92 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.102 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.89 61.21 2.34 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 123.441 2.76 . . . . 0.0 113.543 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.427 ' CD2' HG22 ' A' ' 10' ' ' ILE . 2.1 m-85 65.75 15.78 10.2 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 123.667 0.787 . . . . 0.0 110.658 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.79 155.85 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' CYS . . . . . 0.891 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 7.0 t -88.33 158.27 18.48 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.6 m . . . . . 0 C--O 1.248 0.984 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.129 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.8 p . . . . . 0 C--O 1.234 0.262 0 CA-C-O 121.042 0.448 . . . . 0.0 110.642 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.2 m -76.87 143.37 39.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.137 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.776 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.1 mttp -79.87 152.48 29.63 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 1.036 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.8 tttt -47.4 -72.58 0.05 Allowed 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 113.716 1.006 . . . . 0.0 113.716 -177.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.411 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.8 m95 -82.41 33.34 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.326 -0.859 . . . . 0.0 110.728 -178.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.776 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 27.0 tt0 . . . . . 0 C--N 1.33 -0.244 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.951 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.515 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 62.7 m . . . . . 0 CA--C 1.517 -0.306 0 CA-C-O 120.811 0.339 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 24.8 m -68.23 153.42 95.52 Favored Pre-proline 0 C--N 1.327 -0.39 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_exo -51.53 114.51 1.6 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.808 1.672 . . . . 0.0 112.033 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.13 -31.38 4.93 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.396 -1.275 . . . . 0.0 112.185 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.538 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.0 mt -105.3 149.33 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.673 0.237 . . . . 0.0 110.443 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.412 HD13 ' N ' ' A' ' 24' ' ' ILE . 0.2 OUTLIER -130.43 135.12 61.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.984 0.421 . . . . 0.0 111.216 179.687 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.7 m -61.75 148.03 44.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.636 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.77 -126.3 1.8 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.633 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.21 68.02 1.39 Allowed 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 123.506 2.804 . . . . 0.0 113.722 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.47 22.1 11.86 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 123.33 0.652 . . . . 0.0 110.858 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.3 m -150.13 -160.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -133.87 156.72 47.57 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.6 m . . . . . 0 C--O 1.246 0.871 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.143 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.0 p . . . . . 0 N--CA 1.454 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 109.992 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.56 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 16.9 m -76.94 143.98 39.14 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.092 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.83 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.4 mttp -77.73 150.74 34.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.852 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.9 tttt -50.31 -66.9 0.31 Allowed 'General case' 0 C--O 1.218 -0.605 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -177.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -82.01 29.14 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.316 -0.865 . . . . 0.0 111.085 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.83 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 38.6 tt0 . . . . . 0 C--N 1.328 -0.363 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.56 ' HA ' ' H ' ' A' ' 3' ' ' SER . 65.8 m . . . . . 0 N--CA 1.452 -0.369 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.754 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 25.1 m -68.07 152.78 96.19 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.26 112.72 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 121.863 1.709 . . . . 0.0 112.303 -178.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.22 -29.46 5.51 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.299 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.53 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 33.4 mt -105.12 148.85 26.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.788 0.294 . . . . 0.0 110.642 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.6 pt -137.74 135.52 45.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.813 0.34 . . . . 0.0 111.616 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 m -62.09 145.82 52.17 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.39 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -149.48 -110.78 0.55 Allowed Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.594 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.99 63.67 3.3 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.419 2.746 . . . . 0.0 113.716 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 64.26 20.65 12.26 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 123.408 0.683 . . . . 0.0 111.059 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 m -151.12 -164.84 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.852 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 10.5 t -124.52 156.24 37.63 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.425 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.245 0.867 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.23 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.741 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 22.8 p . . . . . 0 N--CA 1.453 -0.29 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.0 m -79.13 150.13 31.84 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.605 -178.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.693 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 6.6 ttpm? -65.81 145.48 55.91 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.326 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.964 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.1 tttt -50.6 -66.08 0.45 Allowed 'General case' 0 C--O 1.217 -0.636 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.9 m95 -80.8 32.47 0.31 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.328 -0.857 . . . . 0.0 110.728 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.693 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 31.7 tt0 . . . . . 0 C--N 1.324 -0.543 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.087 178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.47 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 95.0 m . . . . . 0 C--O 1.233 0.211 0 CA-C-O 121.04 0.448 . . . . 0.0 112.172 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.741 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 8.8 m -69.43 152.94 96.24 Favored Pre-proline 0 CA--C 1.517 -0.325 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.18 116.31 2.73 Favored 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 121.679 1.586 . . . . 0.0 111.723 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.91 -31.22 5.41 Favored Glycine 0 C--N 1.312 -0.788 0 CA-C-N 114.563 -1.199 . . . . 0.0 111.862 -178.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.676 HD13 ' HB2' ' A' ' 5' ' ' LYS . 59.1 mt -106.22 151.71 24.44 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.0 pt -142.76 135.22 25.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.892 0.377 . . . . 0.0 111.823 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 33.1 m -64.31 134.65 55.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.793 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.418 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -135.42 -100.99 0.64 Allowed Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.356 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.418 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 8.2 Cg_exo -72.13 58.52 2.88 Favored 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 123.611 2.874 . . . . 0.0 113.052 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 7.6 m-85 64.23 16.06 9.81 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.738 -179.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.8 m -150.11 163.02 3.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.964 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 9.1 t -88.56 151.92 22.19 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.96 0.409 . . . . 0.0 110.292 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.4 m . . . . . 0 C--O 1.246 0.919 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.847 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.714 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.2 p . . . . . 0 N--CA 1.455 -0.181 0 CA-C-O 121.012 0.434 . . . . 0.0 110.671 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -82.97 142.72 31.17 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.769 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.526 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 36.1 mtmm -70.75 157.53 37.89 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.984 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.2 tttt -50.93 -66.33 0.4 Allowed 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -81.72 31.47 0.36 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.694 -0.629 . . . . 0.0 111.264 -178.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 7.0 tp10 . . . . . 0 CA--C 1.534 0.327 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.478 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 97.7 m . . . . . 0 CA--C 1.519 -0.246 0 CA-C-O 120.863 0.364 . . . . 0.0 111.46 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.714 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 33.2 m -70.02 153.23 95.54 Favored Pre-proline 0 C--N 1.326 -0.432 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.56 115.49 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 121.807 1.671 . . . . 0.0 111.932 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 -31.6 4.99 Favored Glycine 0 C--N 1.312 -0.801 0 CA-C-N 114.422 -1.263 . . . . 0.0 112.076 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.514 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 49.3 mt -105.4 150.09 25.55 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.434 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -134.88 131.7 53.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.058 0.456 . . . . 0.0 111.525 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 30.9 t -65.18 140.32 58.75 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.741 179.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.76 -105.7 0.52 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.037 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.53 61.24 2.79 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.374 2.716 . . . . 0.0 113.735 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.75 11.64 8.35 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.691 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 m -150.43 162.41 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.984 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 6.3 t -89.59 155.13 19.46 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.453 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 22.8 m . . . . . 0 C--O 1.247 0.93 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.89 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.713 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.1 p . . . . . 0 N--CA 1.453 -0.286 0 CA-C-O 121.056 0.455 . . . . 0.0 110.625 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -75.51 143.71 42.38 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.359 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.495 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 7.3 ttpm? -64.08 146.47 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.493 178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.659 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.2 tttt -52.9 -57.52 9.99 Favored 'General case' 0 C--O 1.213 -0.836 0 CA-C-O 121.326 0.584 . . . . 0.0 112.282 -178.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -81.13 28.32 0.37 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 111.568 -178.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 3.8 tp10 . . . . . 0 C--N 1.33 -0.264 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 177.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 96.7 m . . . . . 0 C--O 1.233 0.235 0 CA-C-O 121.077 0.465 . . . . 0.0 112.078 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.713 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 16.6 m -68.46 154.03 94.9 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -51.49 115.6 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 121.813 1.676 . . . . 0.0 111.694 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.99 -31.36 5.71 Favored Glycine 0 C--N 1.311 -0.847 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.905 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.588 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 38.0 mt -101.04 148.62 24.83 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.5 pt -141.67 133.4 27.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.94 0.4 . . . . 0.0 111.486 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 72.2 m -60.26 137.95 58.03 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.55 179.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.6 -110.91 0.76 Allowed Glycine 0 CA--C 1.522 0.531 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.456 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.14 63.07 1.43 Allowed 'Trans proline' 0 N--CA 1.479 0.635 0 C-N-CA 123.609 2.872 . . . . 0.0 114.207 -178.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.64 11.74 8.35 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.604 0.762 . . . . 0.0 110.787 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 7' ' ' GLU . 18.6 m -151.94 162.74 2.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.133 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.659 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 24.9 t -89.54 156.01 18.91 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.3 m . . . . . 0 C--N 1.317 -0.832 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.124 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.745 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p . . . . . 0 N--CA 1.453 -0.307 0 CA-C-O 120.984 0.421 . . . . 0.0 110.809 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 m -71.42 141.82 50.29 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.146 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.659 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 4.3 ttmp? -71.77 142.5 49.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.536 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.955 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 37.8 tttt -47.94 -68.61 0.17 Allowed 'General case' 0 C--O 1.218 -0.602 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -177.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -81.74 35.05 0.4 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.269 -0.894 . . . . 0.0 110.299 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 22.6 tt0 . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.429 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.587 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 67.4 m . . . . . 0 CA--C 1.52 -0.182 0 CA-C-O 121.075 0.464 . . . . 0.0 111.57 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.745 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 13.9 m -67.9 153.52 95.11 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_exo -51.65 115.57 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.841 1.694 . . . . 0.0 111.71 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.4 -30.43 6.0 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 114.376 -1.283 . . . . 0.0 111.922 -178.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.587 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 49.5 mt -101.18 147.18 26.56 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.8 pt -130.28 132.97 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 111.509 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 74.0 m -58.93 140.01 55.98 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.118 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.41 -130.22 2.7 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.934 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -66.69 70.5 0.48 Allowed 'Trans proline' 0 N--CA 1.479 0.627 0 C-N-CA 123.823 3.015 . . . . 0.0 113.845 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 64.47 21.4 12.45 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.333 0.653 . . . . 0.0 110.684 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -150.32 -155.88 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.955 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 11.6 t -140.3 155.64 46.75 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.3 m . . . . . 0 C--O 1.245 0.857 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.227 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.775 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.8 p . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.185 0.517 . . . . 0.0 109.655 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.0 p -76.51 142.36 40.92 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.822 -178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.489 ' N ' ' HE3' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -75.02 157.01 35.6 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.297 178.895 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.981 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 31.2 tttt -49.35 -71.71 0.06 Allowed 'General case' 0 C--O 1.216 -0.663 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -80.6 31.39 0.29 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.254 -0.904 . . . . 0.0 110.542 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.488 ' OE1' ' HE3' ' A' ' 4' ' ' LYS . 27.8 tt0 . . . . . 0 C--N 1.324 -0.501 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.023 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 76.4 m . . . . . 0 CA--C 1.519 -0.231 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.775 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 7.8 m -64.67 151.63 91.78 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -51.47 114.6 1.64 Allowed 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 121.748 1.632 . . . . 0.0 111.959 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.56 -35.6 2.75 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.165 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.567 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 69.5 mt -102.27 149.79 23.96 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.637 0.218 . . . . 0.0 110.526 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.6 pt -125.71 131.43 71.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.159 0.504 . . . . 0.0 111.543 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 45.9 t -69.67 141.65 53.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.632 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -138.57 -117.54 1.53 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.986 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.46 63.51 2.2 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.48 2.787 . . . . 0.0 113.698 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 66.29 15.65 10.17 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.766 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.02 155.18 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 177.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.981 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.02 159.51 17.56 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 120.897 0.379 . . . . 0.0 110.54 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 m . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.202 -0.904 . . . . 0.0 109.806 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.2 p . . . . . 0 N--CA 1.453 -0.276 0 CA-C-O 120.979 0.419 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.0 m -81.36 148.81 29.17 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.844 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.629 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 19.7 mtpt -65.46 151.05 47.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.703 179.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.936 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.5 tttt -52.24 -65.02 0.63 Allowed 'General case' 0 C--O 1.214 -0.804 0 N-CA-C 112.824 0.675 . . . . 0.0 112.824 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.7 m95 -80.77 27.73 0.36 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.368 -0.833 . . . . 0.0 111.123 -178.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.629 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 2.3 tp10 . . . . . 0 N--CA 1.452 -0.373 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.3 m . . . . . 0 CA--C 1.521 -0.151 0 CA-C-O 120.665 0.269 . . . . 0.0 110.672 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.8 OUTLIER -69.78 156.32 91.94 Favored Pre-proline 0 C--N 1.326 -0.419 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.032 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.14 114.66 1.84 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.177 1.918 . . . . 0.0 111.584 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.18 -35.25 2.76 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 114.259 -1.337 . . . . 0.0 111.84 -178.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.555 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 2.5 mm? -112.59 150.02 31.95 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.1 pt -138.69 134.11 42.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.781 0.325 . . . . 0.0 111.169 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.632 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 37.1 t -65.8 139.59 58.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.787 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -142.93 -97.92 0.27 Allowed Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.7 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.38 58.76 3.77 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.151 2.567 . . . . 0.0 113.498 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 65.14 14.34 9.32 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.837 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.61 163.76 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.936 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.3 t -89.15 150.72 22.57 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 29.2 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.018 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.728 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 27.9 p . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.904 0.383 . . . . 0.0 110.247 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -83.57 150.93 25.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.844 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 22.5 mtmt -65.51 157.37 29.8 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.869 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.5 tttt -49.8 -61.33 2.19 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 113.982 1.105 . . . . 0.0 113.982 -177.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -80.9 25.57 0.45 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 112.186 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.844 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 70.0 mm-40 . . . . . 0 C--N 1.329 -0.295 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 177.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.5 m . . . . . 0 CA--C 1.52 -0.177 0 CA-C-O 120.665 0.269 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.728 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.5 OUTLIER -72.19 157.03 90.03 Favored Pre-proline 0 CA--C 1.513 -0.45 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.558 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -53.0 114.19 1.61 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.211 1.94 . . . . 0.0 111.664 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.35 -36.06 2.46 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 114.192 -1.367 . . . . 0.0 111.662 -178.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.504 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 71.4 mt -108.25 148.26 30.23 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.9 pt -129.35 131.87 67.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.809 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.514 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.1 t -67.24 138.53 56.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.499 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.1 -116.9 1.57 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.946 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 63.74 1.94 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.549 2.833 . . . . 0.0 113.559 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 65.72 16.58 10.55 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.678 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 m -151.54 154.1 8.79 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.869 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.65 155.82 19.38 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.512 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.6 m . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.121 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.712 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.6 p . . . . . 0 N--CA 1.453 -0.31 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.2 t -169.21 164.25 11.01 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.0 0.364 . . . . 0.0 110.446 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.573 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 30.1 mtmm -69.95 151.84 45.15 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.227 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.792 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.4 tttt -54.3 -60.79 2.86 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -80.85 26.07 0.43 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.47 -0.769 . . . . 0.0 111.206 -178.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.573 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.493 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.1 m . . . . . 0 CA--C 1.516 -0.362 0 CA-C-O 121.087 0.47 . . . . 0.0 111.454 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.712 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.1 m -70.5 151.05 95.63 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -49.69 113.35 0.94 Allowed 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.745 1.63 . . . . 0.0 112.139 -178.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.92 -33.47 3.53 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.497 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.4 mt -104.98 146.45 29.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.564 0.221 . . . . 0.0 110.628 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.3 pt -133.27 133.61 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.972 0.415 . . . . 0.0 111.224 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 51.6 m -66.77 140.0 57.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.98 0.419 . . . . 0.0 111.515 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.35 -112.6 1.14 Allowed Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.198 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.62 62.8 2.27 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.367 2.711 . . . . 0.0 113.704 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 65.4 15.8 10.21 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 123.617 0.767 . . . . 0.0 110.976 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.18 160.33 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.792 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 3.4 t -89.33 156.14 18.91 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.926 0.393 . . . . 0.0 110.158 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.6 m . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.905 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.785 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.9 p . . . . . 0 N--CA 1.455 -0.176 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.427 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 31.0 m -84.97 153.81 22.55 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.151 -179.068 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.596 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -66.16 160.11 24.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.267 179.065 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.943 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.1 tttt -52.05 -63.69 1.06 Allowed 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 -178.442 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -82.02 31.63 0.38 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.781 -0.574 . . . . 0.0 111.153 -178.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.596 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.534 0.35 0 CA-C-O 121.232 0.539 . . . . 0.0 110.006 178.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 94.7 m . . . . . 0 C--O 1.233 0.233 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.785 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 4.5 m -62.64 152.41 81.46 Favored Pre-proline 0 N--CA 1.452 -0.338 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -50.85 115.18 1.84 Allowed 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 121.784 1.656 . . . . 0.0 111.847 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.14 -35.32 3.4 Favored Glycine 0 C--N 1.312 -0.774 0 CA-C-N 114.388 -1.278 . . . . 0.0 111.935 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.612 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 5.2 mp -98.9 147.88 24.52 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 pt -132.74 132.33 59.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.105 0.479 . . . . 0.0 111.766 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.7 t -68.82 143.93 54.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.314 179.477 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.434 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -144.59 -109.43 0.65 Allowed Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.929 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.434 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.5 Cg_exo -70.52 61.87 2.17 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.724 2.949 . . . . 0.0 113.525 -178.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 65.79 13.89 9.24 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.565 -179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 m -150.35 161.04 4.2 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.943 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.3 155.85 19.11 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.877 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.828 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.8 p . . . . . 0 N--CA 1.452 -0.328 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -76.22 146.89 38.74 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.321 -179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.856 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 28.5 mtpt -66.75 148.65 51.64 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.945 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.6 tttt -51.37 -66.06 0.45 Allowed 'General case' 0 C--O 1.218 -0.565 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 10.3 m95 -80.92 29.32 0.33 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.802 -0.561 . . . . 0.0 110.94 -179.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.856 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 13.8 tp10 . . . . . 0 C--N 1.326 -0.451 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.554 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 92.9 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.801 0.334 . . . . 0.0 110.904 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.828 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -68.89 156.6 90.98 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -52.12 113.08 1.03 Allowed 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.095 1.863 . . . . 0.0 111.629 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.84 -34.93 2.87 Favored Glycine 0 C--N 1.311 -0.857 0 CA-C-N 114.114 -1.403 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.554 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 54.6 mt -103.95 139.95 38.39 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.703 0.252 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 21.1 pt -127.31 133.09 68.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.999 0.428 . . . . 0.0 111.573 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -63.4 139.43 58.77 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.7 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.423 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -140.97 -117.22 1.35 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.967 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.0 Cg_exo -70.96 62.68 2.46 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 123.727 2.951 . . . . 0.0 113.222 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.7 16.16 10.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.496 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.4 m -151.15 155.47 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.132 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.945 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 1.8 t -89.52 153.87 20.46 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.515 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.9 m . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.98 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.784 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p . . . . . 0 N--CA 1.455 -0.18 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.3 t -85.21 143.3 28.85 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.613 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.644 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 5.1 ttpm? -66.48 153.37 43.04 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 1.047 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 36.2 tttt -50.54 -68.59 0.16 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.447 0.536 . . . . 0.0 112.447 -178.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.41 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.9 m95 -82.1 32.04 0.38 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.75 -0.593 . . . . 0.0 110.657 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.644 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 2.6 tp10 . . . . . 0 C--N 1.33 -0.253 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.305 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.477 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.0 m . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.807 0.337 . . . . 0.0 111.303 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.784 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 12.3 m -66.33 151.88 95.22 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.47 116.25 2.73 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 121.806 1.671 . . . . 0.0 111.758 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.18 -29.66 5.89 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.958 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.511 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.9 mt -106.15 147.17 29.32 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.9 pt -130.09 132.47 65.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.063 0.459 . . . . 0.0 111.473 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.2 t -64.1 140.77 58.9 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -140.68 -117.96 1.44 Allowed Glycine 0 CA--C 1.522 0.513 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.954 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 64.74 2.33 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.494 2.796 . . . . 0.0 113.814 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 67.02 13.1 9.35 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.8 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 m -150.46 159.26 4.85 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 1.047 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.5 t -89.29 154.06 20.4 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.52 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.3 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.042 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.672 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.5 p . . . . . 0 N--CA 1.454 -0.27 0 CA-C-O 121.038 0.447 . . . . 0.0 110.544 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -80.18 143.12 34.09 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.051 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.814 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 12.7 mtmt -67.98 149.48 49.68 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.879 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.6 tttt -51.81 -57.12 10.23 Favored 'General case' 0 C--O 1.213 -0.828 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 20.4 m95 -81.23 23.02 0.62 Allowed 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 112.689 -177.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.814 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 6.0 mm-40 . . . . . 0 CA--C 1.518 -0.286 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.471 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 93.6 m . . . . . 0 CA--C 1.519 -0.226 0 CA-C-O 121.139 0.495 . . . . 0.0 111.824 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.672 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 21.2 m -72.64 154.23 91.44 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 177.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -51.62 115.16 1.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.801 1.667 . . . . 0.0 111.9 -179.509 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.25 -31.71 5.35 Favored Glycine 0 C--N 1.311 -0.81 0 CA-C-N 114.479 -1.237 . . . . 0.0 112.179 -178.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.618 HD13 ' HB2' ' A' ' 5' ' ' LYS . 44.4 mt -103.45 150.48 23.83 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -143.7 132.74 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.856 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.662 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 99.0 m -68.24 134.41 50.35 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.377 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.16 -84.02 0.05 OUTLIER Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.72 -0.753 . . . . 0.0 113.131 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.13 55.5 4.03 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 123.284 2.656 . . . . 0.0 112.966 -179.188 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 64.74 12.42 7.62 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.36 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.4 m -151.77 167.45 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.879 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 15.0 t -89.38 153.19 21.05 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.016 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.446 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 34.9 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.852 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.813 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 15.7 p . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -115.2 -162.86 0.84 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.222 0.534 . . . . 0.0 112.251 -177.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -80.65 150.05 29.57 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.123 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.691 ' HB2' HD13 ' A' ' 23' ' ' LEU . 29.0 tttt -57.39 -55.54 33.48 Favored 'General case' 0 C--O 1.211 -0.969 0 CA-C-O 121.514 0.673 . . . . 0.0 112.063 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.7 m95 -81.04 24.01 0.53 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.936 -1.103 . . . . 0.0 111.596 -178.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 . . . . . 0 C--O 1.235 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.857 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 66.0 m . . . . . 0 CA--C 1.515 -0.383 0 CA-C-O 121.185 0.517 . . . . 0.0 111.41 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.813 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -70.89 160.62 81.65 Favored Pre-proline 0 N--CA 1.445 -0.702 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.96 111.45 0.52 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.254 1.969 . . . . 0.0 112.056 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.31 -39.28 1.67 Allowed Glycine 0 C--N 1.309 -0.944 0 CA-C-N 113.847 -1.524 . . . . 0.0 111.659 -178.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 5' ' ' LYS . 64.5 mt -111.17 145.46 38.61 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 120.535 0.207 . . . . 0.0 110.47 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.0 pt -138.91 140.4 38.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.957 0.408 . . . . 0.0 111.591 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.733 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 22.7 m -77.5 139.5 39.62 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.103 0.478 . . . . 0.0 111.445 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.91 -85.73 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.079 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -75.78 55.43 4.35 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.826 2.351 . . . . 0.0 112.793 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 63.95 15.2 9.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.889 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.4 m -147.25 164.33 7.02 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.733 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 6.7 t -90.51 150.92 21.58 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-O 120.931 0.396 . . . . 0.0 109.953 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.519 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 35.2 m . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.963 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.694 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.4 p . . . . . 0 N--CA 1.456 -0.168 0 N-CA-C 110.553 -0.166 . . . . 0.0 110.553 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.3 t -164.22 157.92 18.42 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.794 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 14.2 ttmt -64.35 146.75 53.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.599 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.878 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.1 tttt -52.13 -64.57 0.77 Allowed 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.671 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.0 m95 -80.5 27.35 0.35 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 111.151 -178.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.8 tp10 . . . . . 0 N--CA 1.451 -0.409 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.423 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m . . . . . 0 CA--C 1.52 -0.2 0 CA-C-O 120.821 0.343 . . . . 0.0 110.506 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.694 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 6.4 m -66.45 151.82 95.56 Favored Pre-proline 0 C--N 1.327 -0.403 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.97 115.8 2.37 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 121.913 1.742 . . . . 0.0 112.219 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.73 -21.98 12.11 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.232 -178.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.52 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 45.2 mt -116.72 152.67 33.84 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.8 pt -142.15 135.59 28.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.69 0.281 . . . . 0.0 111.366 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 15.6 m -67.12 136.21 54.78 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.752 0.31 . . . . 0.0 110.964 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -135.71 -105.95 0.82 Allowed Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.204 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.13 60.24 3.11 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.249 2.632 . . . . 0.0 113.34 -179.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 65.08 17.29 11.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.964 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.52 160.52 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 178.041 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.878 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.53 151.18 22.68 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.54 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 23.3 m . . . . . 0 C--O 1.244 0.802 0 CA-C-O 118.064 -0.97 . . . . 0.0 110.013 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.717 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.9 p . . . . . 0 N--CA 1.455 -0.198 0 CA-C-O 120.807 0.337 . . . . 0.0 110.548 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m -87.69 148.46 24.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.067 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.514 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 2.7 tmmm? -68.95 145.79 53.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.251 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.966 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 38.0 tttt -49.23 -68.52 0.17 Allowed 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . 0.409 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 8.5 m95 -81.22 32.72 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.461 -0.774 . . . . 0.0 111.048 -178.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.4 tp10 . . . . . 0 C--N 1.33 -0.272 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 99.1 m . . . . . 0 CA--C 1.519 -0.218 0 CA-C-O 121.116 0.484 . . . . 0.0 111.955 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.717 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 23.2 m -71.18 154.04 94.08 Favored Pre-proline 0 CA--C 1.515 -0.375 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.086 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -51.82 115.52 2.18 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 121.85 1.7 . . . . 0.0 111.896 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.02 -31.6 5.07 Favored Glycine 0 C--N 1.312 -0.805 0 CA-C-N 114.491 -1.231 . . . . 0.0 111.963 -178.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 46.7 mt -103.87 149.99 24.57 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.8 pt -136.15 133.57 50.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.042 0.448 . . . . 0.0 111.849 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 20.8 m -63.26 139.31 58.76 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.503 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.33 -118.62 1.6 Allowed Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.622 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.39 65.37 1.12 Allowed 'Trans proline' 0 N--CA 1.479 0.651 0 C-N-CA 123.657 2.905 . . . . 0.0 113.97 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 66.49 12.57 8.79 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 123.601 0.76 . . . . 0.0 110.875 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 m -150.13 161.33 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.966 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.7 t -89.41 152.45 21.48 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.531 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.8 m . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.083 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.733 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 21.4 p . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 121.06 0.457 . . . . 0.0 110.987 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.484 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 34.1 t -75.62 140.84 42.84 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.8 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.852 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -68.68 150.82 47.49 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.6 tttt -54.22 -66.24 0.43 Allowed 'General case' 0 C--O 1.214 -0.798 0 CA-C-O 121.153 0.502 . . . . 0.0 112.211 -178.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m95 -80.59 26.89 0.38 Allowed 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.282 -0.886 . . . . 0.0 111.039 -178.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.852 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 12.4 tp10 . . . . . 0 C--O 1.235 0.308 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 177.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.484 ' HA ' ' H ' ' A' ' 3' ' ' SER . 35.1 m . . . . . 0 CA--C 1.52 -0.191 0 CA-C-O 120.792 0.329 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.733 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 22.5 m -68.03 153.25 95.62 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.27 115.55 2.26 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.863 1.709 . . . . 0.0 111.89 -179.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.9 -26.0 9.13 Favored Glycine 0 C--N 1.312 -0.768 0 CA-C-N 114.429 -1.259 . . . . 0.0 112.231 -178.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.55 HD13 ' HB2' ' A' ' 5' ' ' LYS . 41.6 mt -107.41 149.53 27.79 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.703 0.252 . . . . 0.0 110.453 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.2 pt -137.79 131.41 42.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.9 0.381 . . . . 0.0 111.301 179.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.596 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 42.9 t -67.47 135.5 53.17 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.158 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -136.96 -106.07 0.77 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.869 -0.682 . . . . 0.0 113.054 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.44 60.51 2.66 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 123.389 2.726 . . . . 0.0 113.539 -179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 66.0 14.5 9.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.759 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.3 m -151.15 155.77 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.808 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -88.86 154.68 20.06 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.443 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.2 m . . . . . 0 C--O 1.246 0.905 0 CA-C-O 117.915 -1.04 . . . . 0.0 109.972 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.725 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.3 p . . . . . 0 N--CA 1.454 -0.229 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -169.44 152.88 4.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.838 0.29 . . . . 0.0 110.707 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.638 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 7.2 ttpt -64.29 146.22 54.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.678 179.101 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 1.05 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.9 tttt -51.4 -66.03 0.45 Allowed 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.211 0.529 . . . . 0.0 111.99 -179.032 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -82.04 33.61 0.39 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.882 -0.511 . . . . 0.0 110.839 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.638 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 7.2 tp10 . . . . . 0 CA--C 1.534 0.357 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.538 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 11.3 m . . . . . 0 CA--C 1.514 -0.436 0 CA-C-O 120.783 0.325 . . . . 0.0 110.649 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.725 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.7 m -72.02 152.25 92.82 Favored Pre-proline 0 N--CA 1.448 -0.549 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -50.5 113.85 1.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.772 1.648 . . . . 0.0 112.275 -178.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.0 -28.5 5.85 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.606 -179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.534 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.8 mt -111.91 152.0 28.52 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.942 0.371 . . . . 0.0 111.053 -179.102 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.1 pt -130.85 133.2 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.002 0.43 . . . . 0.0 110.975 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.576 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 46.6 t -75.67 134.54 40.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.446 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.508 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -136.42 -108.29 0.9 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.841 -0.695 . . . . 0.0 113.407 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.508 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 16.4 Cg_exo -68.68 61.61 1.2 Allowed 'Trans proline' 0 N--CA 1.478 0.609 0 C-N-CA 123.99 3.127 . . . . 0.0 113.925 -178.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 65.73 13.04 8.73 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.734 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 m -149.98 160.75 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.332 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 1.05 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.7 t -89.73 153.17 20.91 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.53 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.0 m . . . . . 0 C--O 1.246 0.895 0 CA-C-O 118.105 -0.95 . . . . 0.0 109.927 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.702 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 17.6 p . . . . . 0 N--CA 1.454 -0.259 0 CA-C-O 120.843 0.354 . . . . 0.0 110.578 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.435 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 9.4 t -80.81 145.17 31.56 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.387 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.604 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -75.14 155.93 36.48 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.555 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.891 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.2 tttt -53.07 -66.66 0.35 Allowed 'General case' 0 C--O 1.217 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 112.217 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.0 m95 -81.31 27.29 0.42 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.574 -0.704 . . . . 0.0 110.914 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.604 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 37.4 tt0 . . . . . 0 C--N 1.329 -0.322 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' CYS . . . . . 0.447 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 64.0 m . . . . . 0 CA--C 1.519 -0.226 0 CA-C-O 120.821 0.344 . . . . 0.0 111.368 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.702 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 17.3 m -69.34 153.9 95.43 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.16 116.05 2.56 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 121.76 1.64 . . . . 0.0 111.742 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.19 -27.27 8.65 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.187 -178.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.613 HD23 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -102.83 150.32 23.61 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.5 pt -135.68 131.2 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.052 0.453 . . . . 0.0 111.617 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.6 t -68.78 137.58 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.041 179.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.26 -109.33 0.92 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.102 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.89 61.21 2.34 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 123.441 2.76 . . . . 0.0 113.543 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 65.75 15.78 10.2 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 123.667 0.787 . . . . 0.0 110.658 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.79 155.85 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' CYS . . . . . 0.891 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 7.0 t -88.33 158.27 18.48 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.6 m . . . . . 0 C--O 1.248 0.984 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.129 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.8 p -89.61 132.0 35.33 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 121.042 0.448 . . . . 0.0 110.642 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.2 m -76.87 143.37 39.72 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.137 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.776 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.1 mttp -79.87 152.48 29.63 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 1.036 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.8 tttt -47.4 -72.58 0.05 Allowed 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 113.716 1.006 . . . . 0.0 113.716 -177.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.411 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.8 m95 -82.41 33.34 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.326 -0.859 . . . . 0.0 110.728 -178.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.776 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 27.0 tt0 -96.17 -125.89 0.13 Allowed 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.951 179.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -142.17 131.65 23.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.88 0.372 . . . . 0.0 110.559 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.478 ' SG ' ' HB ' ' A' ' 17' ' ' VAL . 42.1 t -165.04 123.14 1.65 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.42 179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.467 ' C ' ' HD3' ' A' ' 12' ' ' PRO . 14.7 tt -107.67 143.99 17.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.693 ' HA ' ' HB3' ' A' ' 16' ' ' PHE . 5.7 m -120.28 67.43 12.87 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -178.704 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.543 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 12.1 Cg_exo -69.18 137.65 37.67 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.486 2.124 . . . . 0.0 111.385 178.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 13.9 pt -69.52 67.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-O 121.614 0.721 . . . . 0.0 112.126 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.439 HD13 ' O ' ' A' ' 14' ' ' LEU . 1.7 tm? -173.4 -32.31 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.543 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . -179.72 135.47 2.51 Favored Glycine 0 N--CA 1.448 -0.508 0 CA-C-N 114.772 -1.103 . . . . 0.0 110.405 179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.693 ' HB3' ' HA ' ' A' ' 11' ' ' VAL . 1.8 p90 -146.64 166.22 27.2 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 117.203 0.501 . . . . 0.0 111.704 -178.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.759 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.7 t -81.28 -169.43 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.761 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.759 ' H ' HG12 ' A' ' 17' ' ' VAL . 53.0 p90 -149.02 135.81 19.7 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.107 0.479 . . . . 0.0 110.87 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.515 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 62.7 m -83.93 171.86 12.63 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.008 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 24.8 m -68.23 153.42 95.52 Favored Pre-proline 0 C--N 1.327 -0.39 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 178.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_exo -51.53 114.51 1.6 Allowed 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 121.808 1.672 . . . . 0.0 112.033 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.13 -31.38 4.93 Favored Glycine 0 C--N 1.311 -0.813 0 CA-C-N 114.396 -1.275 . . . . 0.0 112.185 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.538 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.0 mt -105.3 149.33 26.12 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.673 0.237 . . . . 0.0 110.443 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.412 HD13 ' N ' ' A' ' 24' ' ' ILE . 0.2 OUTLIER -130.43 135.12 61.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.984 0.421 . . . . 0.0 111.216 179.687 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 73.7 m -61.75 148.03 44.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.636 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.77 -126.3 1.8 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.113 -0.565 . . . . 0.0 112.633 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.21 68.02 1.39 Allowed 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 123.506 2.804 . . . . 0.0 113.722 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.47 22.1 11.86 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 123.33 0.652 . . . . 0.0 110.858 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 28.3 m -150.13 -160.9 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -133.87 156.72 47.57 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.6 m . . . . . 0 C--O 1.246 0.871 0 CA-C-O 118.041 -0.98 . . . . 0.0 110.143 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.986 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.754 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.0 p -150.78 133.55 15.81 Favored 'General case' 0 C--N 1.323 -0.556 0 O-C-N 123.349 0.406 . . . . 0.0 109.992 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.56 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 16.9 m -76.94 143.98 39.14 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.092 -179.139 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.83 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 29.4 mttp -77.73 150.74 34.38 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.852 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.9 tttt -50.31 -66.9 0.31 Allowed 'General case' 0 C--O 1.218 -0.605 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -177.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -82.01 29.14 0.41 Allowed 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.316 -0.865 . . . . 0.0 111.085 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.83 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 38.6 tt0 -97.75 141.12 31.16 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 50.2 t80 -63.24 113.8 3.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.047 0.451 . . . . 0.0 111.283 -179.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 16.7 t -96.49 123.81 40.28 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.557 ' H ' HD12 ' A' ' 10' ' ' ILE . 3.9 mp -59.78 -44.95 95.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.395 -178.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.482 HG11 ' HB3' ' A' ' 16' ' ' PHE . 11.5 p -88.72 128.32 52.92 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.181 0.515 . . . . 0.0 111.223 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.472 ' HB2' ' H ' ' A' ' 13' ' ' ILE . 88.3 Cg_endo -85.21 -148.27 0.03 OUTLIER 'Trans proline' 0 C--O 1.244 0.797 0 C-N-CA 122.694 2.263 . . . . 0.0 112.31 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.472 ' H ' ' HB2' ' A' ' 12' ' ' PRO . 43.2 mt -63.79 81.16 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.289 179.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -171.38 -39.39 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 -178.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.16 147.43 8.16 Favored Glycine 0 C--N 1.333 0.388 0 CA-C-N 115.223 -0.899 . . . . 0.0 113.539 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.482 ' HB3' HG11 ' A' ' 11' ' ' VAL . 28.3 t80 -173.9 -51.09 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.702 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.9 t -91.42 -171.3 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 177.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.702 ' H ' HG12 ' A' ' 17' ' ' VAL . 25.4 t80 -149.73 126.36 10.97 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.297 0.57 . . . . 0.0 111.324 179.609 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.56 ' HA ' ' H ' ' A' ' 3' ' ' SER . 65.8 m -76.96 178.5 6.88 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.139 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.754 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 25.1 m -68.07 152.78 96.19 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -50.26 112.72 0.79 Allowed 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 121.863 1.709 . . . . 0.0 112.303 -178.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.22 -29.46 5.51 Favored Glycine 0 N--CA 1.443 -0.899 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.299 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.53 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 33.4 mt -105.12 148.85 26.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.788 0.294 . . . . 0.0 110.642 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.6 pt -137.74 135.52 45.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.813 0.34 . . . . 0.0 111.616 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 41.2 m -62.09 145.82 52.17 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.39 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -149.48 -110.78 0.55 Allowed Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.594 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.99 63.67 3.3 Favored 'Trans proline' 0 N--CA 1.475 0.435 0 C-N-CA 123.419 2.746 . . . . 0.0 113.716 -179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 64.26 20.65 12.26 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 123.408 0.683 . . . . 0.0 111.059 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 m -151.12 -164.84 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 177.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.852 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 10.5 t -124.52 156.24 37.63 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.425 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.245 0.867 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.23 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.232 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.806 ' HA ' ' O ' ' A' ' 18' ' ' TYR . 22.8 p -125.8 133.54 51.98 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.0 m -79.13 150.13 31.84 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.605 -178.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.693 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 6.6 ttpm? -65.81 145.48 55.91 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.326 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.964 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.1 tttt -50.6 -66.08 0.45 Allowed 'General case' 0 C--O 1.217 -0.636 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -178.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.9 m95 -80.8 32.47 0.31 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.328 -0.857 . . . . 0.0 110.728 -178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.693 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 31.7 tt0 -103.84 138.37 40.53 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.087 178.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.59 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 32.6 t80 -63.13 118.9 8.55 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -179.531 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 77.5 m -75.66 55.85 0.87 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.05 -179.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.59 ' HB ' ' CD2' ' A' ' 8' ' ' TYR . 14.4 tt -80.53 61.82 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 122.305 1.05 . . . . 0.0 109.562 178.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.612 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 27.2 m -64.44 128.29 93.18 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.035 -0.984 . . . . 0.0 111.758 -178.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.459 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 22.9 Cg_exo -64.89 137.29 52.58 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.841 2.361 . . . . 0.0 111.759 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 26.2 pt -55.88 -35.67 41.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.745 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.758 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.5 pt? -101.45 29.1 5.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.753 0.311 . . . . 0.0 111.116 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.428 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . 175.04 57.27 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.321 -0.942 . . . . 0.0 112.18 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.612 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 8.1 p90 -60.5 134.83 57.46 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.247 0.546 . . . . 0.0 111.468 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.759 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.6 t -95.16 -170.71 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.998 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.806 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.7 p90 -157.59 149.18 21.89 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.47 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 95.0 m -71.09 165.8 22.76 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.04 0.448 . . . . 0.0 112.172 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.741 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 8.8 m -69.43 152.94 96.24 Favored Pre-proline 0 CA--C 1.517 -0.325 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.18 116.31 2.73 Favored 'Trans proline' 0 N--CA 1.457 -0.657 0 C-N-CA 121.679 1.586 . . . . 0.0 111.723 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.91 -31.22 5.41 Favored Glycine 0 C--N 1.312 -0.788 0 CA-C-N 114.563 -1.199 . . . . 0.0 111.862 -178.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.676 HD13 ' HB2' ' A' ' 5' ' ' LYS . 59.1 mt -106.22 151.71 24.44 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.0 pt -142.76 135.22 25.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 120.892 0.377 . . . . 0.0 111.823 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.562 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 33.1 m -64.31 134.65 55.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.793 179.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.418 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -135.42 -100.99 0.64 Allowed Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.356 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.418 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 8.2 Cg_exo -72.13 58.52 2.88 Favored 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 123.611 2.874 . . . . 0.0 113.052 -179.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.43 ' HB3' ' CE1' ' A' ' 8' ' ' TYR . 7.6 m-85 64.23 16.06 9.81 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.738 -179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.8 m -150.11 163.02 3.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 178.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.964 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 9.1 t -88.56 151.92 22.19 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.96 0.409 . . . . 0.0 110.292 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.4 m . . . . . 0 C--O 1.246 0.919 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.847 179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.141 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.714 ' HA ' ' O ' ' A' ' 18' ' ' TYR . 20.2 p -94.39 133.35 38.06 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.012 0.434 . . . . 0.0 110.671 -179.642 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -82.97 142.72 31.17 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.769 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.526 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 36.1 mtmm -70.75 157.53 37.89 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.984 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.2 tttt -50.93 -66.33 0.4 Allowed 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.123 0.786 . . . . 0.0 113.123 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 6.7 m95 -81.72 31.47 0.36 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.694 -0.629 . . . . 0.0 111.264 -178.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 7.0 tp10 -77.92 -126.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 37.9 t80 -162.07 133.82 5.44 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 7.4 p -150.69 130.59 13.33 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.258 0.552 . . . . 0.0 111.301 -179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 pt -135.5 48.68 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.5 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.623 ' HB ' ' HA2' ' A' ' 15' ' ' GLY . 35.4 m -68.47 135.44 90.78 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.623 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.86 -162.42 0.16 Allowed 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.629 2.219 . . . . 0.0 112.375 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.46 HG13 ' HG ' ' A' ' 14' ' ' LEU . 28.8 pt -58.72 -35.05 53.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.95 -0.568 . . . . 0.0 112.345 -179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.46 ' HG ' HG13 ' A' ' 13' ' ' ILE . 92.9 mt -96.21 15.93 19.61 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.604 0.24 . . . . 0.0 111.072 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.623 ' HA2' ' HB ' ' A' ' 11' ' ' VAL . . . 62.53 -157.78 36.98 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.523 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.483 ' HB3' HG12 ' A' ' 11' ' ' VAL . 15.1 t80 175.81 -50.82 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 121.336 0.588 . . . . 0.0 109.444 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.667 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.2 t -119.85 -174.24 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.081 179.22 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.714 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 38.4 p90 -162.68 146.15 11.28 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.478 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 97.7 m -77.63 167.95 20.76 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.863 0.364 . . . . 0.0 111.46 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.714 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 33.2 m -70.02 153.23 95.54 Favored Pre-proline 0 C--N 1.326 -0.432 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -52.56 115.49 2.25 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 121.807 1.671 . . . . 0.0 111.932 -179.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.43 -31.6 4.99 Favored Glycine 0 C--N 1.312 -0.801 0 CA-C-N 114.422 -1.263 . . . . 0.0 112.076 -178.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.514 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 49.3 mt -105.4 150.09 25.55 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 -179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.434 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -134.88 131.7 53.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.058 0.456 . . . . 0.0 111.525 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 30.9 t -65.18 140.32 58.75 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.741 179.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.76 -105.7 0.52 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.037 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.53 61.24 2.79 Favored 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 123.374 2.716 . . . . 0.0 113.735 -178.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.439 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 2.2 m-85 66.75 11.64 8.35 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.691 -179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.5 m -150.43 162.41 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.984 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 6.3 t -89.59 155.13 19.46 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.453 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 22.8 m . . . . . 0 C--O 1.247 0.93 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.89 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.216 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.713 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 20.1 p -115.16 132.48 56.59 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.056 0.455 . . . . 0.0 110.625 -179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -75.51 143.71 42.38 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.359 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.495 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 7.3 ttpm? -64.08 146.47 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.493 178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.659 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 29.2 tttt -52.9 -57.52 9.99 Favored 'General case' 0 C--O 1.213 -0.836 0 CA-C-O 121.326 0.584 . . . . 0.0 112.282 -178.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -81.13 28.32 0.37 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 111.568 -178.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 3.8 tp10 -82.99 145.43 29.34 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 177.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -74.96 58.97 0.88 Allowed 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.502 0.668 . . . . 0.0 110.259 179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.22 102.99 3.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.848 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 29.2 pt -113.04 28.63 2.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.579 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.4 m 35.15 59.32 2.52 Favored Pre-proline 0 N--CA 1.476 0.854 0 O-C-N 124.367 1.042 . . . . 0.0 113.604 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.535 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 56.1 Cg_endo -71.25 140.3 36.91 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.042 1.828 . . . . 0.0 111.869 179.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.9 pt -57.5 -29.83 34.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.6 tp -68.92 -24.1 64.25 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.238 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 176.49 80.71 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.088 -179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.535 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 4.0 p90 -69.88 -31.86 69.91 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -179.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.76 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.0 t 58.35 -152.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.203 -179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.76 ' H ' HG12 ' A' ' 17' ' ' VAL . 48.0 p90 -167.81 142.78 3.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.637 -179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 96.7 m -70.61 167.95 17.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.077 0.465 . . . . 0.0 112.078 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.713 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 16.6 m -68.46 154.03 94.9 Favored Pre-proline 0 C--N 1.327 -0.379 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -51.49 115.6 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 121.813 1.676 . . . . 0.0 111.694 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 117.99 -31.36 5.71 Favored Glycine 0 C--N 1.311 -0.847 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.905 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.588 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 38.0 mt -101.04 148.62 24.83 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.5 pt -141.67 133.4 27.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.94 0.4 . . . . 0.0 111.486 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 72.2 m -60.26 137.95 58.03 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.55 179.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -143.6 -110.91 0.76 Allowed Glycine 0 CA--C 1.522 0.531 0 C-N-CA 120.694 -0.765 . . . . 0.0 113.456 -179.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.14 63.07 1.43 Allowed 'Trans proline' 0 N--CA 1.479 0.635 0 C-N-CA 123.609 2.872 . . . . 0.0 114.207 -178.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 66.64 11.74 8.35 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.604 0.762 . . . . 0.0 110.787 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 7' ' ' GLU . 18.6 m -151.94 162.74 2.65 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.133 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.659 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 24.9 t -89.54 156.01 18.91 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.3 m . . . . . 0 C--N 1.317 -0.832 0 CA-C-O 118.047 -0.978 . . . . 0.0 110.124 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.175 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.745 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p -111.23 131.62 54.98 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.984 0.421 . . . . 0.0 110.809 -179.512 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 m -71.42 141.82 50.29 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.146 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.659 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 4.3 ttmp? -71.77 142.5 49.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.536 179.51 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.955 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 37.8 tttt -47.94 -68.61 0.17 Allowed 'General case' 0 C--O 1.218 -0.602 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -177.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -81.74 35.05 0.4 Allowed 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.269 -0.894 . . . . 0.0 110.299 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.659 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 22.6 tt0 -127.1 151.64 48.37 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.429 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 4.0 m-85 -61.31 126.36 27.09 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.73 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.5 t -59.69 -42.62 93.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.47 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.437 ' O ' HG23 ' A' ' 17' ' ' VAL . 46.5 mm 70.93 133.28 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 O-C-N 123.83 0.706 . . . . 0.0 111.786 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.418 HG12 ' HB2' ' A' ' 16' ' ' PHE . 16.7 m -137.11 108.37 8.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-O 121.415 0.626 . . . . 0.0 110.141 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.471 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 8.2 Cg_exo -72.74 149.38 48.32 Favored 'Trans proline' 0 N--CA 1.463 -0.265 0 C-N-CA 123.03 2.487 . . . . 0.0 111.913 -179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 19.9 mt -71.54 64.8 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 121.44 0.638 . . . . 0.0 110.475 179.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.6 pp -176.84 -21.42 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.052 -0.977 . . . . 0.0 109.398 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -175.07 -134.93 1.98 Allowed Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.222 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.471 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 14.2 p90 -167.55 154.45 8.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.77 0.285 . . . . 0.0 110.261 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.852 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.2 t -86.01 -166.68 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.852 ' H ' HG12 ' A' ' 17' ' ' VAL . 48.6 p90 -156.56 143.64 18.84 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.587 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 67.4 m -74.31 168.53 19.46 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.075 0.464 . . . . 0.0 111.57 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.745 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 13.9 m -67.9 153.52 95.11 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_exo -51.65 115.57 2.19 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 121.841 1.694 . . . . 0.0 111.71 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.4 -30.43 6.0 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 114.376 -1.283 . . . . 0.0 111.922 -178.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.587 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 49.5 mt -101.18 147.18 26.56 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.8 pt -130.28 132.97 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.98 0.419 . . . . 0.0 111.509 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 74.0 m -58.93 140.01 55.98 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.118 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.41 -130.22 2.7 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.934 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -66.69 70.5 0.48 Allowed 'Trans proline' 0 N--CA 1.479 0.627 0 C-N-CA 123.823 3.015 . . . . 0.0 113.845 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 64.47 21.4 12.45 Favored 'General case' 0 N--CA 1.465 0.313 0 C-N-CA 123.333 0.653 . . . . 0.0 110.684 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 m -150.32 -155.88 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.955 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 11.6 t -140.3 155.64 46.75 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 17.3 m . . . . . 0 C--O 1.245 0.857 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.227 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.225 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.775 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.8 p -87.97 126.57 35.14 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.185 0.517 . . . . 0.0 109.655 179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.0 p -76.51 142.36 40.92 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.822 -178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.489 ' N ' ' HE3' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -75.02 157.01 35.6 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.297 178.895 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.981 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 31.2 tttt -49.35 -71.71 0.06 Allowed 'General case' 0 C--O 1.216 -0.663 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.6 m95 -80.6 31.39 0.29 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.254 -0.904 . . . . 0.0 110.542 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.488 ' OE1' ' HE3' ' A' ' 4' ' ' LYS . 27.8 tt0 -108.99 143.07 38.74 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.023 178.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.43 ' HE1' ' HD2' ' A' ' 28' ' ' PHE . 40.3 t80 -59.32 134.42 56.99 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.965 0.412 . . . . 0.0 111.223 -179.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 30.1 p -151.63 158.19 43.14 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.507 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.419 HD12 ' O ' ' A' ' 10' ' ' ILE . 1.6 pp -145.39 145.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.578 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 1.052 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 3.3 m -72.97 125.63 90.97 Favored Pre-proline 0 CA--C 1.538 0.486 0 CA-C-O 121.1 0.476 . . . . 0.0 110.19 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -69.86 54.97 1.27 Allowed 'Trans proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.362 2.708 . . . . 0.0 114.233 -178.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 39.1 mm 53.81 -86.11 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 C-N-CA 123.814 0.845 . . . . 0.0 113.025 178.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.414 ' H ' ' HG ' ' A' ' 14' ' ' LEU . 2.8 pp -67.4 -11.36 57.56 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.558 0.694 . . . . 0.0 109.97 179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -127.54 158.04 21.1 Favored Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 178.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 1.052 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 8.5 m-85 -121.64 -32.44 3.8 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 117.303 0.551 . . . . 0.0 111.107 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.56 HG12 ' H ' ' A' ' 18' ' ' TYR . 0.8 OUTLIER -76.14 174.26 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.579 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.684 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 10.5 t80 179.09 -34.29 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.309 179.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.431 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 76.4 m -59.93 163.76 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.402 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.775 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 7.8 m -64.67 151.63 91.78 Favored Pre-proline 0 N--CA 1.452 -0.347 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_exo -51.47 114.6 1.64 Allowed 'Trans proline' 0 N--CA 1.457 -0.642 0 C-N-CA 121.748 1.632 . . . . 0.0 111.959 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.56 -35.6 2.75 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.165 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.567 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 69.5 mt -102.27 149.79 23.96 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 116.637 0.218 . . . . 0.0 110.526 -179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.6 pt -125.71 131.43 71.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.159 0.504 . . . . 0.0 111.543 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 45.9 t -69.67 141.65 53.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.632 -179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -138.57 -117.54 1.53 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.986 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.46 63.51 2.2 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.48 2.787 . . . . 0.0 113.698 -179.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.43 ' HD2' ' HE1' ' A' ' 8' ' ' TYR . 2.9 m-85 66.29 15.65 10.17 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.766 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.02 155.18 7.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 177.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.981 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.02 159.51 17.56 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 120.897 0.379 . . . . 0.0 110.54 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.476 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 m . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.202 -0.904 . . . . 0.0 109.806 179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.215 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.77 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.2 p -137.65 134.97 36.09 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.979 0.419 . . . . 0.0 110.927 -179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.0 m -81.36 148.81 29.17 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.844 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.629 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 19.7 mtpt -65.46 151.05 47.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.703 179.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.936 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.5 tttt -52.24 -65.02 0.63 Allowed 'General case' 0 C--O 1.214 -0.804 0 N-CA-C 112.824 0.675 . . . . 0.0 112.824 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.7 m95 -80.77 27.73 0.36 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.368 -0.833 . . . . 0.0 111.123 -178.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.629 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 2.3 tp10 -94.98 138.46 32.68 Favored 'General case' 0 N--CA 1.452 -0.373 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.163 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.433 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 49.6 t80 -64.49 130.41 43.61 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 74.0 m -73.54 61.95 0.73 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.772 -179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.433 ' HB ' ' CD2' ' A' ' 8' ' ' TYR . 15.1 tt -79.01 52.7 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 122.484 1.135 . . . . 0.0 109.626 178.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.692 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 35.3 m -79.31 134.63 58.54 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.517 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.415 ' HD2' ' O ' ' A' ' 15' ' ' GLY . 21.6 Cg_exo -65.23 136.01 45.71 Favored 'Trans proline' 0 N--CA 1.463 -0.3 0 C-N-CA 122.612 2.208 . . . . 0.0 111.493 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 12.4 tt -55.07 -37.87 44.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.665 -179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.773 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.5 pt? -99.8 29.78 3.99 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.687 0.28 . . . . 0.0 111.217 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.415 ' O ' ' HD2' ' A' ' 12' ' ' PRO . . . 174.89 55.77 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.313 -0.946 . . . . 0.0 112.203 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.692 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 23.6 p90 -62.54 138.2 58.43 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.181 0.515 . . . . 0.0 111.554 -179.269 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.784 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.9 t -87.34 -169.19 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.697 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.784 ' H ' HG12 ' A' ' 17' ' ' VAL . 51.8 p90 -150.61 147.54 27.54 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 98.3 m -75.73 162.4 28.24 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.665 0.269 . . . . 0.0 110.672 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.77 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.8 OUTLIER -69.78 156.32 91.94 Favored Pre-proline 0 C--N 1.326 -0.419 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.032 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.14 114.66 1.84 Allowed 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.177 1.918 . . . . 0.0 111.584 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.18 -35.25 2.76 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 114.259 -1.337 . . . . 0.0 111.84 -178.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.555 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 2.5 mm? -112.59 150.02 31.95 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.1 pt -138.69 134.11 42.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.781 0.325 . . . . 0.0 111.169 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.632 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 37.1 t -65.8 139.59 58.34 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.787 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -142.93 -97.92 0.27 Allowed Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.064 -0.589 . . . . 0.0 112.7 -179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.38 58.76 3.77 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.151 2.567 . . . . 0.0 113.498 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 65.14 14.34 9.32 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.837 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.61 163.76 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.323 0 N-CA-C 107.062 -1.459 . . . . 0.0 107.062 178.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.936 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.3 t -89.15 150.72 22.57 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.525 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 29.2 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.018 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.171 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.728 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 27.9 p -118.3 129.33 55.39 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.904 0.383 . . . . 0.0 110.247 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -83.57 150.93 25.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.88 -179.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.844 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 22.5 mtmt -65.51 157.37 29.8 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.869 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 33.5 tttt -49.8 -61.33 2.19 Favored 'General case' 0 C--O 1.216 -0.707 0 N-CA-C 113.982 1.105 . . . . 0.0 113.982 -177.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -80.9 25.57 0.45 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 112.186 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.844 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 70.0 mm-40 -97.53 145.37 26.3 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 177.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.572 ' HA ' ' O ' ' A' ' 28' ' ' PHE . 5.5 m-85 -72.78 94.38 1.78 Allowed 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.8 p -75.79 49.2 0.51 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.081 -179.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.81 127.56 33.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.276 179.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.478 HG12 ' H ' ' A' ' 17' ' ' VAL . 20.7 m -75.85 130.76 77.84 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-O 121.109 0.481 . . . . 0.0 111.409 -179.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 11' ' ' VAL . 12.2 Cg_exo -70.07 144.0 51.03 Favored 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.846 2.364 . . . . 0.0 111.303 179.644 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.577 HG23 ' HG ' ' A' ' 14' ' ' LEU . 8.6 tp -53.87 -30.63 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.611 -179.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.577 ' HG ' HG23 ' A' ' 13' ' ' ILE . 95.1 mt -105.62 33.81 3.57 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.598 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 171.55 -144.74 8.34 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.944 -1.122 . . . . 0.0 113.101 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -171.15 151.59 3.23 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.67 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.0 OUTLIER -112.45 -177.02 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.613 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.681 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 41.2 p90 -170.46 151.57 3.73 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 71.5 m -84.06 162.3 20.39 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.484 -0.325 . . . . 0.0 110.904 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.728 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 0.5 OUTLIER -72.19 157.03 90.03 Favored Pre-proline 0 CA--C 1.513 -0.45 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.558 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -53.0 114.19 1.61 Allowed 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.211 1.94 . . . . 0.0 111.664 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.35 -36.06 2.46 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 114.192 -1.367 . . . . 0.0 111.662 -178.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.504 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 71.4 mt -108.25 148.26 30.23 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.9 pt -129.35 131.87 67.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 121.151 0.5 . . . . 0.0 111.809 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.514 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.1 t -67.24 138.53 56.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.499 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.1 -116.9 1.57 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.946 -179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.01 63.74 1.94 Allowed 'Trans proline' 0 C--N 1.347 0.464 0 C-N-CA 123.549 2.833 . . . . 0.0 113.559 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.572 ' O ' ' HA ' ' A' ' 8' ' ' TYR . 4.1 m-85 65.72 16.58 10.55 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.678 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.9 m -151.54 154.1 8.79 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.376 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.869 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.65 155.82 19.38 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.512 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.6 m . . . . . 0 C--O 1.249 1.031 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.121 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.024 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.712 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.6 p -150.96 -148.64 0.27 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.2 t -169.21 164.25 11.01 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 118.0 0.364 . . . . 0.0 110.446 -179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.573 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 30.1 mtmm -69.95 151.84 45.15 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.227 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.792 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.4 tttt -54.3 -60.79 2.86 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 12.8 m95 -80.85 26.07 0.43 Allowed 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.47 -0.769 . . . . 0.0 111.206 -178.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.573 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 0.6 OUTLIER -92.68 145.1 24.68 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 178.276 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.435 ' HE1' ' HD2' ' A' ' 28' ' ' PHE . 25.9 t80 -67.32 116.93 8.64 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.991 0.424 . . . . 0.0 110.233 179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 72.1 m -76.45 78.12 3.17 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.103 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.2 tp -71.23 85.45 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.825 0.822 . . . . 0.0 110.328 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.516 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 29.7 m -74.64 136.95 74.03 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.374 -179.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -68.17 150.66 77.11 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.639 2.226 . . . . 0.0 111.793 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.608 ' H ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -55.67 128.37 15.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.662 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.4 mt 64.36 28.09 13.7 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.394 -179.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -158.83 -158.94 9.33 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.936 179.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.516 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 12.4 p90 -168.07 153.13 6.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.636 0.255 . . . . 0.0 110.448 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.701 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.4 t -94.31 -172.77 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.701 ' H ' HG12 ' A' ' 17' ' ' VAL . 25.0 t80 -146.05 132.29 19.48 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.917 0.389 . . . . 0.0 110.133 179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.493 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.1 m -75.36 177.76 6.36 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.454 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.712 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.1 m -70.5 151.05 95.63 Favored Pre-proline 0 N--CA 1.447 -0.583 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -49.69 113.35 0.94 Allowed 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 121.745 1.63 . . . . 0.0 112.139 -178.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.92 -33.47 3.53 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.497 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.4 mt -104.98 146.45 29.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.564 0.221 . . . . 0.0 110.628 -179.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.3 pt -133.27 133.61 57.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 120.972 0.415 . . . . 0.0 111.224 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 51.6 m -66.77 140.0 57.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.98 0.419 . . . . 0.0 111.515 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.35 -112.6 1.14 Allowed Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.198 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.62 62.8 2.27 Favored 'Trans proline' 0 N--CA 1.477 0.523 0 C-N-CA 123.367 2.711 . . . . 0.0 113.704 -179.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.435 ' HD2' ' HE1' ' A' ' 8' ' ' TYR . 4.4 m-85 65.4 15.8 10.21 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 123.617 0.767 . . . . 0.0 110.976 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -150.18 160.33 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 178.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.792 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 3.4 t -89.33 156.14 18.91 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.926 0.393 . . . . 0.0 110.158 -179.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.507 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.6 m . . . . . 0 C--O 1.246 0.915 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.905 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.043 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.785 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 30.9 p -150.27 130.56 13.7 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.427 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 31.0 m -84.97 153.81 22.55 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.151 -179.068 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.596 ' O ' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -66.16 160.11 24.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.267 179.065 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.943 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.1 tttt -52.05 -63.69 1.06 Allowed 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 -178.442 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.4 m95 -82.02 31.63 0.38 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.781 -0.574 . . . . 0.0 111.153 -178.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.596 ' HB2' ' O ' ' A' ' 4' ' ' LYS . 0.5 OUTLIER -79.34 -125.55 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.232 0.539 . . . . 0.0 110.006 178.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.41 ' H ' ' HB3' ' A' ' 7' ' ' GLU . 46.9 t80 -160.53 134.37 7.03 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 7.5 p -160.15 139.64 11.07 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.943 0.402 . . . . 0.0 111.007 -179.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 5.6 tp -122.11 74.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 122.101 0.953 . . . . 0.0 109.996 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.43 ' HB ' ' HB3' ' A' ' 16' ' ' PHE . 27.8 m -80.25 141.82 54.13 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.862 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.1 140.4 89.32 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.679 2.253 . . . . 0.0 112.04 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 52.5 mt -54.62 -28.89 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.815 -179.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.441 HD22 ' H ' ' A' ' 14' ' ' LEU . 3.1 mm? -59.23 -29.5 67.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.146 179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 127.1 127.53 3.03 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.152 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.43 ' HB3' ' HB ' ' A' ' 11' ' ' VAL . 21.9 t80 -173.11 136.97 0.67 Allowed 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.635 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.1 t -106.54 -176.91 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.635 ' H ' HG12 ' A' ' 17' ' ' VAL . 15.7 t80 179.69 -37.43 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.961 0.41 . . . . 0.0 110.009 179.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.488 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 94.7 m -59.27 160.64 6.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.006 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.785 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 4.5 m -62.64 152.41 81.46 Favored Pre-proline 0 N--CA 1.452 -0.338 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -50.85 115.18 1.84 Allowed 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 121.784 1.656 . . . . 0.0 111.847 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.14 -35.32 3.4 Favored Glycine 0 C--N 1.312 -0.774 0 CA-C-N 114.388 -1.278 . . . . 0.0 111.935 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.612 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 5.2 mp -98.9 147.88 24.52 Favored 'General case' 0 C--O 1.236 0.343 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 pt -132.74 132.33 59.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.105 0.479 . . . . 0.0 111.766 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 53.7 t -68.82 143.93 54.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.314 179.477 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.434 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -144.59 -109.43 0.65 Allowed Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.929 -179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.434 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.5 Cg_exo -70.52 61.87 2.17 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.724 2.949 . . . . 0.0 113.525 -178.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 3.1 m-85 65.79 13.89 9.24 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.565 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.6 m -150.35 161.04 4.2 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.943 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.2 t -89.3 155.85 19.11 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.502 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 19.5 m . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.877 179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.073 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.828 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 29.8 p -150.85 135.13 16.94 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -76.22 146.89 38.74 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.321 -179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.856 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 28.5 mtpt -66.75 148.65 51.64 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.945 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.6 tttt -51.37 -66.06 0.45 Allowed 'General case' 0 C--O 1.218 -0.565 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 10.3 m95 -80.92 29.32 0.33 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.802 -0.561 . . . . 0.0 110.94 -179.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.856 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 13.8 tp10 -110.71 147.58 34.08 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 21.5 t80 -65.2 113.43 3.98 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.983 0.42 . . . . 0.0 110.345 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.7 p -82.44 116.28 21.83 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 178.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.565 HG22 ' HD3' ' A' ' 12' ' ' PRO . 22.5 mt -68.79 130.85 34.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.491 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.1 m -126.56 67.69 66.8 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.96 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.896 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 25.4 Cg_exo -62.78 147.79 94.24 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.549 2.166 . . . . 0.0 112.018 179.496 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.59 117.24 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.677 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 11.1 mp 60.18 32.01 20.73 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.601 -179.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.71 41.79 0.22 Allowed Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.028 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.896 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 11.1 p90 -70.96 146.42 49.48 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.767 0.318 . . . . 0.0 111.209 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.751 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.7 t -83.87 -172.26 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.751 ' H ' HG12 ' A' ' 17' ' ' VAL . 23.6 t80 -152.19 141.39 21.38 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.839 0.352 . . . . 0.0 110.259 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.554 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 92.9 m -74.0 173.52 9.89 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.904 179.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.828 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -68.89 156.6 90.98 Favored Pre-proline 0 N--CA 1.449 -0.487 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -52.12 113.08 1.03 Allowed 'Trans proline' 0 N--CA 1.453 -0.853 0 C-N-CA 122.095 1.863 . . . . 0.0 111.629 -179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.84 -34.93 2.87 Favored Glycine 0 C--N 1.311 -0.857 0 CA-C-N 114.114 -1.403 . . . . 0.0 111.942 -178.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.554 ' HB2' ' HB3' ' A' ' 19' ' ' CYS . 54.6 mt -103.95 139.95 38.39 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 116.703 0.252 . . . . 0.0 110.343 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 21.1 pt -127.31 133.09 68.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 120.999 0.428 . . . . 0.0 111.573 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -63.4 139.43 58.77 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.7 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.423 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -140.97 -117.22 1.35 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.967 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 12.0 Cg_exo -70.96 62.68 2.46 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 123.727 2.951 . . . . 0.0 113.222 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 65.7 16.16 10.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.496 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.4 m -151.15 155.47 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.132 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.945 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 1.8 t -89.52 153.87 20.46 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.515 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 18.9 m . . . . . 0 C--O 1.246 0.892 0 CA-C-O 117.956 -1.021 . . . . 0.0 109.98 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.784 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 24.0 p -149.98 136.87 19.39 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.3 t -85.21 143.3 28.85 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.613 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.644 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 5.1 ttpm? -66.48 153.37 43.04 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 179.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 1.047 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 36.2 tttt -50.54 -68.59 0.16 Allowed 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 112.447 0.536 . . . . 0.0 112.447 -178.516 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.41 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 6.9 m95 -82.1 32.04 0.38 Allowed 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.75 -0.593 . . . . 0.0 110.657 -179.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.644 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 2.6 tp10 -85.98 -116.76 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -160.31 140.29 11.35 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 28' ' ' PHE . 28.8 p -157.32 151.25 24.52 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.233 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.7 tp -167.83 -32.04 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.831 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 20.0 m -59.92 144.27 86.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.747 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.04 103.11 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.861 2.374 . . . . 0.0 112.939 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.526 ' HA ' ' O ' ' A' ' 17' ' ' VAL . 33.6 pt -62.32 -17.2 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.118 179.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 47.2 tp -65.82 -23.24 66.64 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.272 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -166.0 57.91 0.24 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 119.48 -1.343 . . . . 0.0 113.971 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -165.41 -65.46 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.917 0.358 . . . . 0.0 110.275 178.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.67 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.2 t -144.3 -178.23 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.714 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 16.4 t80 -172.6 154.61 3.12 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.477 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 56.0 m -68.0 166.3 16.12 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.807 0.337 . . . . 0.0 111.303 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.784 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 12.3 m -66.33 151.88 95.22 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.47 116.25 2.73 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 121.806 1.671 . . . . 0.0 111.758 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.18 -29.66 5.89 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.958 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.511 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 57.9 mt -106.15 147.17 29.32 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 22.9 pt -130.09 132.47 65.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-O 121.063 0.459 . . . . 0.0 111.473 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.2 t -64.1 140.77 58.9 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.978 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -140.68 -117.96 1.44 Allowed Glycine 0 CA--C 1.522 0.513 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.954 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 64.74 2.33 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.494 2.796 . . . . 0.0 113.814 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.452 ' HA ' ' O ' ' A' ' 9' ' ' CYS . 3.8 m-85 67.02 13.1 9.35 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.8 -179.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.0 m -150.46 159.26 4.85 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 1.047 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.5 t -89.29 154.06 20.4 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.52 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 21.3 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.042 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.068 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.672 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.5 p -91.98 134.17 35.04 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.038 0.447 . . . . 0.0 110.544 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.0 t -80.18 143.12 34.09 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.051 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.814 ' HB2' ' HG2' ' A' ' 7' ' ' GLU . 12.7 mtmt -67.98 149.48 49.68 Favored 'General case' 0 C--O 1.233 0.216 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 178.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.879 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 32.6 tttt -51.81 -57.12 10.23 Favored 'General case' 0 C--O 1.213 -0.828 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 -177.691 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 20.4 m95 -81.23 23.02 0.62 Allowed 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 112.689 -177.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.814 ' HG2' ' HB2' ' A' ' 4' ' ' LYS . 6.0 mm-40 -81.24 142.04 33.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 176.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -76.35 58.47 1.3 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.231 0.539 . . . . 0.0 110.462 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 p -79.19 75.57 5.73 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.452 0.644 . . . . 0.0 110.948 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 9.8 tt -61.81 -30.23 48.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.469 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.518 ' HB ' ' HB3' ' A' ' 16' ' ' PHE . 15.5 m -68.5 134.11 90.85 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.017 179.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.578 ' HB2' HD22 ' A' ' 14' ' ' LEU . 45.6 Cg_endo -69.13 140.94 46.37 Favored 'Trans proline' 0 N--CA 1.464 -0.241 0 C-N-CA 122.67 2.246 . . . . 0.0 112.566 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.528 HD11 ' H ' ' A' ' 25' ' ' CYS . 65.3 mt -51.96 -42.76 34.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.882 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.823 ' H ' HD13 ' A' ' 14' ' ' LEU . 0.0 OUTLIER -83.83 33.24 0.48 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.064 179.021 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -150.17 -42.75 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 121.171 -0.538 . . . . 0.0 111.902 179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.518 ' HB3' ' HB ' ' A' ' 11' ' ' VAL . 7.1 t80 -162.71 133.14 4.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.671 0.272 . . . . 0.0 110.416 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.844 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.8 t 62.12 -173.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 123.59 0.756 . . . . 0.0 110.838 -179.568 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.844 ' H ' HG12 ' A' ' 17' ' ' VAL . 45.0 p90 -176.37 144.12 0.53 Allowed 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.471 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 93.6 m -76.33 172.8 12.29 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.139 0.495 . . . . 0.0 111.824 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.672 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 21.2 m -72.64 154.23 91.44 Favored Pre-proline 0 CA--C 1.515 -0.39 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 177.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -51.62 115.16 1.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 121.801 1.667 . . . . 0.0 111.9 -179.509 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 119.25 -31.71 5.35 Favored Glycine 0 C--N 1.311 -0.81 0 CA-C-N 114.479 -1.237 . . . . 0.0 112.179 -178.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.618 HD13 ' HB2' ' A' ' 5' ' ' LYS . 44.4 mt -103.45 150.48 23.83 Favored 'General case' 0 N--CA 1.453 -0.308 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.435 ' N ' HD13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -143.7 132.74 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.856 179.945 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.662 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 99.0 m -68.24 134.41 50.35 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.377 179.074 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -146.16 -84.02 0.05 OUTLIER Glycine 0 CA--C 1.521 0.417 0 C-N-CA 120.72 -0.753 . . . . 0.0 113.131 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.13 55.5 4.03 Favored 'Trans proline' 0 C--N 1.347 0.453 0 C-N-CA 123.284 2.656 . . . . 0.0 112.966 -179.188 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 64.74 12.42 7.62 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.36 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.4 m -151.77 167.45 1.68 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.879 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 15.0 t -89.38 153.19 21.05 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.016 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.446 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 34.9 m . . . . . 0 C--O 1.246 0.873 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.852 -179.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.005 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.813 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 15.7 p -88.74 143.09 27.15 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.9 t -115.2 -162.86 0.84 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.222 0.534 . . . . 0.0 112.251 -177.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.6 mttp -80.65 150.05 29.57 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 115.316 -0.856 . . . . 0.0 111.123 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.691 ' HB2' HD13 ' A' ' 23' ' ' LEU . 29.0 tttt -57.39 -55.54 33.48 Favored 'General case' 0 C--O 1.211 -0.969 0 CA-C-O 121.514 0.673 . . . . 0.0 112.063 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 16.7 m95 -81.04 24.01 0.53 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 120.936 -1.103 . . . . 0.0 111.596 -178.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 13.9 tp10 -77.47 134.44 38.36 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.416 ' CE2' HD11 ' A' ' 10' ' ' ILE . 0.7 OUTLIER -77.71 67.04 3.53 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.7 p -60.41 -26.39 66.65 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.299 0.852 . . . . 0.0 113.299 -178.093 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.416 HD11 ' CE2' ' A' ' 8' ' ' TYR . 45.5 mm 65.27 84.41 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.654 0.74 . . . . 0.0 110.313 -179.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.765 HG21 ' HB3' ' A' ' 25' ' ' CYS . 35.5 m -137.35 159.31 69.98 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.086 -179.516 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -59.66 140.06 91.81 Favored 'Trans proline' 0 N--CA 1.463 -0.301 0 C-N-CA 122.51 2.14 . . . . 0.0 111.495 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 10.1 tp -55.36 -22.6 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.97 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.431 HD22 ' H ' ' A' ' 14' ' ' LEU . 3.1 mm? -61.43 -30.42 70.56 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.077 179.492 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 118.96 139.09 5.96 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.419 ' O ' ' HB2' ' A' ' 25' ' ' CYS . 21.6 t80 -162.99 133.65 4.66 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.626 HG13 HG22 ' A' ' 24' ' ' ILE . 0.7 OUTLIER -73.41 169.71 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 121.038 0.447 . . . . 0.0 110.195 -179.477 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.501 ' H ' HG12 ' A' ' 17' ' ' VAL . 24.4 t80 178.18 -44.6 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.861 179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 66.0 m -70.54 174.45 5.81 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 114.872 -1.058 . . . . 0.0 111.41 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.813 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 1.2 m -70.89 160.62 81.65 Favored Pre-proline 0 N--CA 1.445 -0.702 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -49.96 111.45 0.52 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.254 1.969 . . . . 0.0 112.056 -179.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 136.31 -39.28 1.67 Allowed Glycine 0 C--N 1.309 -0.944 0 CA-C-N 113.847 -1.524 . . . . 0.0 111.659 -178.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 5' ' ' LYS . 64.5 mt -111.17 145.46 38.61 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 120.535 0.207 . . . . 0.0 110.47 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.626 HG22 HG13 ' A' ' 17' ' ' VAL . 22.0 pt -138.91 140.4 38.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.957 0.408 . . . . 0.0 111.591 -179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.765 ' HB3' HG21 ' A' ' 11' ' ' VAL . 22.7 m -77.5 139.5 39.62 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.103 0.478 . . . . 0.0 111.445 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.91 -85.73 0.11 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.079 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 68.7 Cg_endo -75.78 55.43 4.35 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.826 2.351 . . . . 0.0 112.793 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.555 ' HA ' ' H ' ' A' ' 11' ' ' VAL . 12.4 m-85 63.95 15.2 9.0 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.889 -179.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.4 m -147.25 164.33 7.02 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.733 ' HA ' ' HA ' ' A' ' 25' ' ' CYS . 6.7 t -90.51 150.92 21.58 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-O 120.931 0.396 . . . . 0.0 109.953 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.519 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 35.2 m . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.067 -0.968 . . . . 0.0 109.963 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.198 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.694 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.4 p -150.43 -149.45 0.3 Allowed 'General case' 0 C--N 1.325 -0.496 0 O-C-N 123.05 0.219 . . . . 0.0 110.553 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 28.3 t -164.22 157.92 18.42 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 110.291 -0.263 . . . . 0.0 110.291 -179.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.794 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 14.2 ttmt -64.35 146.75 53.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.599 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.878 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 34.1 tttt -52.13 -64.57 0.77 Allowed 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.671 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 14.0 m95 -80.5 27.35 0.35 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 111.151 -178.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.8 tp10 -95.93 138.49 33.49 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 41.9 t80 -62.41 119.18 8.62 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.209 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 71.4 m -73.79 87.64 1.74 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.422 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.623 HD13 ' H ' ' A' ' 10' ' ' ILE . 0.2 OUTLIER -65.92 -23.75 32.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.533 -179.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 35.5 m -66.95 137.58 94.76 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.828 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 16' ' ' PHE . 55.8 Cg_exo -53.24 121.66 9.82 Favored 'Trans proline' 0 C--O 1.24 0.601 0 C-N-CA 122.777 2.318 . . . . 0.0 112.723 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 16.5 tt -55.54 -17.07 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.774 -179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 55.7 tp -55.43 -35.56 65.55 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.789 179.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.38 47.97 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.773 179.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.444 ' HB2' ' HD2' ' A' ' 12' ' ' PRO . 5.0 m-85 -108.74 131.91 54.47 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 122.696 -0.296 . . . . 0.0 110.539 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.88 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.5 t 61.47 -161.13 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.363 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.977 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.88 ' H ' HG12 ' A' ' 17' ' ' VAL . 51.6 p90 -166.96 151.11 6.95 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.485 0.183 . . . . 0.0 110.545 -178.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.423 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 1.6 m -74.08 170.86 14.62 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.821 0.343 . . . . 0.0 110.506 178.425 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.694 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 6.4 m -66.45 151.82 95.56 Favored Pre-proline 0 C--N 1.327 -0.403 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.97 115.8 2.37 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 121.913 1.742 . . . . 0.0 112.219 -179.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.73 -21.98 12.11 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.232 -178.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.52 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 45.2 mt -116.72 152.67 33.84 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 -179.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 15.8 pt -142.15 135.59 28.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.69 0.281 . . . . 0.0 111.366 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 15.6 m -67.12 136.21 54.78 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.752 0.31 . . . . 0.0 110.964 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -135.71 -105.95 0.82 Allowed Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.204 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.13 60.24 3.11 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.249 2.632 . . . . 0.0 113.34 -179.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 65.08 17.29 11.0 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.964 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.52 160.52 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.372 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 178.041 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.878 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 5.9 t -88.53 151.18 22.68 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.54 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 23.3 m . . . . . 0 C--O 1.244 0.802 0 CA-C-O 118.064 -0.97 . . . . 0.0 110.013 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.717 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 18.9 p -92.22 137.5 32.32 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 123.311 0.382 . . . . 0.0 110.548 -179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.7 m -87.69 148.46 24.76 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.067 -178.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.514 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 2.7 tmmm? -68.95 145.79 53.32 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.251 179.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.966 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 38.0 tttt -49.23 -68.52 0.17 Allowed 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . 0.409 ' CZ2' ' HE2' ' A' ' 5' ' ' LYS . 8.5 m95 -81.22 32.72 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.461 -0.774 . . . . 0.0 111.048 -178.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.514 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 1.4 tp10 -86.91 -119.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.158 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.454 ' H ' ' HB3' ' A' ' 7' ' ' GLU . 31.9 t80 -151.27 136.76 17.78 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 93.1 m -119.69 -178.77 3.7 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.375 -179.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 27.4 mt 68.06 50.54 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 CA-C-O 122.175 0.988 . . . . 0.0 109.734 -179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.444 ' CG1' ' HD2' ' A' ' 12' ' ' PRO . 17.4 t -132.06 142.26 44.46 Favored Pre-proline 0 C--N 1.326 -0.425 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.482 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.444 ' HD2' ' CG1' ' A' ' 11' ' ' VAL . 4.3 Cg_endo -47.6 154.74 1.66 Allowed 'Trans proline' 0 C--N 1.352 0.722 0 C-N-CA 123.448 2.765 . . . . 0.0 113.496 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.3 mm -46.83 -23.34 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.862 0.865 . . . . 0.0 113.091 -179.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 85.8 mt -57.27 -31.0 65.14 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 111.796 0.295 . . . . 0.0 111.796 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -173.76 151.67 13.73 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.545 -0.836 . . . . 0.0 112.336 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 63.29 48.55 3.58 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 121.663 0.744 . . . . 0.0 110.613 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.44 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.0 OUTLIER -90.66 -142.3 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.756 -179.829 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.713 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 48.2 p90 -53.01 143.38 17.44 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.652 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 23' ' ' LEU . 99.1 m -75.16 169.67 17.57 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.955 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.717 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 23.2 m -71.18 154.04 94.08 Favored Pre-proline 0 CA--C 1.515 -0.375 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.086 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -51.82 115.52 2.18 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 121.85 1.7 . . . . 0.0 111.896 -179.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.02 -31.6 5.07 Favored Glycine 0 C--N 1.312 -0.805 0 CA-C-N 114.491 -1.231 . . . . 0.0 111.963 -178.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.572 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 46.7 mt -103.87 149.99 24.57 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 -179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.8 pt -136.15 133.57 50.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.042 0.448 . . . . 0.0 111.849 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 20.8 m -63.26 139.31 58.76 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.503 179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -139.33 -118.62 1.6 Allowed Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.958 -0.565 . . . . 0.0 112.622 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.39 65.37 1.12 Allowed 'Trans proline' 0 N--CA 1.479 0.651 0 C-N-CA 123.657 2.905 . . . . 0.0 113.97 -179.15 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 66.49 12.57 8.79 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 123.601 0.76 . . . . 0.0 110.875 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.9 m -150.13 161.33 4.29 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.481 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.966 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.7 t -89.41 152.45 21.48 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.531 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 24.8 m . . . . . 0 C--O 1.245 0.868 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.083 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.23 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.733 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 21.4 p -121.08 137.1 54.82 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.06 0.457 . . . . 0.0 110.987 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.484 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 34.1 t -75.62 140.84 42.84 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.8 -179.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.852 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -68.68 150.82 47.49 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.788 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.6 tttt -54.22 -66.24 0.43 Allowed 'General case' 0 C--O 1.214 -0.798 0 CA-C-O 121.153 0.502 . . . . 0.0 112.211 -178.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 9.6 m95 -80.59 26.89 0.38 Allowed 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.282 -0.886 . . . . 0.0 111.039 -178.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.852 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 12.4 tp10 -84.67 136.23 33.83 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 177.634 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 10.2 t80 -74.88 77.55 2.13 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 7.3 p -72.41 59.96 0.44 Allowed 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.435 ' O ' HG12 ' A' ' 10' ' ' ILE . 15.0 tt -83.71 41.63 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-O 122.695 1.236 . . . . 0.0 109.17 178.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.725 ' HB ' ' HA ' ' A' ' 16' ' ' PHE . 0.2 OUTLIER -81.68 136.8 47.96 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.963 -179.255 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.81 150.93 83.24 Favored 'Trans proline' 0 N--CA 1.463 -0.278 0 C-N-CA 122.905 2.403 . . . . 0.0 111.941 179.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.601 ' H ' HD13 ' A' ' 13' ' ' ILE . 0.2 OUTLIER -54.13 -23.5 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -179.467 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.422 ' H ' HD22 ' A' ' 14' ' ' LEU . 3.0 mm? -61.63 -29.13 69.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.77 0.319 . . . . 0.0 111.181 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -165.23 61.01 0.24 Allowed Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 111.48 -0.648 . . . . 0.0 111.48 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.725 ' HA ' ' HB ' ' A' ' 11' ' ' VAL . 0.3 OUTLIER -74.94 3.18 8.71 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.785 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.61 HG12 ' H ' ' A' ' 18' ' ' TYR . 2.1 t 55.11 -142.72 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.916 0.388 . . . . 0.0 110.459 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.643 ' O ' ' HA ' ' A' ' 2' ' ' CYS . 51.5 p90 -163.66 145.95 9.6 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.307 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.484 ' HA ' ' H ' ' A' ' 3' ' ' SER . 35.1 m -75.58 171.24 14.64 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.792 0.329 . . . . 0.0 110.927 179.233 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.733 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 22.5 m -68.03 153.25 95.62 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 178.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -52.27 115.55 2.26 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.863 1.709 . . . . 0.0 111.89 -179.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.9 -26.0 9.13 Favored Glycine 0 C--N 1.312 -0.768 0 CA-C-N 114.429 -1.259 . . . . 0.0 112.231 -178.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.55 HD13 ' HB2' ' A' ' 5' ' ' LYS . 41.6 mt -107.41 149.53 27.79 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.703 0.252 . . . . 0.0 110.453 -179.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.2 pt -137.79 131.41 42.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.9 0.381 . . . . 0.0 111.301 179.339 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.596 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 42.9 t -67.47 135.5 53.17 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.158 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -136.96 -106.07 0.77 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.869 -0.682 . . . . 0.0 113.054 -178.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.44 60.51 2.66 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 123.389 2.726 . . . . 0.0 113.539 -179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 66.0 14.5 9.64 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.759 -179.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.3 m -151.15 155.77 6.87 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.808 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 8.5 t -88.86 154.68 20.06 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.443 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.2 m . . . . . 0 C--O 1.246 0.905 0 CA-C-O 117.915 -1.04 . . . . 0.0 109.972 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.725 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 31.3 p -88.99 -148.25 0.17 Allowed 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.8 t -169.44 152.88 4.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 117.838 0.29 . . . . 0.0 110.707 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.638 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 7.2 ttpt -64.29 146.22 54.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.678 179.101 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 1.05 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 35.9 tttt -51.4 -66.03 0.45 Allowed 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.211 0.529 . . . . 0.0 111.99 -179.032 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.3 m95 -82.04 33.61 0.39 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.882 -0.511 . . . . 0.0 110.839 -179.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.638 ' HB2' ' HB3' ' A' ' 4' ' ' LYS . 7.2 tp10 -81.74 -123.93 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.51 ' CE2' HD11 ' A' ' 10' ' ' ILE . 1.9 t80 -166.5 56.4 0.09 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.9 p -60.35 -52.4 65.41 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.26 -178.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.693 ' HA ' ' HA ' ' A' ' 28' ' ' PHE . 67.7 mt 66.75 115.49 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 O-C-N 123.592 0.558 . . . . 0.0 111.516 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.5 m -85.51 125.37 69.66 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-O 120.875 0.369 . . . . 0.0 110.605 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.593 ' HD2' ' HA ' ' A' ' 16' ' ' PHE . 37.9 Cg_endo -68.7 138.48 41.49 Favored 'Trans proline' 0 N--CA 1.461 -0.393 0 C-N-CA 122.466 2.111 . . . . 0.0 111.733 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.1 mm -52.26 -37.98 24.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.628 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -95.65 32.98 1.71 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.891 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 169.11 -142.5 7.4 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 179.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . 0.593 ' HA ' ' HD2' ' A' ' 12' ' ' PRO . 22.6 p90 -175.14 147.43 0.92 Allowed 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.745 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.7 t -93.44 -171.77 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 179.483 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.745 ' H ' HG12 ' A' ' 17' ' ' VAL . 52.2 p90 -141.19 137.54 32.72 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.262 0.553 . . . . 0.0 110.49 179.291 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.538 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 11.3 m -95.65 -177.62 4.12 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.573 -0.739 . . . . 0.0 110.649 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.725 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 3.7 m -72.02 152.25 92.82 Favored Pre-proline 0 N--CA 1.448 -0.549 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -50.5 113.85 1.21 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 121.772 1.648 . . . . 0.0 112.275 -178.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.0 -28.5 5.85 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.606 -179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.534 ' HB3' ' SG ' ' A' ' 30' ' ' CYS . 52.8 mt -111.91 152.0 28.52 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.942 0.371 . . . . 0.0 111.053 -179.102 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 20.1 pt -130.85 133.2 63.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.002 0.43 . . . . 0.0 110.975 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.576 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 46.6 t -75.67 134.54 40.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.446 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.508 ' HA3' ' HD3' ' A' ' 27' ' ' PRO . . . -136.42 -108.29 0.9 Allowed Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 120.841 -0.695 . . . . 0.0 113.407 -179.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.508 ' HD3' ' HA3' ' A' ' 26' ' ' GLY . 16.4 Cg_exo -68.68 61.61 1.2 Allowed 'Trans proline' 0 N--CA 1.478 0.609 0 C-N-CA 123.99 3.127 . . . . 0.0 113.925 -178.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.693 ' HA ' ' HA ' ' A' ' 10' ' ' ILE . 2.2 m-85 65.73 13.04 8.73 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.734 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 m -149.98 160.75 4.63 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.45 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.332 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 1.05 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 4.7 t -89.73 153.17 20.91 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.53 ' HA ' ' HE3' ' A' ' 5' ' ' LYS . 27.0 m . . . . . 0 C--O 1.246 0.895 0 CA-C-O 118.105 -0.95 . . . . 0.0 109.927 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.112 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.702 ' HB2' ' N ' ' A' ' 20' ' ' CYS . 17.6 p -95.44 139.22 32.03 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.578 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.435 ' H ' ' HA ' ' A' ' 19' ' ' CYS . 9.4 t -80.81 145.17 31.56 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.387 -179.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.604 ' HB2' ' HB2' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -75.14 155.93 36.48 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.555 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.891 ' HA ' ' HB3' ' A' ' 30' ' ' CYS . 30.2 tttt -53.07 -66.66 0.35 Allowed 'General case' 0 C--O 1.217 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 112.217 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' TRP . . . . . . . . . . . . . 7.0 m95 -81.31 27.29 0.42 Allowed 'General case' 0 C--N 1.3 -1.575 0 O-C-N 121.574 -0.704 . . . . 0.0 110.914 -179.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.604 ' HB2' ' HB2' ' A' ' 4' ' ' LYS . 37.4 tt0 -93.32 133.44 36.55 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -71.0 86.4 0.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.995 0.426 . . . . 0.0 112.124 -178.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 6.6 p -78.61 64.0 3.54 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.279 178.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.427 HG22 ' CD2' ' A' ' 28' ' ' PHE . 1.6 pp -70.34 52.93 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.633 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.705 ' HB ' ' HA2' ' A' ' 15' ' ' GLY . 16.2 m -75.0 130.99 79.67 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 121.168 0.508 . . . . 0.0 111.401 179.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.685 ' HB2' HD13 ' A' ' 13' ' ' ILE . 97.4 Cg_endo -81.72 156.32 18.38 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.888 2.392 . . . . 0.0 112.605 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.685 HD13 ' HB2' ' A' ' 12' ' ' PRO . 0.1 OUTLIER 41.06 -122.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.823 0.849 . . . . 0.0 113.18 -179.857 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.8 mt -75.61 28.78 0.1 Allowed 'General case' 0 N--CA 1.462 0.169 0 CA-C-O 120.902 0.382 . . . . 0.0 111.631 -179.361 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.705 ' HA2' ' HB ' ' A' ' 11' ' ' VAL . . . 75.95 -149.76 38.32 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 121.175 -0.536 . . . . 0.0 113.117 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 24.6 t80 179.39 -51.52 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.772 HG12 ' H ' ' A' ' 18' ' ' TYR . 1.9 t -93.82 -170.91 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.25 179.194 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.772 ' H ' HG12 ' A' ' 17' ' ' VAL . 41.7 p90 -157.34 146.29 19.83 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 -179.569 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . 0.447 ' C ' ' HB2' ' A' ' 2' ' ' CYS . 64.0 m -76.76 169.28 18.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.821 0.344 . . . . 0.0 111.368 179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.702 ' N ' ' HB2' ' A' ' 2' ' ' CYS . 17.3 m -69.34 153.9 95.43 Favored Pre-proline 0 C--N 1.326 -0.423 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.16 116.05 2.56 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 121.76 1.64 . . . . 0.0 111.742 -179.55 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 115.19 -27.27 8.65 Favored Glycine 0 C--N 1.312 -0.763 0 CA-C-N 114.532 -1.213 . . . . 0.0 112.187 -178.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.613 HD23 ' HB2' ' A' ' 5' ' ' LYS . 5.2 mp -102.83 150.32 23.61 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 110.148 -0.316 . . . . 0.0 110.148 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 19.5 pt -135.68 131.2 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.052 0.453 . . . . 0.0 111.617 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 30' ' ' CYS . 43.6 t -68.78 137.58 54.12 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.041 179.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.26 -109.33 0.92 Allowed Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.809 -0.71 . . . . 0.0 113.102 -179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.89 61.21 2.34 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 123.441 2.76 . . . . 0.0 113.543 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.427 ' CD2' HG22 ' A' ' 10' ' ' ILE . 2.1 m-85 65.75 15.78 10.2 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 123.667 0.787 . . . . 0.0 110.658 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 m -151.79 155.85 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' CYS . . . . . 0.891 ' HB3' ' HA ' ' A' ' 5' ' ' LYS . 7.0 t -88.33 158.27 18.48 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 19.6 m . . . . . 0 C--O 1.248 0.984 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.129 179.688 . . . . . . . . 0 0 . 1 stop_ save_